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ABVD  doxorubicine, bleomycine, vinblastine, dacarbazine 
AC  adriamycine 
ACE-27 Adult Comorbidity Evaluation 
AD  Alzheimer’s disease 
ADL  Activities of Daily Living 
APOE  alipoproteine E 
ARHL  age-related hearing loss 
ASCO  American Society of Clinical Oncology 
ASHA  American Speech-Language-Hearing Association 
AUC  area under the curve 
B 
BBB  blood-brain barrier 
BOMT  Blessed-Orientation Memory Test 
C 
C+  patients receiving chemotherapy 
C-  patients not receiving chemotherapy 
CARG  Cancer and Aging Research Group 
CCI  Charlson Comorbidity Index 
CDT  clock drawing test 
CFT  complex figure test 
CFQ  cognitive failure questionnaire 
CGA  comprehensive geriatric assessment 
CI  confidence interval 
CIRS-G Cumulative Illness Rating Scale for Geriatrics 
COWA  controlled oral word association 
CRCI  cancer-related cognitive impairment 
CVD  cardiovascular disease 
D 
DART  Dutch adult reading test 
dB  decibel 
DBI  drug burden index 
DDI  drug-drug interactions 
DNA  deoxyribonucleic acid 
DOR  diagnostic odds ratio 
DPOAE distortion product oto-acoustic emission 
DSM-IV Diagnostic and statistical manual of mental disorders – version IV 
DT  distress thermometer 
E 
ECOG  Eastern Cooperative Oncology Group 
EFT  emotional freedom techniques 
EORTC European Organization for Research and Treatment of Cancer 
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F 
FACIT  Functional Assessment of Chronic Illness Therapy 
FEC  fluorouracil, epirubicine, cyclofosfamide 
FF  free-field  
FU  fluouracil 
G 
G-8 or G8 G8-questionnaire 
GA  geriatric assessment 
GDS  Geriatric Depression Scale 
GG  general geriatric 
H 
HADS  Hospital Anxiety and Depression Scale 
HDL  high density lipoprotein 
HHIE  Hearing Handicap Inventory for the Elderly 
HHIE-S Hearing Handicap Inventory for the Elderly – short form 
HL  hearing level 
HNCA  head and neck cancer 
I 
IADL  Instrumental Activities of Daily Living 
ICCTF  International Cognition and Cancer Task Force 
IL  Illinois 
ISO  International Organization for Standardization 
IQ  intelligence quotient 
K 
KPS  Karnofsky’s performance status   
M 
MCI  mild cognitive impairment 
MMSE  mini mental state examination 
MNA  mini nutritional assessment 
MoCA  Montreal cognitive assessment 
MRI  magnetic resonance imaging 
N 
NA  not applicable 
NAT2  N-acetyltransferase 2 
NCCN  National Comprehensive Cancer Network 
NCs  no-cancer controls 
NEG  negative 
NHTSA National Highway Traffic Safety Administration 
NIHL  noise-induced hearing loss 
NPV  negative predictive value 
NY  New York 




OAE  oto-acoustic emission 
OG  oncogeriatric 
OS  operating system 
P 
POS  positive 
PROMs patient-reported outcome measures 
PS  performance status 
PTA   pure tone average 
PTS  permanent threshold shift 
PPV  positive predictive value 
Q 
Qol  quality of life 
R 
RAVLT Rey’s auditory verbal learning test 
RCHOP rituximab ,vincristine, adriamycine, cyclofosfamide, prednisone 
RCI  reliable change index 
RNA  ribonucleic acid 
ROC  receiver operating characteristics 
ROS  reactive oxygen species 
S 
S or Se sensitivity 
SD  standard deviation 
SE  standard error 
SIOG  Société Internationale d’Onco Gériatrie 
SNP  single-nucleotide polymorphism 
Sp  specificity 
SPIN  speech-in-noise test 
SPL  sound pressure level 
SPSS  Statistical Package for the Social Sciences 
T 
T0  time 0 - baseline assessment 
T1  time 1 – assessment six months after treatment initiation 
TEOAE transient evoked oto-acoustic emission 
TMT  trail making test 
TTS  temporary threshold shift 
TUG  timed up and go 
U 
UK  United Kingdom 
US or USA United States (of America) 
16 | L I S T  O F  A B B R E V I A T I O N S  
 
V 
VEP  visual evoked potential 
VES-13 Vulnerable Elders Survey-13 
W 
w/o  without 
WAIS  Wechsler Adult Intelligence Scale 
WDR  word delayed recall 
WRAT-3 Wide Range Achievement Test‐3 
WVT  whispered voice test
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Clinicians have started to pay more interest to the psychosocial problems that are related to a 
cancer diagnosis and cancer treatment. Hearing loss and cognitive dysfunctions are two 
conditions that may seriously interfere with the patient’s ability to deal properly with all aspects 
of their cancer disease and may drastically affect the patient’s quality of life. Therefore, proper 
screening of those conditions is essential in order to optimize the patient’s comfort during and 
after treatment. This thesis focusses on screening tools that could enable health care providers 
to easily detect hearing loss and cognitive deficits in (older) cancer patients.  
In older cancer patients, cognitive and hearing loss were addressed as part of a 
Comprehensive Geriatric Assessment (CGA), a multidisciplinary evaluation in which multiple 
health domains are assessed in order to develop a coordinated care plan. In case of cognition, 
the Freund Clock Drawing Test (CDT) was evaluated for use within the CGA and compared to 
the well-known Mini-Mental State Examination (MMSE). One of the main problems with the 
CDT was its lack of a proper scoring system and cut-off score in an oncogeriatric population. 
After establishing a cut-off score of ≤4, results showed an excellent diagnostic accuracy and 
reduced assessment time when compared to the MMSE.  
Cancer-related cognitive impairment (CRCI) is currently a hot topic within the field of psycho-
oncology. Many patients may experience subjective cognitive complaints and only little is 
known about its existence. Initially, CRCI was considered as a consequence of treatment with 
chemotherapy. However, although some cytotoxic agents may induce cognitive changes, most 
chemotherapeutics cannot cross the blood-brain barrier. Psychosocial factors, on the contrary, 
have been recently suggested as possible cofounders of CRCI. In this thesis, the distress 
thermometer (DT) was used as a screening tool to detect cognitive impairments six months 
after treatment initiation. Although, the DT failed to screen for objective CRCI, results did 
indicate that the DT could be used to screen for subjective cognitive complaints. Further, 
screening for fatigue may even be more suitable to detect subjective cognitive difficulties in 
cancer patients. Our findings also indicated that receiving chemotherapy did not influence 
neuropsychological test results when comparing patients with and without chemotherapy.  
Assessing hearing loss is mostly omitted when conducting a CGA. In this thesis, uHear™ - an 
iOS-based application - was examined as a screening tool to detect hearing loss in older 
cancer patients. Initial results indicated that uHear™ was not feasible when using a scoring 
method based on the Pure Tone Average. A follow up trial, investigating uHear™ with a pass 
or fail screening cut-off based on hearing grades improved the diagnostic accuracy of the test, 
but results did not meet the validation criteria. 
In conclusion, this work presents screening tools that could aid clinicians to screen for hearing 
loss and cognitive dysfunctions in (older) cancer patients. The Freund CDT has shown 
excellent results and can be directly implemented in routine geriatric oncology practice. In case 
of screening for hearing loss and CRCI, more research is necessary before the tools 
investigated here can be used in routine practice. In terms of screening for CRCI, this work 
provides a first insight into the use of psychosocial measures to screen for cognition. As 
psychosocial factors are highly related to the amount of subjective cognitive complaints that 
patients experience, more research in this specific area is necessary in order to optimize the 
patient’s quality of life after treatment. As we failed to validate uHear™, more research is 
warranted in order to select the proper screening tool for hearing loss within the CGA. 
Nevertheless, it should be noted that addressing hearing loss in older cancer patients is 
essential, as patients may not admit they have a hearing problem and it is crucial to know if 
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Artsen besteden meer aandacht aan de psychosociale problemen die gepaard gaan met de 
diagnose en behandeling van kanker. Gehoorverlies en cognitieve disfuncties zijn twee 
condities die ernstig kunnen interfereren met de manier waarop de patiënt omgaat met alle 
aspecten van de ziekte. Daarnaast kunnen ze ook de levenskwaliteit van de patiënt negatief 
beïnvloeden. Bijgevolg is een adequate screening van deze condities essentieel om de 
levenskwaliteit van de patiënt tijdens en na de behandeling te optimaliseren. Deze thesis focust 
zich op screening tools die gezondheidsprofessionals in staat stelt op een eenvoudige manier 
gehoorverlies en cognitieve problemen op te sporen bij (oudere) kankerpatiënten. 
Bij de oudere kankerpatiënten worden geheugen- en gehoorverlies opgespoord in het kader 
van een uitgebreide geriatrische beoordeling (CGA). Dergelijke CGA kan omschreven worden 
als een multidisciplinaire evaluatie van meerdere gezondheidsdomeinen met als doel een 
gecoördineerd zorgplan op te stellen. Om cognitieve problemen op te sporen werd de Freund 
kloktekentest (CDT) onderzocht en vergeleken met de welgekende Mini-Mental State 
Examination (MMSE). Een van de grootste problemen van de CDT is het gebrek aan een 
adequaat scoresysteem en gevalideerde cut-off score in een oncogeriatrische populatie. Bij 
gebruik van een gepredefinieerde cut-off score van ≤4, werd aangetoond dat de CDT in minder 
tijd kan afgenomen worden dan de MMSE alsook toont de test excellente diagnostische 
eigenschappen.  
Kanker-gerelateerde cognitieve disfuncties (CRCI) zijn een hot topic binnen de 
oncopsychologie. Hoewel veel patiënten cognitieve problemen ervaren, is slechts weinig 
gekend over het ontstaan ervan. Initieel werden deze problemen dikwijls toegeschreven aan 
de chemotherapeutische behandeling. Hoewel sommige cytotoxische producten cognitieve 
veranderingen kunnen teweegbrengen, zijn er heel wat die de bloed-hersenbarrière niet 
kunnen doorkruisen. Recent bleek dat ook psychosociale factoren een rol kunnen spelen in 
het ontstaan van CRCI. In deze thesis werd nagegaan of de distress thermometer (DT) kon 
gebruikt worden om CRCI op te sporen zes maanden na de start van de behandeling. Dit bleek 
niet het geval. Wel werd aangetoond dat de DT subjectieve cognitieve klachten kon opsporen. 
Daarnaast toonde screenen naar vermoeidheid nog betere resultaten om dergelijke klachten 
te detecteren. De toediening van chemotherapie had geen invloed op het resultaat van de 
neuropsychologische testen.  
Gehoorverlies wordt vaak niet opgespoord binnen een CGA. In deze thesis werd uHear™, een 
iOS-applicatie, onderzocht om gehoorverlies op te sporen als onderdeel van de CGA. De 
eerste resultaten toonden aan dat uHear™ niet gebruikt kon worden wanneer het 
scoresysteem gebaseerd was op de Pure Tone Average. Een follow-up studie werd opgezet 
waarbij een scoringsmethode onderzocht werd die zich baseert op graden van gehoorverlies. 
Hoewel deze scoringsmethode verbeterde diagnostische eigenschappen met zich meebracht, 
bleek dit niet voldoende om de test te valideren. 
We kunnen besluiten dat dit werk screening tools aanreikt die gezondheidsprofessionals 
kunnen helpen om gehoor- en cognitief verlies op te sporen bij (oudere) kankerpatiënten. De 
Freund CDT gaf excellente resultaten en kan meteen geïmplementeerd worden in de 
dagelijkse praktijk. Betreffende CRCI biedt dit werk een eerste inzicht in het gebruik van 
psychosociale vragenlijsten om cognitieve klachten op te sporen. Gezien de sterke correlatie 
tussen psychosociale factoren en subjectieve cognitieve klachten, zou vervolgonderzoek zich 
hierop moeten focussen zodoende de levenskwaliteit van de patiënt te verbeteren. Meer 
onderzoek is nodig om een geschikte screeningtool inzake gehoorverlies te selecteren voor 
gebruik binnen de CGA. Niettemin blijft het wel belangrijk gehoorverlies op te sporen 
aangezien patiënten dergelijke problemen vaak verzwijgen en het toch essentieel is te weten 
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Due to growth of the ageing population and a prolonged exposure to carcinogens, cancer has 
become an important disease in older people 1, 2. It has been reported that individuals aged 65 
or older have an 11-fold higher risk of developing cancer compared to their younger 
counterparts. Further, they have a 15 percent greater cancer-related mortality rate 2. In the 
European Union, an approximate 14% increase of the total projected cancer incidence is 
estimated to occur from 2009 to 2020 3, 4.  
Cancer is a very serious health problem at any age, however, combined with increasing age, 
it creates even more challenging situations for health care providers. Decreasing physiologic 
reserves, leading to distinct variations in functional status, cognition and co-morbidity may 
affect life expectancy in an individualized manner. As a consequence, their chronological and 
functional age may not correspond 5. The spectrum of impairment ranges from more 
independent individuals, to those who are at moderate risk of health deterioration, to patients 
who have a high risk at functional decline or mortality 6. Therefore, proper patient selection is 
an important step to administering a safe and effective cancer treatment 7.  
Medical and radiation oncologists are faced with another challenge since evidence-based data 
of the risks and benefits of cancer treatments in older patients are lacking. Currently applied 
tools describing the patient’s functional status, such as the Eastern Cooperative Oncology 
Group (ECOG) performance status (PS) and Karnofsky (K) PS, have proven to be insensitive 
in estimating the functional capabilities of an older patient 8. Consequently, as a result of doubts 
concerning the patients’ fitness and their ability to tolerate treatment, physicians are less likely 
to provide appropriate and curative life-saving therapies to older patients when compared to 
their younger counterparts 9, 10. For this reason, a Comprehensive Geriatric Assessment (CGA) 
has become the cornerstone in modern geriatric oncology care 11, 12. 
THE INTEGRATION OF GERIATRIC PRINCIPLES IN ONCOLOGY 
The initial geriatric assessment was developed in 1930 by Marjory Warren. She established 
the first geriatric care unit in the UK in which ill older patients were more adequately managed 
through assessment of a CGA. A CGA can be defined as “a multidisciplinary evaluation in 
which the multiple problems of older persons are uncovered, described and explained, if 
possible, and in which the resources and strengths of the person are catalogued, need for 
services assessed, and a coordinated care plan is developed to focus interventions and long-
term follow up on the person’s detected vulnerabilities” 13, 14. Since those first steps of Marjory 
Warren, a CGA has been the advised approach in the evaluation and treatment of general 
geriatric patients and has been applied all over the world as it is known to have multiple 
advantages (Table 1) 15, 16.  
Table 1. Overview of the advantages of performing a CGA in oncology 
Advantage Reference 
Guides treatment decision 17-19 
Predicts and improves survival 20, 21 
Prevents functional decline 22, 23 
Predicts and improves quality of life 24, 25 
Predicts the risk on chemotherapy toxicity  7, 26 
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These geriatric principles have found their way into oncology practice since the nineties, when 
Monfardini and colleagues made a first attempt to adapt the CGA for use in cancer patients 27. 
Their adapted CGA has later been prospectively validated by the Italian Group of Geriatric 
Oncology 28. Around the year 2000, several research groups indicated the value of using a 
CGA in routine oncology practice 29, 30. In an ideal situation, a CGA should be performed by a 
multidisciplinary geriatric team, which includes a geriatrician, nurse, social worker, pharmacist, 
dietician and an occupational therapist 31. However, other approaches, including for example 
a geriatric oncology nurse, have also been proposed as they are more feasible in an 
ambulatory oncology practice 32. 
Extermann and Terret were the first to report that a CGA could detect multiple problems in 
older breast and prostate cancer patients respectively 21, 33. Many papers followed describing 
different health problems in distinct cancer populations 6, 19, 34-37. Further, Repetto et al. 
suggested that a CGA has an added value to ECOG PS and KPS 25, 28. 
THE CONTENT OF A CGA 
In oncology, a CGA is described as a multidisciplinary, in-depth evaluation to assess the risk 
of morbidity and mortality 29, 38. It aims at identifying vulnerabilities in different age-related 
domains such as functional status, physical performance, cognition, nutrition, social state, 
emotional status, co-morbidity and polypharmacy. Though only a limited number of oncology 
trials could be found that examined the psychometric properties of CGA as a whole, 
researchers generally agreed about the CGA’s feasibility, reliability and validity 37, 39-41. 
Hamaker reported a median number of seven examined domains within a CGA, resulting in a 
different estimation of vulnerability prevalence (ranging from 28% to 94%) 42. Moreover, for 
each health domain, a plethora of validated tools is in use and no consensus exists as to which 
one is most suited. International oncology societies such as the National Comprehensive 
Cancer Network (NCCN) (http://www.nccn.org), the International Society for Geriatric 
Oncology (http://www.siog.org) and the European Organization for Research and Treatment 
of Cancer (EORTC) (http://www.eortc.org), have published guidelines suggesting those core 
domains that should be incorporated within a CGA and that could be assessed by a 
multidisciplinary geriatric oncology team including geriatric oncology nurses, dietitians, 
psychologist, oncologist, geriatricians and other health care professionals (Table 2) 39, 43-45.  
Assessing the functional and physical status are cardinal components of geriatric care. Cancer 
is considered to be life changing in all its aspects because it induces major changes in the 
living patterns of older adults 46. Further, there is evidence that the level of dependence in daily 
activities influences survival in older patients 47. The most commonly used instruments to 
screen for functional dependence are the Activities of Daily Living (ADL) and the Instrumental 
Activities of Daily Living (IADL) 48, 49. The ADL rates the patient’s ability to fulfil basic activities 
of daily living including bathing, dressing, toileting, transferring, continence and feeding. The 
IADL looks at activities that require a higher level of cognition and judgement such as cooking, 
shopping, transportation and others 50. Ideally, grip strength and an evaluation of gait, balance 
and risk of falls should also be included as a direct measure of the patient’s physical status 39. 
Another essential domain within a CGA is the assessment of the patient’s cognitive function. 
Studies have shown that up to 50% of patients can present with cognitive abnormalities that 
need further attention. It is further shown that a cognitive disorder can impact the ability to 
weigh the risks and benefits of the suggested treatment plan and that it may cause difficulties 
in recognising signs of adverse effects that warrant closer observation 29. Cognitive functioning 
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within a CGA is mostly evaluated with the well-known Folstein Mini-Mental Status Examination 
(MMSE) 51. Although validated in multiple populations, others have encountered difficulties 
when having to perform the MMSE in older cancer patients. Therefore, other measures such 
as the MoCA and Mini-Cog have been proposed 52, 53.  




Description Most commonly applied  
validated tools  
Functional 
status 
Assessment to estimate patients self-
sufficiency, as well as their ability to live 
independently and function in the community 
Katz’ Activities of daily living 
(ADL)48, Barthel-index55, Lawtons’ 




Mobility, gait, balance, muscle strength 
 
Tinetti Balance and Gait test56, 
Timed up and go (TUG)57, Grip 
strength58 
Cognition Assessment of patient’s cognitive 
performance 
Mini Mental State Examination 
(MMSE)51, Montreal Cognitive 
Assessment (MoCA)52, Mini-Cog53 
Nutrition Assessment of patient’s nourishment, weight 
changes 
Mini Nutritional Assessment (MNA) 
59 
Emotional state  Assessment of the patient’s emotional status Geriatric depression scale (GDS)60  
Co-morbidities Rating of the number and severity of co-
existing morbidities 
Charlson Comorbidity Index 
(CCI)61, Cumulative Illness Rating 
Scale for Geriatrics (CIRS-G)62, 
Adult Comorbidity Evaluation 
(ACE-27)63 
Polypharmacy Assessment of the number of medications, 
possible drug-drug and drug-disease 
interactions, medications contraindicated in 
older patients (principles of geriatric 
pharmacology) 
Online drug interaction tool64, Drug 
burden index (DBI)65, Beers criteria 
66 
Nutrition is another crucial element included in a CGA. Several studies have demonstrated the 
importance of weight loss as a prognostic factor for survival in patients with cancer 29. Up to 
40% of general geriatric patients are found to be at risk for malnutrition, and without proper 
nutritional support, an intensive cancer treatment could induce cachexia. Nutrition can be 
assessed through the Mini-Nutritional Assessment (MNA) which is frequently used to identify 
geriatric patients at risk of malnutrition 59.  
The emotional status should be assessed within a CGA, as up to 50% of older patients have 
been found to show signs of a depression 13, 28. Depression in older adults has been associated 
with increased risk for resource requirements and informal care giving needs. An assessment 
of the older patient’s psychological state is becoming increasingly important as the care of 
oncology patients is primarily moving to the outpatients settings, with an increased reliance on 
caregivers to assist with symptom management and daily activities 29. The Geriatric 
Depression Scale (GDS) is a commonly used tool to screen for depression in older patients 21. 
The GDS was originally developed and included 30 questions, however, shorter versions exist 
as well 60, 67.  
The relative incidence of comorbidities increases with age. Research has shown an 
association between the presence of comorbidities and the older cancer patient’s prognosis 68. 
Further, it is stated that concomitant diseases not only influence survival but that they also may 
influence the behaviour of the cancer itself. Therefore, screening for comorbidities forms an 
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essential part of the CGA 29. Comorbidities can be assessed through the Charlson Comorbidity 
Index which includes 19 diseases weighted from one to six points 61 or through the Cumulative 
Illness Rating Scale for Geriatrics 62. 
Another element included in the older cancer patient’s assessment is polypharmacy, which 
can be defined as the administration of five or more drugs and may lead to an increased risk 
of side-effects and drug-drug interactions 69. Although the reported prevalence of concomitant 
drug use in the elderly ranges widely and is dependent on the population under study 68, it is 
known that medication intake increases as patients receive cancer treatment 69. Further, as 
the number of medications increases, older patients may have difficulties with treatment 
compliance and may need more help with their medication intake. Poor treatment adherence 
may negatively impact the patient’s health and quality of life. Further, it may lead to increased 
visits to the emergency room and drug-related hospitalization 70. Therefore, a medication 
review as part of the CGA is essential 71.  
A final important aspect to consider when approaching older cancer patients is the social state 
of the patient. Social isolation in older adults leads to psychological distress and the absence 
of social support is a predictor of mortality, independent of the age of the patient 29, 72. To 
examine the social state of the patients, specific questions can be asked regarding their marital 
status, living situation, number of children, etc.  
CGA IN ROUTINE PRACTICE 
When the CGA was first introduced into oncology, the assessment could take up to two hours, 
without incorporating the time needed to review the data, score the patient’s health status and 
develop an individualized care plan. To overcome this limitation, researchers have focused on 
a two-step approach in which older patients are first assessed with a brief screening tool, 
followed by a more comprehensive geriatric assessment for those who screen positive (Figure 
1) 73.  
Hamaker and her colleagues provided an overview of the screening tools, such as the G8-
questionnaire (G8), Vulnerable Elders Survey (VES)-13 and others, that have been 
investigated for use in oncogeriatric patients. All of these screening tools assess functional 
status and most of those, also address psychosocial functioning. However, the inclusion of 
other geriatric domains was observed to vary widely among the different screening methods. 
Further, the use of different contents and cut-off scores leads to a large discrepancy in 
sensitivity and specificity to identify vulnerability. Nevertheless, the G8-questionnaire remains 
the most favourable screening tool for use as it has a strong prognostic value for functional 
decline and overall survival 24, 74, 75.  
In case the patient screens positive and a full CGA is performed, the multidisciplinary geriatric 
oncology team can make a conclusion of the patient’s fitness which can be categorized into 
‘fit’, ‘vulnerable’ or ‘frail’ (Figure 1.) according to the criteria applied. Balducci was the first to 
publish three classes of fitness in the older patient, based on the presence of co-morbidities, 
geriatric syndromes (e.g. incontinence, distress, delirium, ...) or functional dependence 76. 
Further, some have included parameters such as muscle weakness, weight loss and other 77, 
78. At present, an impairment on a CGA is defined as meeting the cut-off scores for impairment 
in at least one 34 or at least two 6, 35, 36, 79 domains within CGA, based on the finding that deficits 
in two or more of the CGA scales indicate an increased risk of disability or death 80, 81. In this 
thesis, the latter will be used to define vulnerability on the CGA. 




Figure 1. Schematic overview of CGA approach in oncology  
It should be noted that conducting a CGA alone does not add any value to the patient’s 
treatment plan without tailored interventions. Based on the CGA, problems or vulnerabilities in 
the several health domains can be detected. Therefore, when such vulnerability is detected, a 
proper referral should be made in order to decrease the risk on morbidity and mortality. For 
example, when a patient shows limited mobility, which influences the patient’s ability to perform 
daily activities, a referral to the geriatric day clinic could be made so that the patient can be 
assessed by the geriatric team and proper interventions, such as cleaning help or the delivery 
of meals or physical therapy, can be arranged. Ideally, the results of the CGA are discussed 
with a geriatrician and are presented at the multidisciplinary oncologic consult, when a 
multidisciplinary team decides on the patient’s treatment. In vulnerable patients, serial CGA 




































When growing older, adults are aware that memory loss occurs more frequently than in their 
younger years. Their mental speed slows down, they have more difficulties in adjusting to 
newer technologies and they find it harder to remember recent events or peoples’ names 83. 
On the contrary, cognitive ageing does not affect all aspects of cognition. For example, the so-
called crystallized intelligence, such as our knowledge and vocabulary, is stable across the 
lifespan 83, 84. In general, the magnitude of normal cognitive decline as a result of the ageing 
brain tends to be small and does not impair a person’s ability to carry out activities of daily 
living 85. Although this process develops in all subjects as a result of ageing, it shows an 
individual pattern and may evolve more rapidly in some persons than in others 83. Further, in 
cancer patients, cognitive impairment can interfere with the patient’s ability to understand a 
cancer diagnosis and its treatment. As a result, the NCCN Guidelines in Older Adult Oncology 
advise to assess the patient’s cognitive abilities and to screen for delirium, mild cognitive 
impairment and dementia 86.  
Although delirium lays not within the scope of this thesis, this is addressed briefly, as it remains 
poorly understood. Delirium can be defined as an acute decline of the patient’s cognitive 
function 87. It is characterized by disorganized thoughts, incoherent speech and attention 
deficits and can manifest itself as agitation or hypo-activation 88. In cancer patients, delirium is 
associated with an increased morbidity, an increased mortality and prolonged hospitalization 
89, 90. The condition is often unrecognized in both cancer and non-cancer patients and even 
when it is diagnosed, it remains untreated or inappropriately treated in many patients. 
Treatment exist of both pharmacological and non-pharmacological interventions 91.  
A mild cognitive impairment (MCI) can be described as a transitional state between normal 
ageing and dementia. It is characterized by a cognitive decline greater than expected 
according to the person’s age and educational level, but has no severe impact on the person’s 
daily functioning 92. People who suffer from an MCI experience cognitive complaints, that can 
be objectively measured but do not meet the criteria for dementia 93. It is estimated that up to 
19% of adults over the age of 65 suffer from MCI. In some, the MCI may remain stable over 
the years, although it progresses into dementia in more than half 92. Further, it has a greater 
progression in females than in males 94. When diagnosing MCI, it is crucial to exclude 
conditions that may induce cognitive complaints such as depression, alcohol or drug abuse, 
learning disabilities, anxiety or other conditions, through clinical and psychological 
examinations. Although evidence is lacking, it is said that detecting an MCI has several benefits 
as early treatment may prevent progressing to dementia 95. Further, it is stated that MCI is 
associated with a lack of appreciation and understanding of consent materials for medical 
treatments, poorer decision-making and difficulties with financial issues such as counting 
money and writing checks 96. 
Dementia is a progressive neurodegenerative condition that interferes with the ability to 
perform daily activities 86. The prevalence of dementia increases with age, ranging from 1.3% 
between the ages of 65 – 69, up to 32.5% in persons over 95 years old in developed countries. 
In developing countries, prevalence rates tend to be lower. Possible explanations may be that 
there are fewer risk factors for dementia, that early detection of dementia is lower and that 
fewer individuals reach the age of 65 in some very poor countries. Prevalence rates are higher 
in women than in males and are not influenced by racial differences 97. Although there are 
several forms of dementia, Alzheimer’s disease (AD) is without doubt the most frequently 
occurring cause of pathologic cognitive ageing, accounting for up to 70% of all dementia cases 
98, 99.    
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Since both dementia and cancer have age as a common risk factor, older cancer patients pose 
unique challenges to healthcare professionals. As a result, Solomons et al. (2013) recently 
published a review on the genetic link between both mechanisms. They state that it is not 
surprising that various pathways and genes involved in cell-cycle regulation may link dementia 
and cancer, since the fundamental biologic of cancer is an uncontrolled cell proliferation and/or 
prolonged cell survival, while dementia involves neuronal cell degeneration and cell death. 
Some of the possible genetic factors include tumour suppressor genes, peptidyl-propyl 
cis/trans isomerase, DNA repair genes, miRNA genes and genes on chromosome 21 100.  
ASSESSMENT AS PART OF A CGA 
As previously mentioned, one of the domains covered within a CGA is the patient’s cognitive 
functioning. Presenting with both cancer and a cognitive impairment may lead to functional 
dependence, higher risk on depression and higher mortality rates 101. Further, having cognitive 
difficulties may influence the patient’s ability to weigh the risks and benefits of the proposed 
cancer treatment. The NCCN Guidelines in Older Adult Oncology state that cognition, as part 
of the CGA, can be assessed by the Blessed Orientation-Memory Test (BOMT), the Mini 
Mental State Examination (MMSE), the Montreal Cognitive Assessment (MoCA) or the Mini-
Cog 102.  
Katzman et al. (1983) have originally developed the BOMT. The BOMT is a 6-item screening 
tool that allows health care providers to screen for dementia in older adults. Scores range from 
zero to 28 with a cut-off score of ≥9 indicating a positive test. The test can also be administered 
by non-clinicians and has shown to discriminate among mild, moderate, and severe cognitive 
deficits. Although advised by the NCCN Guidelines in Older Adult Oncology, the BOMT is a 
rather unknown screening tool that has been rarely used within the CGA given the other more 
validated and more well-known tests that are available 103.  
The Folstein MMSE is a brief 30-point questionnaire that is used to screen for cognitive 
impairment and is considered the gold standard to screen for dementia. It is validated in several 
patient populations and available in multiple languages. The MMSE assesses orientation, 
memory, attention, language, planning and visuoconstruction, and can be administered in a 
time span of approximately ten minutes. It is further stated that the MMSE can estimate the 
severity of the cognitive impairment at a given point in time, making it an effective way to 
document an individual’s response to treatment. However, the ability to detect little and subtle 
changes in cognitive function is limited with this screening tool and it cannot predict future 
decline 29, 51. Further, it has been reported that the MMSE is influenced by education age 104.  
The MoCA was recently developed by Nasreddine et al. (2005) as a brief screening tool to 
detect cognitive impairments in several clinical settings and is available in multiple languages. 
Scores range from 0 to 30 with scores of 26 or higher indicating a normal test 52. The MoCA 
assesses visuo-spatial abilities by a clock drawing test, executive functioning, attention, 
memory, concentration, language and orientation. Testing time is set to an average of ten 
minutes. As it has a test–retest reliability of 0.92 and validity of 0.87 to MMSE, the MoCA 
seems to be superior to the MMSE to detect MCI. The main difference between both screening 
measures is that the MoCA also includes tasks assessing executive function and abstraction. 
Fewer points are given for orientation in time and place while extra weight is given on tasks 
including recall, attention and calculation 105. Further, it has also been stated that the MoCA is 
a superior prognostic indicator to the MMSE in patients with brain metastases 102, 106. 
As both the MMSE and MoCA take at least ten minutes to assess, the NCCN Guidelines in 
Older Adult Oncology also advise the Mini-Cog as a possible alternative cognitive screening 
tool 102. The Mini-Cog assesses visuo-spatial abilities by a clock drawing test, combined with 
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the three word delayed recall test as used in the MMSE, assessing short-term memory 53. 
Combining these two tasks would lead to psychometric properties that are comparable to those 
of the MMSE 107. While the Mini-Cog has shown good diagnostic accuracy for detecting 
dementia, it has a rather low sensitivity for detecting MCI 108, 109. The Mini-Cog can be easily 
administered by a wide range of healthcare professionals and is not influenced by the 
educational level or health literacy of the patient. In comparison with other screening tools 
proposed within the CGA, the Mini-Cog only takes two to three minutes to administer. Scores 




















Over the years, advances in the early detection of cancer and its treatment have resulted in a 
longer life expectancy in patients of all ages who are diagnosed with cancer. Although survival 
rates have increased, many patients suffer from treatment-related side effects that may 
adversely affect their health-related quality of life. Along with the changes in therapeutic 
strategies, physicians have paid more attention to the psychosocial problems secondary to 
cancer as it is well recognized that the diagnosis of cancer and its treatment are extremely 
stressful and emotional for the cancer patient 111. Whereas some of these side effects are well 
recognized, well understood and effectively managed, others are more subtle and not as clear. 
The improvements in cancer treatments have led to substantial long-term side effects such as 
fatigue, pain and cognitive alterations which are associated with an anti-cancer treatment or in 
some cases with the cancer itself 112.  
Cancer-related cognitive impairment (CRCI) was first described as chemobrain or chemofog, 
as it was a common concern among breast cancer patients receiving chemotherapy, which is 
also the most studied group with regard to this symptom 113. In paediatric patients on the 
contrary, neurocognitive adverse effects of chemotherapy and brain radiotherapy have long 
been recognized as a major concern in long-term survivors 114. Later however, it became clear 
to researchers that psychosocial elements such as distress and fatigue also play a role in the 
development of CRCI and that chemotherapy may not be the sole cause of cancer-related side 
effects 115. Nonetheless, a clear understanding of CRCI is critical, as there is a growing group 
of malignancy survivors who often want to return to their former occupational, scholastic and 
other social activities 116. Research into CRCI is rather new within the field of cancer studies 
and can still be considered as a hot topic.  
EFFECT OF CANCER TREATMENT 
Chemotherapy is a widely used treatment strategy in the management of cancer. It can be 
given in a neoadjuvant or adjuvant setting, or in a combination of both. Common side effects 
of a chemotherapeutic treatment include nausea, vomiting, anorexia, hair loss, neutropenia, 
skin rashes, peripheral neuropathy, fragile nails, impaired sexual function, early-onset induced 
menopause in women and other 117, 118. First studies into CRCI in breast cancer patients also 
found evidence that chemotherapy may disrupt the central nervous system as women 
receiving an adjuvant treatment with chemotherapy reported alterations in memory, thinking 
clearly and concentration. Further, those patients reported significantly more troubles than 
breast cancer controls who did not receive any chemotherapeutic regimen 117, 119, 120. Other 
common changes in cognitive functioning due to chemotherapy include executive functioning, 
processing speed, working memory, and organizational skills. Chemotherapy-induced 
impairment of language ability, concentration, memory and/or attention can have a detrimental 
effect on a patient’s quality of life, influencing one’s ability to use complex thinking in making 
treatment decisions 120-122. 
While initial studies were criticized by their lack of including a baseline cognitive assessment 
and their retrospective design, recent prospective research has indicated that CRCI occurs in 
a substantial number of patients. Studies in breast cancer patients have reported prevalence 
rates affecting up to 40% of patients, while other longitudinal studies in adult cancer survivors 
report that cognitive alterations are more commonly found than anticipated with incidence 
numbers ranging from 15% to 80% of patients being affected 114. The perceived cognitive 
problems can persist throughout the whole illness trajectory and in some domains, complaints 
maintain long after the treatment has ended. A recent meta-analysis by Jim et al. (2012) 
suggests that breast cancer patients can experience deficits in verbal and visuospatial ability 
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up to six months and more after the chemotherapy has ended 123. Furthermore, these problems 
may even persist 20 years post treatment 124.  
Though initial trials focused on breast cancer patients, these last years it has become clear 
that other cancer patients also experience cognitive difficulties following cancer treatment. It 
has been reported by several researchers that androgen deprivation therapy, which is used in 
case of prostate cancer, adversely affects verbal memory, visuomotor function, attention and 
executive function 125, 126. CRCI has also been found in patients with haematological 
malignancies. Treatment-related cognitive decline was noticed in terms of executive 
functioning, attention, language, memory, spatial ability and psychomotor speed 127. Cognitive 
changes have also been reported in lung cancer 128. 
Despite the large number of patients with cancer who receive a chemotherapeutic regimen, 
cognitive alterations develop and manifest itself on an individual and unpredictable basis. 
While one person may suffer from serious cognitive deficits, another may not be affected at 
all. Consequently, researchers began to pay more interest into the etiology of CRCI. While it 
is known that some cytotoxic drugs such as cisplatin and cytarabine can cross the blood-brain 
barrier (BBB) and induce neurotoxicity, others cannot cross the BBB and are therefore unable 
to cause damage to brain cells114, 129, 130. As a result, researchers began to wonder whether 
structural or functional changes to the brain could be detected after a chemotherapeutic 
treatment. The team of Deprez et al. (2011) evaluated chemotherapy-induced structural 
changes in cerebral white matter and its correlation with impaired cognitive functioning in 
breast cancer. They compared both imaging and neuropsychological test results of breast 
cancer patients who received chemotherapy compared to healthy controls. Results indicated 
that chemotherapy seems to affect the brain’s white matter integrity 131. Further, the research 
team of Deprez et al. (2013) examined changes in brain activation after chemotherapy. For 
this study, the team included cancer patients who were scheduled to receive chemotherapy, 
cancer patients who would not receive chemotherapy and healthy controls. At baseline, no 
differences in brain activation were detected. After treatment, a significant difference was found 
between the chemotherapy group who reported more cognitive complaints and showed altered 
brain activation. These results suggest that changes in brain activity may underlie 
chemotherapy-induced cognitive complaints and that the observed changes might be related 
to chemotherapy-induced damage to the brain or to reduced connectivity between brain 
regions even after controlling for effort and functional strategy 132.  Structural changes in gray 
and white matter were also found in lung cancer patients after receiving chemotherapy 128.  
These findings strongly suggest that cytostatics influence the brain’s functioning and that 
cognitive alterations can be expected after receiving chemotherapy. On the contrary, however, 
not all trials investigating the role of chemotherapy as an etiology of CRCI could detect changes 
after the treatment had ended. A recent meta-analysis by Lindner et al. (2014) reported that in 
some longitudinal studies, it was found that patients perform better after cancer treatment 133.  
PSYCHOLOGICAL AND DEMOGRAPHIC FACTORS 
As mentioned, one of the major flaws in initial studies on CRCI was that researchers did not 
include a baseline neuropsychological assessment. However, a baseline assessment is crucial 
if one wants to report the degree of cognitive loss following a cancer treatment. When including 
a baseline assessment, studies have reported high rates of CRCI prior to adjuvant 
chemotherapy, increasing problems following chemotherapy and a resolution of the findings 
to baseline levels when performing longer follow-up assessments 134. Although researchers do 
not pay a lot of attention to these pre-treatment impairments, some have tried to find a possible 
explanation as to why cognitive problems are already detected before the administration of 
any treatment.  
C H A P T E R  1 ∙ P A R T  I I I  | 43 
 
 
In 2012, it was first reported that the term ‘chemobrain’ might not be fully accurate, because 
pre-treatment-altered neural activation, coping, fatigue and psychological stress or distress 
(including worry, sadness and anxiety) can also contribute to cognitive problems 135-137. Coping, 
or the way patients deal with cancer, has been reported to negatively influence patients’ 
cognition. Further, ineffective coping mechanisms may lead to an increased perceived 
psychological stress level 137. Distress, on the other hand, can be defined as a multifactorial 
unpleasant emotional experience of psychological (cognitive, behavioural and emotional), 
social and/or spiritual nature that may interfere with the ability to cope with cancer effectively, 
its physical symptoms and its treatment. It extends along a continuum ranging from common 
normal feelings of vulnerability, sadness and fear, to problems that can become disabling such 
as depression, anxiety, panic, social isolation, and existential and spiritual crisis. Distress can 
be easily detected through the Distress Thermometer, which is a well-known tool for initial 
screening that asks the patients how much distress they perceived during the last week. It 
uses a 11-point rating scale from zero (no distress) to 10 (extreme distress) to represent the 
amount of distress experienced by the cancer patient 138. In a more detailed report by Berman 
et al. (2014), it was stated that worry appears to be a significant contributor to the patient’s 
cognitive functioning, independent of adjuvant treatment for breast cancer as they found lower 
cognitive performance and lower brain deactivation in patients with breast cancer. Their results 
suggest that alterations in cognitive function may develop before the administration of 
chemotherapy and that worry may contribute to reports of CRCI during treatment 139. Further, 
it has been found in non-cancer subjects that worry affects working memory capacity 140. A 
recent trial by Oh et al. (2016) also reported significant correlations between objective and self-
reported cognitive functioning and psychological distress 141. Another recent study by Moretta 
et al. (2017) also reported reduced executive functioning and visuospatial learning to be related 
to psychological distress in a group of non-cancer subjects 142.  
Menning et al. (2015) reported the role of fatigue in the cognitive functioning of breast cancer 
patients prior to adjuvant treatment. The researchers included patients with breast cancer 
scheduled to receive chemotherapy (C+), patients with breast cancer not scheduled (C-) for 
chemotherapy and no-cancer controls (NCs). Patients were assessed through 
neuropsychological testing, imaging with multimodal magnetic resonance imaging (MRI) and 
self-reported aspects of psychosocial functioning. Lower white matter integrity and higher 
levels of fatigue and stress were found in both C+ and C- patients when compared to NCs. 
When combining the cognitive and imaging data, it was found that symptoms of fatigue were 
associated with the observed abnormalities. These results suggest that cancer-related 
psychological or biological processes may adversely affect cognition and associated aspects 
of brain structure and function before the start of adjuvant treatment in breast cancer patients 
143. Another trial by Visovatti et al. (2016) in patients with colorectal cancer found that older 
age, less education and fatigue can lead to worse cognitive performance and increased self-
reported cognitive problems, stressing the importance of evaluating psychosocial factors when 
looking into CRCI 144. 
Lange et al. (2014) examined baseline cognitive function in elderly breast cancer patients. 
They reported that more than 40% of patients presented with cognitive deficits prior to any 
adjuvant treatment 145. The team of Ahles et al. (2010) investigated the impact of age and 
cognitive reserve in breast cancer patients receiving adjuvant treatment for breast cancer. 
Their data indicated that age and pre-treatment cognitive reserve is related to the cognitive 
decline detected post treatment 146. Mandelblatt et al. (2014), however, could not detect 
differences in cognitive function between older breast cancer patients and healthy controls 
before systemic treatment 147. Nevertheless, older patients with cancer pose a big challenge 
to health care providers as they can already present with a pre-existing cognitive impairment 
and can develop cognitive decline by the cancer diagnosis and/or its treatment.   
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ASSESSMENT/SCREENING 
When researchers began to investigate CRCI, there were no assessment guidelines. As a 
result, every research team implemented their own idea of a good neuropsychological test 
battery. Although each of those assessments can be considered as adequate for measuring 
the patients’ cognitive functioning, this does make it difficult when one research team wants to 
compare assessment results with others. Therefore, an International Cognition and Cancer 
Task Force (ICCTF) was assembled and proposed guidelines to use when investigating CRCI 
148.  
The ICCTF states that the ideal research design to examine the effect of a certain treatment is 
a double-blind placebo-controlled, prospective, longitudinal trial including both a baseline and 
follow-up assessment. However, as in most cases this will not be feasible since cognitive 
studies are observational, they advise to include an appropriate control group. They further 
recommend including tests that measure at least learning and memory, processing speed and 
executive function. If possible, an additional measure assessing working memory and 
subjective cognitive complaints can be included. Regarding the latter, it is stated that research 
has shown a stronger association between subjective cognitive complaints and mood or 
fatigue than between subjective and objective neuropsychological findings 149. 
The ICCTF also published recommended criteria to establish the frequency of CRCI. They 
state that a person can be diagnosed as having a CRCI if the person presents with two or more 
test scores at or below -1.5 standard deviations (SDs) from the normative mean or if the person 
presents with one test score at or below -2.0 SDs 148. Using these criteria could ultimately ease 
the process in comparing results with other researchers in the field.  
The ICCTF further stated that it would be beneficial to use a prespecified Reliable Change 
Index (RCI) to determine change in cognitive function. The RCI allows evaluation of meaningful 
changes in test scores following treatment interventions. The RCI addresses whether a found 
change is of sufficient magnitude to be sure that the change is not the result of a measurement 
error 148, 150. While advised by the ICCTF, only few researchers define the RCI in their trial. 
Mohile et al. (2010) examined the cognitive effects of androgen deprivation therapy in older 
patients with cancer and defined decline by use of the RCI. Results demonstrated a decline in 
executive functioning in 38% of patients while an improvement was noticed on measures of 
visuospatial abilities 150. Lange et al. (2016) evaluated cognitive decline in older cancer patients 
with early-stage breast cancer by use of the RCI. About half of patients showed an objective 
cognitive decline, mainly in terms of working memory, after adjuvant treatment 151. A reason 
why many researchers do not define cognitive decline by use of the RCI may be that the RCI 
defines decline as an absolute score reduction outside a test's standard error. So in order to 
achieve this absolute score reduction, a patients who has a substantially lower baseline score 
would need a greater percentage of decrease in the follow-up score, while it has been reported 
that even small changes can have detrimental effects 152, 153. 















Older cancer patients are a vulnerable group of individuals as they present with comorbidities 
that have naturally developed as a consequence of ageing. One of those comorbidities is age-
related hearing loss (ARHL), also referred to as presbyacusis or presbycusis. Presbyacusis is 
the most common cause of hearing loss in adults and refers to a degenerative process that 
results in a progressive bilateral hearing loss, starting in the higher frequency region 154, 155. 
ARHL is characterized by a reduction in hearing sensitivity and decreased ability to understand 
speech in noise. It also results in a slowed central processing of sound and impaired 
localization of acoustic stimuli 156, 157.  
Although its onset and rate of progression may vary widely among individuals, the prevalence 
of ARHL increases with age. A review by Roth et al. (2005) indicated that at the age of 70, 
20% of European women and 30% of European men present with a loss of at least 30 decibel 
Hearing Loss (dB HL). At the age of 80, numbers increase to 55% of men and 45% of women 
being affected 155. In the United States of America (USA), similar numbers are reported 157. In 
male individuals, the first signs of presbyacusis may already be detected around the third to 
fourth decade when the higher frequency range from 10.0 to 16.0 kHz is affected. During the 
fourth decade, damage in lower frequencies ranging from 6.0 – 8.0 kHz can be found. In 
females, ARHL starts later in life. First signs are usually noticed a decade later than in males. 
Although authors remain inconclusive, some attribute these changes to the more frequently 
occurring noise exposure in men 158. Ovarian steroid hormones and cardiovascular diseases, 
affecting inner ear blood flow, have also been reported to account for the better hearing 
thresholds in women 159. In both men and women, decreased hearing sensitivity in the most 
important region for speech ranging from 0.5 to 4.0 kHz, starts around the sixth life decade 160. 
Besides these differences in gender, it is also reported that Caucasian individuals can be more 
affected by AHRL than their African-American counterparts 161.  
Based on post-mortem histological analysis, presbyacusis can be classified into four 
categories: sensory, neural, metabolic and mechanical 162. Sensory presbyacusis accounts for 
only 5% of the total incidence of ARHL and is characterized by the loss of hair cells and 
supporting cells at the basal end of the cochlea. As it is mostly limited to the most basal end, 
it affects the higher frequency region, affecting those frequencies vital for speech perception 
163, 164. Sensory ARHL is most likely a result of excessive noise exposure during life and is not 
believed to be a consequence of ageing 165. The second type, neural presbyacusis, manifests 
itself later in life and is marked by a loss of auditory neurons. It becomes apparent for the 
individual when the number of functional neurons is less than those required for an effective 
transmission and decoding of neural patterns resulting in poor speech discrimination scores 
163. Metabolic or strial presbyacusis refers to hearing loss caused by atrophy of the stria 
vascularis leading to sensorineural hearing loss. Gacek & Schuknecht (1969) reported that this 
type of ARHL is characterized by an equal or nearly equal hearing loss across all frequencies 
with a slow progression rate and that it has only a minimal effect on speech discrimination. 
They presume it appears as a result of a biochemical deficiency of the endolymph. Animal 
studies have indicated a degeneration of the stria vascularis and decreased endolymphatic 
potential along with hearing loss in gerbil 163, 166 Further, severe degeneration of the spiral 
ligament was observed in autosomal-dominant non-syndromic hearing loss among genetic 
hearing loss 167. Others however, stated that strial presbyacusis is a result of strial atrophy and 
its associated damage to the stereocilia resulting in a hearing loss that is more pronounced in 
the higher frequency region 165. Mechanical ARHL is a slowly progressive variant that appears 
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without the interference of a disorder in the organ of Corti, auditory neurons or stria vascularis. 
The audiogram is characterized by an increasing hearing sensitivity with increasing frequency. 
Mechanical presbyacusis is thought to be caused by a deficiency in the motion mechanics of 
the cochlear partition such as a stiffened basilar membrane or atrophy of the spiral ligament 
163.  
ARHL can be influenced by both genetic and environmental factors. Studies investigating 
ARHL in humans have estimated that – depending on the population under study and the 
definition of ARHL – at least half of the variation is influenced by a genetic component 168-170. 
One of those genes is the apolipoproteine E (APOE) allele. The APOE genotype is known to 
play a role in the maintenance and repair of neuronal cell membranes and contributes to 
several age-related diseases including Alzheimer’s disease, degeneration of the macula and 
generalized atherosclerosis 171-173. Kurniawan et al. (2012) compared audiometry results of 435 
participants in relation to APOE-ε4 genotype. They have found that, even after adjusting for 
cardiovascular disease, stroke, and cognition, the APOE-ε4 allele influence the etiology of 
ARHL 174. However, a recent trial conducted by Dawes et al. (2015) could not find an 
association between APOE-ε4 and presbyacusis 168. Several single nucleotide polymorphisms 
(SNP’s) have also been identified. Dawes et al. (2015) investigated to role of the N-
Acetyltransferase 2 (NAT2) gene. The NAT2 gene codes for an enzyme that metabolizes 
carcinogens such as hydrazine an arylamine drugs. In previous literature, studies have 
reported an association of an SNP in the NAT2 gene and ARHL 175-177. Nevertheless, Dawes 
et al. (2015) could not reproduce these results in their study 168. Another SNP was found in the 
GRM7 gene. The GRM7 gene encodes the metaboprotic glutamate receptor type 7. This 
receptor is activated through L-glutamate, which is the primary excitatory neurotransmitter in 
the hair cells of the cochlea 178, 179. Newman et al. (2012) investigated the role of GRM7 in 
relation to ARHL and found that GRM7 alleles are primarily associated with peripheral 
measures of hearing loss. Further, they stated that GRM7 alleles are also associated with 
speech detection in older adults 180. Although evidence exist that some individual genetic 
factors may play a role in the etiology of ARHL, its exact impact in humans remains unclear. 
Raynor et al. (2009) reported that familial aggregation influences its development. Siblings of 
participants diagnosed with a hearing loss had a 4.7 times greater odds of having a reduced 
hearing sensitivity than siblings of individuals without a hearing loss. Further, siblings of those 
with a hearing loss were 30% more likely to have a hearing loss themselves when compared 
to the average population 181. To date, researchers believe that there are probably no major 
genes involved in the development of ARHL and that presbyacusis is more of polygenic nature. 
While some can be attributed to SNPs, it is stated that this is partly the result of the small 
effects of many causal alleles that never reach genome-wide significance 179.  
Non-genetic risk factors of ARHL have also been described extensively and can be categorized 
into either environmental or medical factors. It is not clear whether environmental factors, such 
as noise exposure, induce an accelerated ageing process in the ear or that they act on specific 
pathways 182. Wright et al. (1987) stated that they believe that ARHL is more the result of a 
sum of minor insults occurring throughout life 183. Of all the environmental factors reported, 
noise exposure is the one the most frequently examined. Noise-induced hearing loss (NIHL), 
comparable to ARHL, occurs in the high frequency region, typically first affecting frequencies 
from 3.0-6.0 kHz. It is known that excessive noise exposure can result into either mechanical 
damage in the cochlea due to noise with a high intensity, which induces a temporary threshold 
shift (TTS). A TTS occurs as the result of the buckling of the pillar bodies and uncoupling of 
the stereocilia of the outer hair cells from the tectorial membrane. While it is believed that a 
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TTS recovers, prolonged or frequent noise exposure can lead to permanent threshold shifts 
184. Asides to mechanical damage, metabolic changes, as a consequence of lower noise levels 
during a longer time span, can also lead to NIHL 185, 186. Presumably, free radicals and other 
reactive endogenous substances have an influence in the etiology of this process 182, 187-189. 
Emmerich et al. (2000) investigated the impact of industrial noise in guinea pigs and found that 
industrial noise exposure leads to severe damage of the outer hair cells. Further, it has been 
noted that noise exposed ears are more prone to develop ARHL. Kujawa et al. (2006) 
addressed this issue in an animal model and found that pathologic but sublethal changes in 
the cochlea, initiated by early noise exposure, render the inner ears significantly more 
vulnerable to aging 190. Xiong et al. (2006) compared audiometry results of two groups of men 
where one group had served in the military during the sino-Vietnamese war whereas the other 
group had no military experience. They have found that the pure-tone thresholds at 4.0, 6.0 
and 8.0 kHz of the first group were poorer than those of the men without military experience, 
concluding that impulse noise exposure accelerates ARHL 191. As it is known that noise 
influences hearing thresholds, the International Organization for Standardization (ISO) 
published reference values regarding the estimation of noise-induced hearing loss (ISO 1999) 
in older subjects 192. The formula suggested by ISO 1999 states that the total amount of hearing 
loss is the sum of the age-related hearing loss and noise induced PTS, minus a compression 
factor that is used when the threshold shifts exceeds 20-25 dB 193. Based on the above 
findings, one would believe that noise exposure accelerates ARHL. Gates et al. (2000) 
however, examined noise-notches in elderly men. They found a reduced progress of hearing 
loss over time at 3.0, 4.0 and 6.0 kHz and an accelerated hearing loss in frequency areas 
adjacent to noise damaged frequencies, especially for 2.0 kHz. These findings suggest that 
there is less threshold deterioration in a noise-damaged ear in the NIHL frequency region (3.0-
6.0 kHz) than in a non-damaged ear, while thresholds increase in adjacent frequencies 194. 
Another environmental factor, more frequently investigated in younger individuals than in older 
adults, is ototoxic medication 182. Aminoglycosides and drugs containing platinum are the most 
frequently reported medications that induces ototoxicity. Aminoglycoside drugs damage the 
outer hair cells in a similar way as noise, causing non-reversible hearing loss in the higher 
frequencies. Further, aminoglycosides seem to potentiate the effect of noise exposure and 
vice versa 195. Ototoxicity from platinum compounds, such as cisplatin and carboplatin, also 
occurs in the higher frequency region 196. The cisplatin-induced cochlear toxicity is the result 
of the production of reactive oxygen species (ROS). Cisplatin-induced hearing loss is dose-
dependent and occurs mainly in the high-frequency region. It occurs in about 10–25% of adults 
receiving the drug, 50% of individuals receiving high doses (>400 mg/m2 cumulative dose) 
and 41–61% of children 197. Pre-treatment hearing loss (≥ grade 2) has been proposed as a 
relative contraindication and predictive factor to define a patients’ eligibility for treatment with 
cisplatin 198, 199. In addition, cumulative cisplatin dose, cumulative radiation therapy dose and 
young age were identified as risk factors for increased sensorineural hearing loss due to 
cisplatin based treatment. However, the pre-treatment hearing threshold at frequencies vital 
for speech perception proved to be the only independent predictive risk factor for post-
treatment hearing capability which means that the more unfavourable the hearing level prior 
to therapy, the more unfavourable the hearing capability will be after cisplatin-based 
chemotherapy 200.  
Environmental influences are not the only non-genetic factors that accelerate the process of 
ARHL. Several other mediators such as alcohol and tobacco use and some medical risk factors 
have been described. In literature, there is no consensus whether alcohol and tobacco use 
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influence ARHL. It seems that these factors could accelerate ARHL, however, other factors 
may play a more crucial role 201-203. A highly reported medical condition possibly influencing 
ARHL are cardiovascular diseases 182. It is known that older individuals are more prone to 
develop some form of cardiovascular disease (CVD) 204. Although some trials did not detect 
an association between CVD and ARHL, there is reason to believe that CVD accelerates ARHL 
given its rich capillary supply to the stria vascularis and its sensitivity to disruptions in the 
arterial blood supply 205. Park et al. (2007) found an association between the presence of 
hearing loss in older adults and low HDL cholesterol levels 206. Gates et al. (1993) also reported 
an association between CVD and a predominantly low frequency hearing loss 207. Helzner et 
al. (2011) concluded that certain CVD risk factors such as a higher body mass index (BMI) in 
women and a faster resting heart rate in both males and females are associated with elevated 
hearing thresholds 205. Dietary influences, such as type 2 diabetes - often as a result of a high 
BMI, have also been published as a risk factor for ARHL 208, 209.  
AGE-RELATED HEARING LOSS AND QUALITY OF LIFE 
Presbyacusis is known to have a serious impact on the patients’ daily life. It does not only 
affect their physical, cognitive and emotional activities, but it also influences patients' social 
functioning. As patients lose their hearing, they feel left out as they have difficulties 
communicating with others. Even without hearing loss, it has been reported that listening effort 
increases with age 210. As a result, their quality of life deteriorates with various symptoms such 
as depression, social isolation and lowered self-esteem 211. Further, ARHL is also associated 
with a future loss of functional abilities and functional dependence 212. However, despites its 
prevalence and morbidity, presbyacusis is often left unrecognised and untreated. It is reported 
that only 25% of patients who have a hearing loss great enough to be aided with hearing aids, 
actually receive proper rehabilitation 213. On the contrary, many people who own hearing aids 
do not use them on a regular basis and even when they are wearing them, some still have 
socially disabling levels of hearing loss 214. There are multiple reasons why patients are 
somewhat reluctant towards amplification. The process of accepting the need of hearing aids, 
selecting, trying and purchasing them and using them afterwards is challenging for many 
patients. The most common barrier however, is the dissatisfaction with its performance 215. 
Patients often believe that wearing hearing aids can be compared to wearing glasses. Once 
you put them on, you hear as you heard before. During the adaptation process, they often feel 
discouraged as the device does not exactly performs as they had hoped. Conversations in 
noisy environments remain difficult and are often unpleasant due to the excessive noise. As a 
result, the hearing aids disappear in their closets and are almost never used 216, 217. 
Despite these difficulties, in cancer patients, who already have a lower quality of life, 
optimization of such condition is crucial. Therefore, the NCCN guidelines in Older Adult 
Oncology recommend an assessment of sensory functions such as vision and hearing 131 as 
part of a CGA. Within the CGA, it is not the main objective to diagnose patients as having a 
significant hearing loss and to refer them to a hearing aid specialist. The purpose is merely to 
select those patients who show signs of decreased hearing sensitivity so that proper measures 
can be taken. One of those measures can include a referral to the otolaryngologist for a full 
examination or a referral to a hearing aid specialist. Others can include taking notes, a more 
pronounced articulation, etc.  




Pure-tone audiometry is known as the gold standard to assess hearing loss since its 
introduction as a clinical tool more than seventy years ago. A necessary requirement for 
optimal testing is a controlled test environment with ambient noise levels as close to 0 dB 
sound pressure level (SPL) (ISO 8253) 218. In that way, it is prevented that environmental noise 
masks hearing thresholds at this level 219. Therefore, pure-tone testing is usually performed in 
a sound-isolated room or sound booth. Both the American Speech-Language-Hearing 
Association (ASHA) and the British Society of Audiology (BSA) have published similar 
guidelines on how to perform pure-tone audiometry 220, 221. The ASHA distinguishes three types 
of pure-tone threshold audiometry: manual or conventional audiometry, automatic or Békésy 
audiometry and computerized audiometry. Diagnostic standard pure-tone threshold 
audiometry usually includes manual air-conduction measurements at the conventional octave 
frequencies including 0.25, 0.5, 1.0, 2.0, 4.0 and 8.0 kHz. Bone conduction threshold may be 
established in order to provide the type of hearing loss (sensorineural, conductive or mixed). 
High frequency audiometry, including frequencies from 9.0 to 16.0 kHz, may be performed in 
some cases including ototoxicity monitoring and noise-induced hearing loss 220, 222, 223. 
Thresholds are usually established by the Hughson-Westlake technique using a simple 10 dB 
down and 5 dB up approach 224. Based on the results of the pure-tone threshold audiometry, 
the physician can give an overview of the patient’s hearing degree, calculated as the pure-tone 
average or PTA. The PTA is calculated as the average air-conduction threshold found at 0.5, 
1.0 and 2.0 kHz. The ASHA distinguishes seven degrees of hearing loss ranging from normal 
hearing with PTA from -10 to 15 dB, to a profound hearing loss when a PTA of more than 90 
dB is found 225. A downside on using the ASHA-regulations for calculating the PTA is that it 
does not include those frequencies that are most affected by ARHL. Including 4.0 kHz could 
in part solve this issue. Further, though pure tone audiometry is considered as the gold 
standard to asses a person’s hearing, it is less suited to implement within the CGA as it requires 
a transfer to the audiology department and may be cumbersome for patients who are 
bedridden or who have a limited mobility due to their intravenous infusion. 
Another method to define the patient’s hearing is by use of a speech-in-noise (SPIN) test as 
these give more accurate results in terms of speech intelligibility. SPIN tests give an idea of 
the patient’s ability to understand meaningful sentences in noisy situations and provide 
valuable information as listeners find themselves surrounded by background noise multiple 
times a day. Although commonly used to assess the patient’s speech intelligibility, there are 
up to today no Dutch eHealth applications available that include SPIN tests and can therefore 
not be used as a screening method within the CGA 226, 227.  
Other measures, such as oto-acoustic emissions (OAEs), could also be used to evaluate the 
patient’s hearing. OAEs are an objective and fast measure to establish the function of the outer 
hair cells within the cochlea. It is widely used as a neonatal screening method and to establish 
an audiological diagnosis. When conducting the test, brief acoustic stimuli are produced into 
the external ear canal. As a result, OAEs can be measured, which are low-volume sounds that 
originate from the cochlea 228. OAEs can be divided into transient-evoked (TEOAE) and 
distortion-product (DPOAE) OAEs, based on the type of stimuli that is presented to the patient. 
TEOAEs are measured within the 0.5 to 4.0 kHz frequency range and use a brief pure tone 
stimulus while DPOAEs include frequencies up to 8.0 kHz and uses two pure tones that are 
produced simultaneously 229, 230. Although it is known that the amplitude of OAEs decreases 
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with increasing age and increasing hearing thresholds, OAEs are not optimal to use within the 
CGA as the test is highly influenced by environmental noise 231, 232.  
The NCCN Guidelines in Older Adult Oncology recommend using a quick and simple screening 
tool. The test is performed by whispering the sentence “What is your name?” while standing 
behind the patient and occluding one ear. The patient fails if he does not hear the sentence. 
The test is repeated for the contralateral ear 131, 233. Free-field voice testing was one of the 
easiest methods to get an idea of someone’s hearing and was used as the standard method 
before clinical audiometers became available in the 1940s. The test proposed by the NCCN is 
not validated and therefore several issues arise. Nonetheless, several researchers have 
published reliable forms of whispered voice testing 234-236. All of the proposed tests use more 
or less the same methodology. The examiner has to stand behind the patient in order to 
remove the ability of speechreading. In addition, the non-tested ear has to be excluded to rule 
out interference. The easiest way to mask the non-tested ear is to gently occlude the external 
auditory canal with a finger while rubbing it in a circular manner. Whispering is done after the 
examiner exhaled completely. This set up is similar in all types of whispered voice tests. The 
distance between the patient and the examiner, and the words expressed to the patient may 
differ. Swan et al. (1985) described a whispered voice test (WVT) to identify those individuals 
who may benefit from management of their hearing loss. In their test, the patient needed to 
repeat a combination of three numerals and letters. A new combination was expressed when 
the patient repeated an incorrect combination or if he or she did not repeat anything at all. The 
researcher did not mention the distance between the patient and the examiner 234. Macphee 
et al. (1985) investigated whether the WVT could be implemented for use in a group of patients 
admitted to a geriatric unit. They performed the test in multiple conditions: conversational voice 
at 6 inches and at 2 feet from the ear, and whispered voice at 6 inches and at 2 feet from the 
ear. Results indicated that using a whispered voice at 2 feet was the most discriminant test 
with a sensitivity of 100% and specificity of 84% 235. Eekhof et al. (1996) compared the WVT 
to other screening measures. The first was the Pat-225, which is a handheld device that 
produces mixed noise with frequencies ranging from 0.5 kHz to 4.0 kHz at 30 dB HL. The 
second was the Audioscope-3, an otoscope with a built-in screening audiometer that produces 
pure tones at 0.5 kHz, 1.0 kHz, 2.0 kHz and 4.0 kHz. Eekhof and his colleagues considered 
an inability of hearing tones at 40 dB HL as having a hearing loss of 40 dB or greater. The last 
instrument was a screening audiometer called the Micromate-304, which could only generate 
tones at 2.0 and 4.0 kHz at 40 dB HL. Patients passed the test if they could hear both tones.  
Results indicated  that the WVT was the best tool to use. Although the WVT showed promising 
results, they were the first to report that they had found a broad variation between outcomes 
of several examiners 236. The problem with the WVT is that the words are pronounced live and 
are not pre-recorded. Therefore, it is difficult to standardise the technique, to control the pitch 
of the whisper and to control the background noise. Further, different acoustic environments 
may also play a role in the outcome of the test 236-238. A recent trial investigated the effect of 
experience on the sensitivity and specificity of the WVT. They have found that the sound 
intensity of the whispered voice of experienced examiners is 8 to 10 dB higher than the whisper 
of an examiner without experience. They state that this problem can be addressed by training 
through voice measurement in order to ensure an nearly equal loud intensity of the whispers 
239.  
As the WVT has many problems when accounting for the interrater-reliability, researchers have 
examined other, more objective measures to screen for hearing loss. A popular objective tool 
is the Audioscope (Welch Allyn Medical Products, Skaneateles Falls, NY) 240. The Audioscope 
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is a handheld otoscope that is able to generate a set of pure tones at 0.5, 1.0, 2.0 and 4.0 kHz 
with an intensity of either 25 or 40 dB HL. It also enables an inspection of the tympanic 
membrane and auditory canal. The examiner needs to hold the Audioscope directly into the 
external auditory canal. A probe tip on the device occludes the canal. The listener is asked to 
indicate whether the given tone is heard. For screening purposes, a pass is given when the 
patient hears the pure-tone at 40 dB. Although the Audioscope has an excellent diagnostic 
accuracy, the device provided by Welch Allyn is rather expensive as it may cost up to €600 213, 
241-243. 
Since its development in 1982 by Ventry and Weinstein, the Hearing Handicap Inventory for 
the Elderly (HHIE) has gained a lot of interest in terms of screening for hearing loss in an older 
population 244. The HHIE is a self-assessment tool containing 25 items on emotional and 
situational problems that are associated with hearing loss. The HHIE guides in determining the 
need for rehabilitation and assists in the planning and implementation of an aural rehabilitation 
program. Weinstein et al. (1986) reported that the test-retest reliability for the questionnaire 
was high for both face-to-face as well as for paper-and-pencil administration 245. Ventry & 
Weinstein published a shortened version of their self-administering questionnaire including 10 
items 246. Per question, a score of maximum four is given leading to a total of 40 points. Final 
scores of at least 26 indicate an 84% probability of having a hearing impairment and moderate 
to severe handicap 243, 247. Lichtenstein et al. (1988) examined the diagnostic performed of the 
HHIE-Screening version (HHIE-S) against different definitions of hearing loss. Sensitivity 
ranged from 53% to 72%, whereas specificity reached a maximum of 84%. They concluded 
that the HHIE-S was a robust and valid test for identifying older individuals with a hearing 
impairment, irrespective of the definition used to define the patient’s hearing status 248. Over 
the years, the HHIE-S has gained interest and has been translated and subsequently validated 
in several languages 249-251. The HHIE-S is easy and straightforward. However, it should be 
noted that it measures functional and not physical hearing loss, therefore resulting in poor 
sensitivity results 213.  
In our developing world, eHealth applications are gaining more and more interest. Using 
information and communication in healthcare, can result in improved healthcare access and 
improved quality of service delivery 252. In a systematic review by Swanepoel et al. (2010), 
several eHealth applications in audiology are described 253. The most interesting tools, 
however, are those developed for use on mobile phones running on Android, iOS or other 
operating systems (OS), since mobile phones are small and can easily be carried around. 
EarTrumpet and uHear™ both run on iOS devices such as an iPod, iPad or iPhone. 
EarTrumpet (PraxisBiosciences, Irvine, California) was released in the iTunes Store in 2010 
and is calibrated with standard Apple earbuds. The test is performed according to the 
Hughson-Westlake technique and allows basic (0.5, 1.0, 4.0 and 8.0 kHz), comprehensive 
(0.25 - 8.0 kHz) or custom testing. Test tones are pulsating with a 0.8 seconds duration while 
the silence interval varies between one and two seconds. Masking is done automatically when 
a difference of at least 35 dB is found between both ears. In a quiet room, 94% (95% 
confidence interval (CI): 87-100%) of the thresholds detected with EarTrumpet were within 10 
dB of the pure-tone threshold obtained through conventional audiometry 254. Derin et al. (2016) 
confirmed that Eartrumpet gives reliable results 255. Kam et al. (2012) developed a 
computerized self-administered hearing test that can be used on iOS devices. An iPhone 3GS 
with iOS4 software and standard iPhone earbuds were used. Although the application seemed 
promising, it is not freely available in the iTunes Store 256. uHear™ on the other hand, is a 
freely available iOS-based application that is more frequently examined by several 
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independent researchers in the field. uHear™ was developed by Unitron (Kitchener, Ontario, 
Canada) by Don Hayes, the director of the audiology department. It offers three tests: (1) a 
hearing sensitivity test that takes approximately five minutes to administer, (2) a one-minute 
speech-in-noise test and (3) a 12-item questionnaire in order to create a hearing profile. Of all 
the available tests, the hearing sensitivity test is most examined. Pure-tone air conduction 
thresholds at 0.25, 0.5, 1.0, 2.0, 4.0 and 6.0 kHz are established. Results are presented in a 
graphic display 257-260. Szudek et al. (2012) were the first to report on the diagnostic 
performance of the tool. They evaluated 100 adult subjects and compared the results of the 
uHear™ app to conventional audiometry based on the PTA. With a sensitivity of 98% and a 
specificity of 82%, they concluded that uHear™ could be used as a screening to rule out 
moderate hearing loss 257. Khoza-Shangase et al. (2013) determined the accuracy of uHear™ 
in young children with a mean age of 9.0 years old. They stated that the screening tool was 
not as accurate as conventional audiometry in determining pure-tone thresholds in school-
aged children. They attributed the differences between both test to the ambient noise levels 
that were present during uHear™ testing and the lack of calibration of the tool 258. Peer et al. 
(2015) tested 50 ears in three environments: a waiting room, a quiet room and a soundproof 
room. Sensitivity was excellent (100%) in all conditions. Specificity differed and was 88% in 
the soundproof room, 73% in the quiet room and 68% in the waiting room 259. The most recently 
published trial on the performance of uHear™ was conducted by Abu-Ghanem et al. (2016) in 
older patients. They included 26 subjects with a mean age of 84.4±6.7 years and detected a 
sensitivity of 100% and specificity of 60% compared to conventional audiometry. They also 
evaluated the hearing questionnaire included in the app, however, results were less accurate 
than those of the hearing sensitivity test 260. Swanepoel et al. (2014) developed the 
hearScreen™ application on an inexpensive Android OS cell phone. The application was 
validated in a group of schoolchildren. The idea behind the screening is somewhat similar to 
that of the Audioscope. The children hear a specific frequency (1.0, 2.0 or 4.0 kHz) at an 
intensity level of 25 dB HL. A pass or fail score is given. HearScreen™ showed similar results 
to those of screening with conventional audiometry 261. Wenjin et al. (2014) evaluated the 
Smart Hearing app in schoolchildren. Smart Hearing runs on Android OS and is able to deliver 
pure tones (1.0, 2.0 and 4.0 kHz) at an intensity level ranging from 20 dB HL to 60 dB HL. The 
pass or fail screening cut-off was set at >30 dB HL.  Results indicated a low sensitivity of 37.5% 
and a high specificity of 92.6%. They concluded that further improvements of the app needed 
to be undertaken in order to improve the sensitivity of the test 262. Na et al. (2014) developed 
a screening tool that runs on Android software. Although their test is not yet available for public 
use, it showed some promising results. The researchers used the built-in microphone of the 
smartphone to measure the surrounding environmental noise. As a result, the known threshold 
shift was much lower than it is in other mobile hearing screening apps 263. Other apps, such as 
Hearing Test for Android users, have also been described. However, no accuracy results have 
been published 264. 
THE RELATION BETWEEN HEARING LOSS AND COGNITION 
Though not within the scope of this thesis, it is interesting to briefly discuss the interaction 
between hearing and cognition as it has been shown that persons with impaired hearing score 
worse on psychological tests examining working memory and selective attention 265, 266. 
Further, verbal tests were more impaired than non-verbal assessments 267. Communication is 
a process that involves more than solely the peripheral auditory functions. Once a sound 
reaches the concha and is transferred through the external ear canal to the auditory nerve and 
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further on, multiple cognitive processes including selectively attending sound sources, storing 
information in memory, using context information to improve understanding, resolving 
ambiguities and generating appropriate responses, are set in motion 268. Consequently, 
researchers started to realise that a reduced hearing may negatively affect cognition and that 
it may not only influence cognition at a certain time but that it also may enhance cognitive 
decline. Lin et al. (2012) for example, examined older subjects at baseline and annually over 
a six-year period. They reported that older patients with impaired hearing showed poorer test 
scores on a modified MMSE and in terms of executive functioning compared to patients with 
no hearing deficit. Further, impaired hearing led to a greater decline in test scores over the 
years. It should also be noted that impaired cognitive functioning may lead to 
miscommunication and could therefore result in poorer hearing test scores. Objective testing, 
such as OAEs, may offer a solution in these persons 269.  
Another frequent studied variable regarding the interaction between hearing loss and cognition 
is listening effort. Listening effort can be described as the energy patients have to put into 
understanding speech. For persons experiencing hearing loss, listening is often reported to be 
exhausting. As a logical consequence, they may complain of fatigue caused by the greater 
amount of concentration that is required to understand speech in everyday listening 
environments 270. Commonly used measures to report listening effort include self-reported 
measures, single- and multi-task paradigms and clinical measures such as imaging and 
pupillometry 271. While examining the patient’s hearing status through the listening effort offers 
useful information, it is less suited as a screening tool for use within the CGA as it does not 
provide results on what patients can hear but rather on the amount of work the patient has to 
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Based on the findings of the introduction, it can be noted that there is a need to validate 
screening tools that can detect cognitive dysfunctions and hearing loss in cancer patients, as 
both may impact adequate treatment selection. For both cognitive and hearing disorders, 
screening tools have been developed. However, they have not been validated in the target 
population. Therefore, the aim of this thesis is to explore screening measures to examine 
screening tools to detect cognitive dysfunctions in both young and older cancer subjects to 
detect hearing loss in older cancer patients. An overview of the main research questions are 
presented in Table 1. 
In older cancer patients, not being able to understand what physicians and other health care 
workers are saying, can seriously affect the patients’ quality of life. In line with the NCCN 
Guidelines in Older Adult Oncology, many hospitals in Belgium have started to implement a 
comprehensive geriatric assessment (CGA) in which multiple health domains are evaluated. 
The CGA has been a cornerstone in the management of older cancer patients for many years 
and gives physicians a clear understanding of the patient’s abilities in order to select the most 
optimal treatment plan. The most frequent used tool to assess cognitive functioning within the 
CGA is the well-known and widely validated Mini Mental State Examination (MMSE). It is 
considered the gold standard within the CGA in most institutions in Belgium and is therefore 
selected for use within this thesis. Although the MMSE has multiple benefits, it takes rather 
long to assess in an already exhausting list of screening tools that are assessed within the 
CGA. Further, as the majority of older cancer patients have a good cognition, it is not that well 
accepted. The more rapid Clock Drawing Test (CDT), developed by Dr. Barbara Freund, has 
recently been proposed as a quick and easy screening tool and could be more optimal for use 
within this population 272. It was selected above other measures such as the MoCA, as it 
reduces total CGA assessment time while still providing sufficient information. However, a fast 
and simple scoring system was lacking. Further, while the scoring system of Dr. Freund had 
been reported as easy and straightforward, cut-off scores for use in a geriatric oncology 
population are not provided. Therefore, in Chapter 3, Part I, a cut-off score for the Clock 
Drawing Test, when using the Freund scoring system as part of the CGA is determined. In Part 
II, this retrospectively determined cut-off score is validated in a new set of subjects.  
Though the CGA assesses existing age-associated cognitive functioning, both young and older 
cancer patients can develop cancer-related cognitive impairments (CRCI). However, the exact 
pathophysiology remains unclear. Chapter 4, Part I, addresses this issue and evaluates if there 
are variables that can be attributed to baseline CRCI as CRCI has been reported to occur even 
before the treatment has started. Further, while CRCI was first ascribed as a result of the 
chemotherapy treatment, resulting in a term coined chemobrain; recent findings suggest that 
other conditions, such as psychological factors, may cause CRCI, as problems may already 
be present upon the first presentation with the medical or radiation oncologist. While the way 
a patient copes with cancer may be one the most prominent psychological variables, distress 
– which is a result of coping, can be easily assessed by the NCCN’s developed Distress 
Thermometer (DT). Therefore, Chapter 4, Part II, examines whether the DT can be used to 
predict long-term CRCI.    
In case of hearing in older cancer patients, the NCCN proposes a screening measure that uses 
a whispered voice. Though this test did not seem to be validated, it has several similarities to 
the Whispered Voice Test (WVT). The WVT uses a whispered voice and has shown good 
sensitivity and specificity results, but problems arise when accounting the interrater variability, 
caused by the difference in loudness of the examiners’ voices. With the upcoming mobile 
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health systems, using smartphone or tablets could be an interesting way of screening the 
patient’s hearing in a hospital room. Although several applications have been developed, most 
validation studies did not include older subjects; therefore limiting the use of those within the 
CGA. The uHear™ application, originally designed by Don Hayes, runs on iOS devices and 
shows promising results in youngsters and in older adults. Data in a large subset of older 
cancer subjects, however, is lacking and the application itself does not give the person a pass 
or fail result. Further, uHear™ was chosen above other screening tools given its accessibility 
and use in multiple clinical trials. Chapter 5, Part I, examines whether uHear™ can be used 
within the CGA when using a cut-off score based on the PTA or if the scoring method needs 
to be adjusted. The latter is addressed in Chapter 5, Part II.    
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Table 1. Overview of the chapters, research papers and main research questions  
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We aimed to determine an optimal cut-off score for the Clock Drawing Test (CDT), scored by 
the scale of Freund, for efficient screening for cognitive impairment in older (cancer) patients 
within a Comprehensive Geriatric Assessment (CGA) and to compare the Freund CDT to the 
Mini-Cog. 
METHODS 
Data of 221 older (≥ 70 years) patients, comprising of an OncoGeriatric (OG) and General 
Geriatric (GG) group, were retrospectively reviewed. All patients were evaluated with both the 
CDT and Mini Mental State Examination (MMSE) as the gold standard. Receiver Operating 
Characteristics (ROC) analysis was used to determine diagnostic performance. A pre-
established algorithm was applied to retrieve Mini-Cog results through a combination of the 
CDT and the 3-word delayed recall (3-WDR) test (included within MMSE).  
RESULTS 
Data of 105 OG and 116 GG patients were evaluated. Potential cognitive impairment (MMSE 
≤ 23) was detected in 29.5% and 65.8% of patients, respectively. The CDT showed good 
diagnostic accuracy in the OG (0.88±0.03) and GG (0.85±0.03) group, based on the Area 
Under the ROC Curve (AUC ± SE). CDT (cut-off ≤ 4) provided good sensitivity (80.7%) and 
specificity (81.1%) in the OG group and excellent sensitivity (89.6%) and moderate specificity 
(51.3%) in the GG group. Addition of the 3-WDR test, to form the Mini-Cog, resulted in similar 
positive and negative predictive values for the OG group and higher negative predictive value 
for the GG group. 
CONCLUSION 
These data suggest that the Freund CDT, at the cut-off score of ≤ 4, is promising for use within 









Older persons have an eleven times greater risk of developing cancer than their younger 
counterparts. Up to two-thirds of persons affected by cancer are aged ≥ 65 years. A 
Comprehensive Geriatric Assessment (CGA) is one of the procedures designed to improve 
the health-related outcome of this population, and its use has in recent years been suggested 
as a key component in the treatment approach of older patients with cancer 273, 274. A CGA is 
a multidimensional evaluation in which problems in different health domains are uncovered 
and a coordinated individualised treatment plan is developed 275.  
Cognitive status is one of the domains that is examined within a CGA. Some studies have 
demonstrated that up to 50% of older patients with cancer have cognitive abnormalities that 
warrant further evaluation. Cognitive function influences the diagnosis and treatment of older 
adults with cancer 276. It determines if patients have the decisional capacity to consent to a 
proposed therapeutic plan and reflects if patients are predisposed to delirium and are at high 
risk for concomitant depression. Because effective measures exist to reduce complications 
associated with impaired cognitive function in patients undergoing intensive treatment, careful 
attention should be paid to identify patients at risk 277, 278. 
The Folstein Mini Mental State Examination (MMSE) is a validated cognitive screening 
instrument, which is widely used in an older population and often included within a CGA. It is 
designed to detect moderate to severe dementia, yet it has shown to lack sensitivity to detect 
mild cognitive impairment (MCI) 279. Moreover, even though it is not a comprehensive 
diagnostic test, it is rather time consuming. 280, 281. Recently, the Clock Drawing Test (CDT) has 
been proposed as a more acceptable and time-efficient cognitive screening instrument 282-284. 
In addition, it has been combined with the 3-word delayed recall (3-WDR) test, a crucial 
element within MMSE, to form the Mini-Cog, which was proven to have comparable 
psychometric properties to the MMSE 285, 286. The reliability and validity of the CDT has been 
extensively reported 287-290, but the majority of these studies were based on relatively small 
sample sizes, focusing solely on a general geriatric population 283. Additionally, over the past 
two decades, more than a dozen scoring systems for the CDT have been developed, but no 
international consensus has been reached 291. Moreover, validated cut-off scores for use in 
different patient populations are still lacking, significantly limiting the utility of CDT in clinical 
and research settings 292. The recently developed Freund scoring system has been reported 
in literature as a fast screening tool, and is easy and trustworthy to score as demonstrated by 
its high interrater reliability 272. 
This study was initiated to determine if the CDT can be used as a screening tool for cognitive 
impairment in an oncogeriatric population within a CGA, if the Freund scoring system is a 
reliable method to score the CDT in both a geriatric and oncogeriatric population, to determine 
the most optimal cut-off scores for use in these populations, and to establish the added value 
of the 3-WDR test to the Freund CDT, that are combined to form the Mini-Cog. 
METHODS 
Patient selection 
We retrospectively reviewed the case records of 221 patients, aged 70 and older, referred to 
the Oncology or Geriatric Departments at the General Hospital Groeninge or Ghent University 
Hospital, between January 2011 and January 2012, and whose data were registered within 
the scope of two observational trials or as part of routine clinical care, respectively. The 
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population comprises two different patient groups. The OncoGeriatric (OG) group consists of 
105 community-dwelling older patients, newly diagnosed with a solid tumour or a 
haematological malignancy. All patients were assessed with a full Comprehensive Geriatric 
Assessment (CGA) prior to therapy start and were treated with palliative or curative intent. 
Eighty-three percent of patients were obtained from the PROGERCAN-trial, an observational 
study registering clinical data from older general oncology patients. In this patient group, a   
CGA is conducted upon positive screening with the Vulnerable Elders Survey-13 (VES-13) or 
G8, or upon specific request by the treating physician 293. The remaining seventeen percent of 
OG patients were included from the OMGIANT-trial, an observational study recruiting head 
and neck cancer patients undergoing radiotherapy with curative intent, with or without systemic 
treatment. In this trial, all patients underwent a full CGA 294. Both studies were approved by the 
institutional review boards. 
The General Geriatric (GG) group consists of 116 hospitalised geriatric patients without a 
known cancer diagnosis, who had been referred to the General Hospital Groeninge by general 
practitioners or family members because of symptoms of functional decline. All patients 
(community-dwelling elderly, institutionalized patients, and elderly admitted to nursing homes 
at discharge from the hospital) had received a cognitive evaluation, comprising of both the Mini 
Mental State Examination (MMSE) and Clock Drawing Test (CDT), at the time of admission. 
Cognitive Measures  
All patients were evaluated with both the CDT and MMSE, as the gold standard, by an 
occupational therapist, a clinical psychologist or a research associate, depending on the 
department of presentation. The latter two had received a training from the occupational 
therapist, enabling them to conduct and score the MMSE, according to standardized guidelines 
280, 295. Patients scoring 23 or less on the MMSE were defined as potentially cognitively 
impaired 280. Assessment of this screening tool took approximately 10 to 15 minutes. 
For assessment of the CDT, patients were given a pre-drawn circle (10 cm in diameter) and 
were verbally instructed to place all the numbers in the correct position on the clock. 
Consequently, patients were requested to place the hands at ten past eleven, which has been 
reported in the literature to be the most sensitive place for detecting neurocognitive dysfunction 
272. Patients were allowed to self-correct, however, no clues were given. All clock drawings 
were scored by the method of Freund, using a 7-point scoring scale, with 0 and 7 indicating 
potentially poor and excellent cognitive status, respectively. The scoring system is divided into 
three categories, namely the ability to correctly reproduce all numbers, to position them 
accurately in the clock and to appropriately replicate the hands at a predefined time (Figure 1, 
Table 1) 272. Although no administration times were recorded, all raters agreed that this test 
never took longer than 5 minutes to complete. The scoring was done by the assessor who 
conducted the test, and afterwards independently by another investigator, to examine interrater 
reliability.  
Freund Mini-Cog results were obtained by combining the three-word delayed recall (3-WDR) 
test performance with the individual CDT results, using an adapted version of the pre-
established algorithm, developed by Borson et al. (Figure 2) 53. Individual 3-WDR test 
performance was obtained by scoring the simple three-item delayed memory task within the 
corresponding MMSE evaluation.   




Figure 1. Examples of the Clock Drawing Test 
Table 1: Freund scoring system for the Clock Drawing Test272 
Statistical analyses 
Descriptive statistics were performed to present patient characteristics, CDT, Mini-Cog, and 
MMSE results. Mann-Whitney U tests and a Pearson Chi-square test were performed to 
examine potential statistical differences in cognitive status (scored by CDT, MMSE, and Mini-
Cog, respectively) between patients in both groups. Potential differences in respectively age 
and gender between (OncoGeriatric versus General Geriatric) and within (based on CDT, 
MMSE, and Mini-Cog performance) both groups were determined with unpaired t-tests and 
Pearson Chi-square tests. For oncogeriatric patients, Pearson Chi-square statistics were 
applied to examine potential statistical differences in screening scores between patients with 
respectively early and advanced disease and curative and palliative treatment intent. A Kappa 
score was calculated for both groups to determine interrater reliability for CDT. Receiver 
Operating Characteristic (ROC) curves were drawn for each group to evaluate the 
discriminatory accuracy of the screening tool, in determining the presence of cognitive 
impairment compared with MMSE, as the gold standard. Sensitivity (S) and specificity (Sp) 
with 95% confidence intervals (95% CI) of the CDT were calculated at different cut-off scores, 
with reference to the gold standard. The optimal cut-off score, enabling highest S and Sp, 
which could be used for the CDT, was determined for both populations under study.  S and Sp 
of the dichotomous Mini-Cog were calculated, based on the applied algorithm (Figure 2), 
enabling comparison of these results with the CDT results. Positive (PPV) and negative 
predictive values (NPV) were also determined. Subsequently, odds-ratios were calculated for 
both screening tools. All analyses were conducted using Prism® software (GraphPad Prism 5, 
Inc., La Jolla, CA) and IBM SPSS v.19 (SPSS Inc., Chicago, USA).  
Time (0-3) - One hand points 2 (or symbol representative of 2) 
- Exactly two hands 
- Absence of intrusive marks, e.g., writing or hands indicating incorrect 
   time, hand points to number 10, tic marks, time written in text 
Numbers (0-2) - Numbers are inside the clock circle 
- All numbers 1-12 are present, no duplicates or omissions 
Spacing (0-2) - Numbers spaced equally or nearly equally from each other 
- Numbers spaced equally or nearly equally from the edge of the circle 
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3-Word Delayed Recall test 
(3-WDR within MMSE)











Figure 2. Applied algorithm, adapted from Borson et al. 53 to derive Mini-Cog scores from a 
combination of the 3-Word Delayed Recall (3-WDR) test within MMSE and the Freund CDT 
score. White, dotted, and grey colour codes relate to normal, potentially impaired, and 
impaired cognitive status, respectively. 
RESULTS 
Patient characteristics 
Medical records of 221 older patients (40.3% men), with a mean age of 81.2 years (range: 70-
96), were reviewed. The OncoGeriatric (OG) group consisted of 105 patients (mean age 78.3 
years, range: 70-91). Patients presented with following tumours: head and neck (19.0%), 
gynaecological (18.1%), urological (15.2%), breast (13.3%), haematological (12.4%), digestive 
system (9.5%), lung (5.7%), melanoma (2.9%), other (1.9%) and unknown primary (1.9%). 
Half of patients were treated with curative intent (50.5%) (Table 2). Potential cognitive deficits 
were identified in 29.5% of patients, scoring 23 or less on the Mini Mental State Examination 
(MMSE). Median Clock Drawing Test (CDT) and MMSE scores were 5 and 25, respectively, 
with a median score of 2 on the 3-word delayed recall (3-WDR) test. The General Geriatric 
(GG) group counted 116 patients (mean age 83.8 years, range: 72-96), of which 66.4% scored 
possibly cognitively impaired according to the MMSE. Median CDT, MMSE, and 3-WDR score 
were 3, 21 and 0, respectively (Figure 3). The GG group comprised a significantly older 
(p<0.001), and mainly female population (p<0.05), compared to the OG group. In the GG 
group, significantly more cognitive impairments were identified with the MMSE as the gold 
standard (p<0.001) (Table 3). 
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Table 2: Cancer types and treatment intent 
Disease and treatment characteristics n (n=105) (%) 
Cancer types 
   Head and neck 
   Gynaecological 
   Urological 
   Breast 
   Haematological 
   Digestive system 
   Lung 
   Melanoma 
   Other 
   Unknown primary 
Treatment intent 
   Curative intent 





























Table 3: Demographic and cognitive characteristics of both groups under study 
 OncoGeriatric 








Age (mean±SD) 78.3 ± 5.1 83.8 ± 4.7 t(219)=8.215, 
p<0.001 
Gender (% male) 51.4% 30.2% χ2=10.352, p<0,05 
MMSE score (0-30) 
  Median 













CDT score (0-7) 
  Median 









































Figure 3. Cognitive characteristics of both the OG group and the GG group presented as 
boxplots, graphically displaying median, inter-quartile range and minimum and maximum 
data values. A) CDT performance, B) 3-WDR test performance, C) MMSE performance 
As presented in Table 4, within-group analyses revealed no significant age differences 
between patients with normal and impaired cognitive function, according to MMSE, CDT and 
Mini-Cog performance, except for CDT performance in the GG group where cognitively 
impaired patients were significantly younger (p<0.01). Pearson Chi-square analyses revealed 
no differences between the percentage of cognitive impaired male versus female GG patients, 
whilst in the OG group men performed significantly better than women according to MMSE, 
CDT, and Mini-Cog (p<0.005, p<0.01, and p<0.05 respectively). Patients with an advanced 
cancer (stage IV), or treated with palliative intent did not screen significantly different on the 
CDT (p=0.277; p=0.192), Mini-Cog (p=0.935; p =0.760) or MMSE (p=0.432; p=0.342) as 
compared to patients diagnosed with an early stage cancer (stages I-III) or treated with curative 
intent, respectively.  
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Table 4: Exploratory within group analyses 
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CDT and Mini-Cog compared to the gold standard MMSE 
The corresponding areas under the Receiver Operating Characteristic (ROC) curves (AUC ± 
SE) of CDT for the OG group (0.88 ± 0.03) and the GG group (0.85 ± 0.03) showed good 
diagnostic accuracy (Figure 4). 
 
Figure 4. Receiver Operating Characteristics (ROC)-curve of both the OG group and the GG 
group. AUC: Area Under the (ROC)-Curve 
ROC analysis revealed an optimal cut-off score of ≤ 4 on CDT for both groups (Figure 5). As 
presented in tables 3 and 5, a cut-off score of ≤ 4 identified 37.1% of OG and 75.9% of GG 
patients as in need of further cognitive evaluation, with a sensitivity (S) of 80.7% (95% CI [61.9-
91.9]) and 89.6% (95% CI [80.0-95.1]), and a specificity (Sp) of 81.1% (95% CI [70.0-88.9]) 
and 51.3% (95% CI [35.0-67.3]), respectively. Combination of the CDT, with 3-WDR test 
performance resulted in Mini-Cog outcomes. At the determined optimal cut-off score for CDT, 
Mini-Cog results showed an S and Sp of 80.7% (95% CI [61.9-91.9]) and 83.8% (95% CI [73.0-
91.0]) for the oncogeriatric patients, similar to S and Sp for CDT alone. In the GG-population, 
the Mini-Cog showed a slightly higher S of 97.4% (95% CI [90.1-99.5]) and a similar Sp of 
51.3% (95% CI [35.0-67.3]), compared to CDT results alone.  In the OG group, the PPVs and 
NPVs were 64.1% (95% CI [47.2-78.3]) and 90.9% (95% CI [80.6-96.3]) for the CDT, and 
67.6% (95% CI [50.1-81.4]) and 91.2% (95% CI [81.1-96.4]) for the Mini-Cog, respectively. In 
the GG group, the PPV’s of the CDT and the Mini-Cog (combination of 3-WDR and CDT, cut-
off ≤ 4) were 78.4% (95% CI [68.1-86.2]) and 79.8% (95% CI [70.0-87.1]), respectively. The 
NPV’s, on the contrary, were 71.4% (95% CI [51.1-86.0]) for the CDT and 90.9% (95% CI 
[69.4-98.4]) for the Mini-Cog. The odds ratios for the CDT and the Mini-Cog were 17.9 (95% 
CI [6.2-51.8]) and 21.5 (95% CI [7.3-63.7]) for the OG group. In the GG group an odds ratio of 
9.1 (95% CI [3.5-23.8]) and 39.5 (95% CI [8.5-183.8]) was calculated for the CDT and for the 
Mini-Cog, respectively. 
The Kappa score, evaluating CDT interrater reliability, for the OG and GG group was 0.84 and 
0.86, respectively, indicating high agreement between both raters, in classifying patients as 
cognitively normal or potentially cognitively impaired. 
  




Figure 5. Sensitivity and specificity values graphically displayed for different cut-off scores 
for the OG group and GG group. 
Table 5: Comparison of predictive value between the CDT and the Mini-Cog for both groups 
Predictive value CDT (cut-off ≤4) 
[95% CI] 
Mini-Cog (CDT: cut-off≤4; 3-WDR) 
[95% CI] 
OncoGeriatric (OG) group (N=105) 
S 80.7% [61.9-91.9] 80.7% [61.9-91.9]  
Sp 81.1% [70.0-88.9] 83.8% [73.0-91.0] 
PPV 64.1% [47.2-78.3] 67.6% [50.1-81.4] 
NPV 90.9% [80.6-96.3] 91.2% [81.1-96.4] 
DOR 17.9 [6.2-51.8] 21.5 [7.3-63.7] 
General Geriatric (GG) group (N=116) 
S 89.6% [80.0-95.1] 97.4% [90.1-99.5] 
Sp 51.3% [35.0-67.3] 51.3% [35.0-67.3] 
PPV 78.4% [68.1-86.2] 79.8% [70.0-87.1] 
NPV 71.4% [51.1-86.0] 90.9% [69.4-98.4] 
DOR 9.1 [3.5-23.8]  39.5 [8.5-183.8] 
CDT: clock drawing test; S: Sensitivity; Sp: Specificity; PPV: positive predictive value; NPV: 
negative predictive value; DOR: diagnostic odds ratio 




The Clock Drawing Test (CDT) has in recent years been widely suggested in literature as a 
cognitive screening tool with clinical utility, as it shows good correlation with the Mini Mental 
State Examination (MMSE) 284. However, the lack of an easily applicable universal scoring 
system and available cut-off scores for use in different patient populations limits its use in 
routine clinical practice. In this retrospective study, we evaluated the use of the CDT -scored 
by the system of Freund- as a screening tool for potential cognitive impairment in older patients 
with and without cancer. The most optimal cut-off scores of the Freund CDT were determined, 
and CDT results were compared with the Mini-Cog.  
These results indicate that the Freund CDT shows good diagnostic accuracy, based on the 
area under the ROC curve, in both populations under study. Moreover, at the optimal cut-off 
score of ≤ 4, the CDT showed high and intermediate negative predictive value (NPV) for the 
OncoGeriatric (OG) and General Geriatric (GG) group, respectively. Addition of the 3-word 
delayed recall (3-WDR) test, as applied in the Mini-Cog, resulted in negative predictive values 
in the 90% range for both populations. In the GG group a cut-off score of 4 was preferable to 
a cut-off score of 3, since the former shows higher sensitivity (>80%). High sensitivity and NPV 
are mandatory characteristics for a good screening tool in an older population, as it reduces 
false negative results, or thus false reassurance about the absence of vulnerability, rather than 
certifying that cognitively competent patients do not receive an unnecessary MMSE.  
Twenty-nine percent of the OG patients were considered cognitively impaired, based on the 
MMSE. These results are in line with literature, reporting cognitive problems in 25% to 50% of 
older patients with cancer, who were evaluated with a MMSE within a full Comprehensive 
Geriatric Assessment (CGA) 276, 296. The GG group, however, comprised more patients with 
cognitive deficits –indicated by positive screening on MMSE- than reported in literature (66.4% 
vs. 17% to 40%) 287, 297-299. This could be partly explained by the fact that our GG patients 
consisted of a highly impaired population, as they had all been referred for a thorough geriatric 
evaluation because of signs of functional decline, and cognitive impairment has been reported 
as a possible determinant of functional disability 300. In contrary, the OG population consisted 
of less frail patients, as they were significantly younger than their general geriatric counterparts 
and comprised of mainly ambulatory (64.8%) patients. 
Determination of cognitive impairment by the CDT required the choice of an appropriate 
scoring system and adequate cut-off score. Out of a variety of possible scoring systems, we 
considered the system developed by Freund to be the most suitable for clinical practice. Its 
use is recommended by the National Highway Traffic Safety Administration (NHTSA), as a 
primary component in the assessment of driving safety among older adults 301. Moreover, a lot 
of clock-drawing errors that are critical for dementia, as determined by Lessig et al. (2008), 
have been taken into account in the scoring manual 302. Additionally, Shulman (2000) 
suggested the use of a simple scoring system, as he found that the more complicated scoring 
systems do not appear to add significant value to the clinical utility of this test 303. Finally, 
Hubbard et al. (2008) reported the Freund scoring system not to be influenced by sex, race or 
education level, and requiring the least amount of time for scoring, compared to other scoring 
systems such as the Mendez and Cahn scale 292.  
Although age, gender and cognitive status of both groups differed significantly, our data 
suggest an optimal cut-off score of ≤ 4 for identification of cognitive problems in both GG and 
OG patients. Moreover, the same cut-off score was established in the original paper by Freund 
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for the driving evaluation of older drivers 272. This suggests robustness of the cut-off score and 
applicability in various settings. 
At the defined cut-off score, the Freund CDT identified more potentially cognitively impaired 
patients compared to the MMSE. This is in line with literature, reporting that disturbances in 
executive functioning, which are detected by the CDT, often precede the memory decline, and 
people with executive cognitive dysfunction can have a normal MMSE score 288. Moreover, this 
could also explain the high number of false positives (specificity: 51.3%) that was found in the 
GG group. Previous studies did indicate a wide range of sensitivity (50-80%) and specificity 
(65-90%) values for the clock scoring methods to screen cognitive impairment 304. Exploratory 
analyses revealed that cognitively impaired GG patients, as defined by CDT, were significantly 
younger. This result could be due to the small number of cognitively normal (n=28/116) 
patients. Male OG patients performed significantly better on all cognitive measures; however, 
this could be attributed to their significantly younger age. Moreover, male patients might have 
received a higher education. However, the significant result of the Freund CDT does not 
correspond to the argumentation that CDT is unaffected by educational level, as reported by 
Hubbard et al. 292. 
Addition of the 3-WDR test, to form the Mini-Cog, seems to add some value to the CDT score 
in the GG group, lowering the number of false negatives (NPV: 71.4% vs 90.9%). This seems 
to be confirmed by an improvement of the odds ratio (9.1 vs. 39.5). Moreover, our results are 
in line with those of the Capita test (S: 90%, Sp: 50%), a Mini-Cog version that is currently the 
standard for cognitive screening in our geriatric departments. The Capita test classifies CDT 
performance as normal or deviant without use of standardized scoring guidelines, such as the 
Freund method 305. In contrast, our results do not support the use of the Mini-Cog over the 
CDT alone in the OG group.  
The results of this study should be interpreted with some caution due to some limitations in the 
design. First, although the MMSE is considered the gold standard for detection of cognitive 
impairment, it is not a diagnostic test. As mentioned earlier, cognitive function detected by the 
CDT might be different from that detected by the MMSE 288. For that reason, it is important to 
emphasize that these tools are merely screening instruments and should always be followed 
by a diagnostic evaluation (i.e. neuropsychological tests and physician diagnosis) 288, 306. 
Second, the Mini-Cog was not directly assessed. It was calculated using an algorithm that 
combined the CDT performance with the 3-WDR as evaluated within the MMSE. Immediate 
sequential assessment of both the CDT and the Mini-Cog separately would lead to strong 
recall bias. Moreover, unlike the currently often applied Capita test, we used a pre-drawn circle 
for conduction of the CDT, as described by Freund 272. A pre-drawn circle prevents participants 
from possibly drawing a circle not large enough to contain the numbers and hands, or from not 
being symmetrical, which might affect the spatial arrangement of the numbers 307. Third, the 
interrater reliability is probably underestimated, since the blinded investigator could not take 
into account immediate patient corrections that were observed during the assessment. Fourth, 
the educational level of patients was not taken into account, while the MMSE has been proven 
to be influenced by this factor 308. However, Hubbard et al. reported the Freund scoring system 
not to be affected by education level 292. Though, for participants with a higher education, the 
CDT is possibly too simple and in the early stages of cognitive decline these patients may 
retain a minimal level of ability to complete the CDT successfully 309. Fifth, since the screening 
tools under study require verbal insight, memory, visuo-spatial abilities and constructive 
qualifications of the patient, chronobiology and mood could influence test results 310. Moreover, 
an alternative test would be required for screening visually impaired patients. Last, both the 
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GG and OG population might not be representative of an actual reference population, as they 
comprise a significantly compromised geriatric population, and a selected cancer population 
resulting in an unequal distribution of cancer types. These results can therefore not be 
extrapolated and further confirmation in a more comprehensive cancer population is 
warranted. 
In conclusion, our results suggest that the Freund CDT at the optimal cut-off score of ≤ 4 is a 
reliable tool for identification of cognitive problems in older patients with a cancer diagnosis, 
and could lead to a more time-efficient CGA, eliminating the need for a MMSE in 62.9% of OG 
patients undergoing CGA. The Freund CDT within the Mini-Cog is possibly the screening tool 
of preference for use in the GG population. A prospective trial is planned for validation of the 
cut-off score of the Freund CDT in a larger multicentre OG sample.  
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We aimed to validate the Freund Clock Drawing Test (CDT), with its predefined cut-off score 
of ≤ 4, as a screening tool to detect older cancer patients in need of a more in-depth cognitive 
evaluation within a Comprehensive Geriatric Assessment (CGA). 
METHODS 
Patients aged 70 or above with a histologically confirmed diagnosis of cancer were evaluated 
with a full CGA, including CDT and Folstein Mini Mental State Examination (MMSE) as gold 
standard. Validation of the Freund CDT was defined in terms of diagnostic accuracy of the test 
through Receiver Operating Characteristics (ROC)-analysis. To accept the Freund CDT as a 
screening tool, we estimated that the Area Under the ROC-curve (AUC) had to differ 
significantly from 0.70 with an AUC of at least 0.85.  
RESULTS 
Two hundred older cancer patients with a mean age of 79.0 years were included. Four patients 
were excluded from the analyses due to invalid results. Potential cognitive impairment (MMSE 
≤23) was observed in 27.0% of patients. Based on the AUC±SE, the Freund CDT showed 
excellent diagnostic performance (0.95±0.17). Furthermore, it provided excellent sensitivity 
(94.3%) and high specificity (87.4%). 
CONCLUSION 
Our results indicate that the Freund CDT can be used as an initial screening tool to detect 








As a result of the ageing of populations, there is currently a demographic evolution particularly 
in Western countries. These demographic changes have triggered an increased interest in the 
multidisciplinary management of older patients since the latter is a heterogeneous group that 
is in need of a more individualized treatment approach 311, 312. Tailored care can be facilitated 
through a Comprehensive Geriatric Assessment (CGA), which has been the cornerstone in 
the management of geriatric patients for years 313. A CGA is a multidisciplinary evaluation 
assessing medical, psychosocial and functional capabilities and limitations in older cancer 
patients. It aims at predicting the functional age of patients including the risk on morbidity and 
mortality through assessing a wide range of domains including functional status, cognition, 
nutrition, emotional status, polypharmacy, comorbidities and geriatric syndromes, each 
evaluated with a commonly used validated tool 19, 37, 312, 314. In addition, it reveals unknown 
problems, predicts toxicity from treatment and quality of life. During the past years, efforts have 
been made to implement a CGA in an older oncology population, with success, as it has now 
been proposed as the key treatment approach 315, 316.  
The Folstein Mini Mental State Examination (MMSE) is a standard validated measure to screen 
cognitive function within a CGA. Studies have noted that up to 40% of older cancer patients 
present with cognitive abnormalities that warranted further evaluation. Cognitive dysfunctions 
can influence the ability to weigh the risks and benefits of cancer therapy, comply with the 
suggested treatment plan, and decreases the ability to recognize the symptoms of toxicity that 
need medical attention 29. The MMSE can be used to screen for dementia and to estimate the 
severity of cognitive impairment in a general population and in older cancer patients 51, 317, 318. 
However, in an oncogeriatric population, where the majority of patients has a normal cognitive 
function, such assessment can be experienced as tedious and time-consuming, as it may take 
up to 10-15 minutes to carry out 281, 319. More recently, the Clock Drawing Test (CDT) has been 
proposed as a quick and simple screening tool to assess cognitive dysfunction as it can be 
completed in only five minutes 320. The CDT evaluates multiple domains of cognition including 
memory, comprehensive and executive function, visuo-spatial ability and abstract thinking 286, 
290. Furthermore, when given a predrawn circle, the CDT is not influenced by education age 
292. Although the CDT has the characteristics of an attractive screening tool, an easy and 
straightforward scoring method and validated cut-off scores were still lacking. Therefore, our 
research group retrospectively reviewed the Freund scoring system, as it has been reported 
in literature as a fast, easy and trustworthy scoring method 292. A retrospective analysis on 105 
older cancer patients at the General Hospital Groeninge showed that a cut-off score of ≤ 4 for 
the CDT had a good Area Under the Curve (AUC), sensitivity (S) and specificity (Sp). The 
same cut-off score appeared optimal in a general geriatric population. Furthermore, the Freund 
scoring system demonstrated high interrater-reliability 272, 318.   
In this prospective trial, our primary endpoint was to prospectively validate the Freund CDT, 
with its predefined cut-off score of ≤4, as a screening tool to detect cognitive deterioration in 
older cancer patients within a comprehensive geriatric assessment. 
  





This prospective study (PROACTIVE trial, ClinicalTrials.gov identifier: NCT01749995) was 
conducted from November 2012 till December 2013 in patients aged 70 or above with a 
histologically confirmed diagnosis of a solid cancer or haematologic malignancy at all four sites 
of the General Hospital Groeninge (Kortrijk, Belgium). Patients, receiving their primary 
oncology care (surgery, course of (neo)adjuvant or palliative chemotherapy, radiotherapy, 
targeted therapy, palliative care, experimental treatment as part of a clinical trial, ...) could be 
included before or at the start of a line of treatment, but not during a line of treatment. Eligible 
patients were screened with the G8-questionnaire before or after they had received their 
cancer diagnosis, as part of routine clinical practice 321. Patients who screened positive on the 
G8 (cut-off ≤14) were evaluated with a full CGA and were subsequently invited to participate 
in this trial. In a limited number of cases, a CGA was performed irrespective of the G8 test 
score due to a referral by the treating physician based on clinical suspicion of vulnerability or 
frailty. This trial was approved by the ethical committee of the General Hospital Groeninge 
(Kortrijk, Belgium). 
CGA and cognitive assessments 
Cognitive function was assessed as part of a routine oncogeriatric assessment or CGA. The 
CGA comprised several domains, each assessed with a standard validated measure: nutrition 
(Mini Nutritional Assessment - Short Form 322), functional status (Activities of Daily Living, 
Instrumental Activities of Daily Living 48, 49), physical status (falling past year 323), depression 
(Geriatric Depression scale – 15 60), cognition (MMSE, Freund CDT 51, 272), polypharmacy 
(number of drugs) and comorbidities (Charlson Comorbidity Index 324). In accordance with 
previous reports, patients were classified into either having a fit or vulnerable profile. Patients 
were deemed vulnerable if they presented with impairments in two or more domains within the 
CGA 6, 313. The CGA, including MMSE and Freund CDT, was conducted by an 
oncopsychologist or research associate with experience in the field of oncogeriatrics. Both had 
received training from an occupational therapist, enabling them to conduct and score the 
Folstein MMSE according to international guidelines 295. Patients were considered to be 
potentially cognitively impaired if they presented with a test score of 23 or less 319. Potentially 
cognitively impaired means that a patient has to be referred to a neurologist or memory clinic 
for a more in-depth cognitive assessment. For the CDT, patients were given a predrawn circle 
and were verbally instructed to put all the numbers of a clock on it and set the time at ten past 
eleven, as this has been reported to be the most sensitive for detecting neurocognitive 
impairments 325. The Freund scoring system uses a 7-point rating scale ranging from 0 to 7, 
indicating a potentially very poor to excellent cognitive function respectively. The scoring 
system is divided into three categories, namely the ability to correctly reproduce all numbers, 
to position them accurately in the circle and to appropriately replicate the hands at the indicated 
time (Table 1). For every item, one point can be awarded 272, 318. According to our predefined 
cut-off score, patients were considered to be potentially cognitively impaired if they had a score 
of 4 or less 318.  
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Table 1: Clock Drawing Test: Freund scoring system 272 and examples 
Statistical analyses 
All statistical analyses were performed by use of SPSS software (version 21; IBM SPSS 
Statistics, Chicago, IL). Descriptive statistics were conducted to present patient and tumour 
characteristics, and CGA and cognitive test results. Scatter graphs were plotted to evaluate if 
a linear relationship was present between education age and MMSE and CDT test scores. 
Based on the linearity of this association, Pearson or Spearman correlation coefficients were 
calculated to examine the association between age, education age and MMSE and CDT test 
scores. Education age can be defined as the number of years that patients went to school, 
starting from primary education. In advance sample size calculations were based on the 
hypothesis of equality with 0.70 of the area under the Receiver Operating Characteristics 
(ROC) curve (ClinicalTrials.gov identifier: NCT01749995). In our scenario, a sample with an 
unequal allocation ratio of four, consisting of a sample of at least 32 from the positive group, 
and at least 128 from the negative group would achieve at least 80% power to detect a 
difference of 0.15 between the area under the ROC curve under the null hypothesis of 0.70 
and an AUC under the alternative hypothesis of 0.85 using a two-sided z-test at a significance 
level of 5%. ROC curves were plotted to evaluate the diagnostic performance, in terms of AUC, 
of the Freund CDT in determining patients who are potentially cognitively impaired compared 
to the Folstein MMSE as gold standard. The cut-off for determining impairment was defined as 
having a MMSE score of 23 or less 319. Sensitivity and specificity with 95% confidence intervals 
(95%CI) were calculated at our predefined cut-off score of ≤4. Positive and negative predictive 





 One hand points 2 (or symbol representative of 2) 
 Exactly two hands 
 Absence of intrusive marks, e.g., writing or hands indicating incorrect 
time, hand points to number 10, tic marks, time written in text 
Numbers  
(0-2 points) 
 Numbers are inside the clock circle 
 All numbers 1-12 are present, no duplicates or omissions 
Spacing  
(0-2 points) 
 Numbers spaced equally or nearly equally from each other 




Excellent clock drawing followed by two poor drawings 





During the inclusion period, 490 patients were evaluated with a routine oncogeriatric screening 
at General Hospital Groeninge. Of those, 320 (65%) patients needed an additional full CGA. 
Two hundred older cancer patients consented to participate in this trial. Four patients were 
excluded from analyses due to an incomplete cognitive assessment. Patients presented with 
a mean age of 79.0 years (range: 70.0-93.0 years) and a mean education age of 10.3 years 
(range: 4.0-22.0 years). The study population comprised slightly more male patients (52.6%). 
Patients presented with cancer of the following regions: digestive (30.6%), genitourinary 
(22.4%), gynaecologic (13.3%), breast (8.7%), haematological malignancies (8.7%), thorax 
(5.6%), head and neck (5.6%), skin (2.0%), musculoskeletal (2.0%) and central nervous 
system (1.0%). More than half of patients were treated with curative intent (55.1%) (Table 2).  
Table 2. Patient and tumour characteristics 
Characteristic (n=196) Mean (range) n (%) 
Age 79.0 (70.0-93.0)  
Gender   
Male  103 (52.6) 
Female  93 (47.4) 
Marital Status   
Single  13 (6.6) 
Married  107 (54.6) 
Divorced  3 (1.5) 
Widow-er  69 (35.2) 
Other  4 (2.1) 
Level of education   
Age 10.3 (4.0-22.0)  
Less than primary education  2 (1.0) 
Primary education  11 (5.6) 
Lower secondary education  109 (55.6) 
Higher secondary education  51 (26.0) 
Higher education  23 (11.8) 
Cancer site   
Digestive   60 (30.6) 
Genitourinary   44 (22.5) 
Gynaecologic   26 (13.3) 
Breast   17 (8.7) 
Hematologic malignancies  17 (8.7) 
Head and neck  11 (5.6) 
Thorax  11 (5.6) 
Skin  4 (2.0) 
Musculoskeletal   4 (2.0) 
Central nervous system  2 (1.0) 
Treatment intent   
Curative  108 (55.1) 
Palliative  77 (39.3) 
No active treatment  11 (5.6) 
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CGA and cognitive measures 
Three patients (1.5%) screened negative on the G8-questionnaire (cut-off ≤14) and were 
evaluated with a full CGA based on a referral from their treating physician. Mean and median 
scores per screening tool assessed within the CGA and the percentage of patients vulnerable 
per test are shown in Table 3. Based on the CGA outcome, 89.8% of patients were deemed 
vulnerable as they presented with a potential impairment in two or more domains. Potential 
cognitive deficits were identified in 27.0% of patients according to the MMSE. To meet the 
criteria of the power analysis, at least 32 patients needed to have a potential cognitive 
impairment based on the MMSE and at least 128 patients needed to score above the cut-off. 
The MMSE selected 53 (27.0%) patients with a potential cognitive impairment, whereas 143 
were marked as having a good cognition. Median MMSE and CDT scores were 27 and 5, 
respectively (Table 3). Scatter graphs did not detect a linear association between age, 
education age and MMSE test scores, nor was this the case for the CDT test results. Spearman 
correlation coefficient showed a significant negative correlation between MMSE and age 
(p<0.01; rs=-0.23) and a significant positive association between MMSE scores and the years 
of education (p<0.01; rs=0.24). We did not find a significant association between age, 
education age and CDT test results (p=0.07; rs=-0.13 and p=0.07; rs=0.13, respectively) (data 
not shown). At our predefined cut-off score of ≤4, the area under the ROC-curve (AUC±SE) of 
the CDT showed excellent diagnostic accuracy (0.95±0.17) (Figure 1). Furthermore, it provided 
a sensitivity of 94.3% (95% CI [83.4-98.5]) and specificity of 87.4% (95% CI [80.6-92.2]). The 
PPV and NPV were 73.5% (95% CI [61.2-83.2]) and 97.7% (95% CI [92.8-99.4]), respectively 
(Table 3). When subdividing patients into groups by age and education age according to Crum 
et al. (1993), the cut-off remained optimal (data not shown) 308. 
Table 3. Overview of median scores and percentage of vulnerable patients per tool (n=196) 
Domain Test Range Median Mean % vulnerable 
Nutrition MNA-SF 0-14 10 9.6 82.1 
Functional status ADL 0-24 7 8.9 87.2 
IADL 0-8 5 4.7 
Physical status Falls past 
year 
NA NA NA 38.3 
Depression GDS-15 
(n=195) 
0-15 2 2.6 15.8 
Cognition MMSE 0-30 27 25.5 27.0 
 CDT 0-7 5 4.9 NA 
Polypharmacy Number of 
drugs 
NA 7 6.6 72.4 
Comorbidities CCI 0-37 2 2.3 23.5 
MNA-SF: Mini Nutritional Assessment-Short Form, ADL: Activities of Daily Living, IADL: 
Instrumental Activities of Daily Living, GDS: Geriatric Depression Scale, MMSE: Mini Mental 








Figure 1. Receiver operating characteristics (ROC) curve of the Clock Drawing Test 
compared with the Mini Mental State Examination as gold standard. AUC, area under the 
(ROC) curve 
DISCUSSION 
Assessing cognitive function provides health care workers valuable information on the mental 
reserve of the patient as patients presenting with a memory impairment can have difficulties 
understanding treatment instructions and may not be attentive for the signs and symptoms of 
treatment related toxicities that need further evaluation 13. The Folstein MMSE is a commonly 
used instrument to screen for dementia and is validated for use in several patient populations. 
Nevertheless, the MMSE is time-consuming and confronting in the many cognitively fit patients 
that undergo a CGA as part of their cancer care. Previous work from our group suggested that 
the Freund CDT with a cut-off score of ≤4 could replace the MMSE within the CGA resulting in 
gain in time for health care providers and increased comfort for patients 318. The current study 
was able to prospectively validate the retrospectively identified cut-off score and could 
therefore be practice changing.  
A good screening tool needs a high sensitivity and high NPV as it reduces the number of false 
negative cases. Our results show that the Freund CDT, with a cut-off score of ≤4, has indeed 
the properties of an excellent screening instrument as we have found a sensitivity of 94.3% 
and NPV of 97.7%. Further, the Freund CDT provided a high specificity of 87.4%. In this trial, 
our primary endpoint was to validate the CDT based on the diagnostic accuracy of the test. 
We stated that a sample with an unequal allocation ratio of four, consisting of a sample of at 
least 32 from the positive group, and at least 128 from the negative group would achieve at 
least 80% power to detect a difference of 0.15 between the AUC under the null hypothesis of 
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0.70 and an AUC under the alternative hypothesis of 0.85 using a two-sided z-test at a 
significance level of 5%. In our sample, results show an AUC (AUC±SE) under the ROC-curve 
of 0.95±0.17. Hereby we can accept the alternative hypothesis as an AUC under the ROC-
curve of at least 0.85 was achieved. As this cut-off score was also determined in our previous 
retrospective study (in oncogeriatric and general geriatric patients) and in the original paper by 
Barbara Freund et al. (2005), we can assume the robustness of this cut-off score 272, 318. 
Further, we can state that the cut-off score of ≤4 is the most optimal cut-off score for use in an 
oncogeriatric population.  
In our sample, 27.0% of patients presented with a potential cognitive deficit that needed further 
evaluation based on the MMSE. This is in line with previous research reporting cognitive 
deterioration in up to 50% of patients 29. Further, it has been noted that the Folstein MMSE can 
be influenced by education age, whereas the CDT is less dependent of education age when 
given a predrawn circle 292, 308. Spearman correlation coefficients showed a significant 
statistical association between MMSE test scores and education age. This was not the case 
for the Freund CDT.    
Initially, it was our objective to validate the Freund CDT as a pre-screener within a CGA. Since 
results show such an excellent AUC of 0.95 with sensitivity of 94.3% and specificity of 87.4%, 
we could assume that an assessment with the MMSE may be redundant and that results on 
both screening tools will be nearly equal. However, McNemar test revealed a significant 
difference between both test outcomes disputing the latter statement (p<0.005; data not 
shown). This highly significant result reflects a minor discordance in 21 out of 196 patients of 
which 18 are considered fit by MMSE and classified vulnerable by CDT, and 3 out of 196 who 
were considered vulnerable by MMSE and classified as fit by CDT. Nevertheless, selecting the 
Freund CDT above the Folstein MMSE has some advantages. First, the Freund CDT defined 
more patients as vulnerable leading to a more sensitive test. Second, within a CGA, we try to 
select those domains that can influence and increase the risk on morbidity and mortality. As it 
is not our intention to diagnose patients but merely to detect potential vulnerabilities, we need 
a screening tool that gives us valuable information in less time. The Freund CDT can be 
administered in approximately five minutes and has been previously reported as a good 
screening tool in other populations that can be carried out in very little time 320. Third, the 
Freund scoring system is user-friendly and has been reported with a high interrater-reliability 
272, 318. Fourth, in our and other patient populations, the MMSE can be experienced as tedious 
and annoying, whereas the CDT has been described previously as a non-threatening cognitive 
assessment 326. Last, it has been noted that the MMSE can be influenced by education age 
whereas the CDT - when given a predrawn circle - is not influenced by education age 292, 308. 
Our results support this statement.   
The results of this trial need to be interpreted with caution due to some limitations. We 
considered the Folstein MMSE as the gold standard against the Freund CDT. Although the 
MMSE is a commonly used validated measure, it is not a diagnostic test. Cognitive malfunction 
detected by the CDT may slightly differ from that detected by our gold standard. Therefore, it 
is important to remember that both MMSE and CDT are screening tools and that they should 
always be followed by an intensive diagnostic neuropsychological assessment when a 
potential cognitive impairment is detected 288. Further, the MMSE cut-off of ≤23 may not be 
sufficient for detecting mild cognitive impairment nor may it be sufficient for detection 
dysfunctions in patients with less than 9 years of education 308, 327. Although our population has 
a mean education age of 10.3 years, 6.6% of patients received less than lower secondary 
education (Table 2). However, in our study we did not intend to diagnose patients but to select 
those who may present with a potential vulnerability that needs closer evaluation. Next, this 
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study was conducted in oncogeriatric patients receiving a routine oncogeriatric assessment. 
Most patients consenting for this trial had been assessed with a CGA due to a positive test 
score on the G8-questionnaire. In our clinic, patients deemed fit - based on their G8 screening 
score - are only evaluated with a CGA when required by the physician. Therefore, this trial 
includes only a minority of fit patients. The cut-off score achieved may thus not be 
representative for patients who screened negative on the G8 or patients who are evaluated 
with other screeners such as VES-13. However, the G8-questionnaire contains seven items 
from the Mini Nutritional Assessment and age. One of the items included in the G8-
questionnaire concerns cognition and depression. This item has previously shown to correlate 
with MMSE test scores 34, 328. Last, we did not consider the chronobiology 329. However, in our 
sample, as patients were seen throughout the day, we suggest a minimal bias by biological 
rhythms.  
Overall, we can conclude that in this prospective trial, we were able to validate the Freund CDT 
with a cut-off score of ≤4 as a screening tool to detect cognitive dysfunction in older cancer 
patients undergoing a Comprehensive Geriatric Assessment. Our results indicate that it could 
potentially replace the MMSE as a stand-alone screening instrument, leading to a more time-
efficient CGA.  
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Recent research in the field of cancer-related cognitive impairments (CRCI) has shown CRCI 
presentation prior to treatment initiation. Some have attributed these problems to worry and 
fatigue whereas others have suggested an influence of age, IQ and other psychosocial and 
medical factors.  
METHODS 
Patients (≥18 years) with a histologically confirmed diagnosis of a solid cancer or 
haematological malignancy, scheduled for a curative treatment, were evaluated with a baseline 
neuropsychological assessment including patient-reported outcome measures (PROMs). 
PROMs entailed distress, anxiety and depression, fatigue and cognitive complaints. The 
neuropsychological assessment comprised several cognitive domains such as premorbid IQ, 
attention, processing speed, flexibility, verbal and visual episodic memory and verbal fluency.  
RESULTS 
Cross-sectional data of 125 patients were collected. Patients had a mean age of 60.9 years 
(range: 30.0-85.0) and comprised primarily females (65.6%). Patients presented with cancer 
of following sites: breast (44.0%), digestive (28.8%), urological (11.2%), gynaecologic (8.0%), 
haematologic malignancy (4.8%) or lung (3.2%). Patients presented with a premorbid IQ of 
105.3 (range: 79.0–124.0). In 29.6% of patients, a CRCI was detected. Binary logistic 
regression analyses showed that a lower premorbid IQ (β=-0.084, p<0.01) and a higher level 
of fatigue (β=-0.054, p<0.05) predicted baseline CRCI. Premorbid IQ also predicted 
performance on individual cognitive domains. Some domains were also influenced by age, 
gender, having a breast cancer diagnosis and an active treatment for hypertension.  
CONCLUSION 
Premorbid IQ and fatigue are important predictors of baseline CRCI. Therefore, we advise 
researchers to implement a short IQ test when conducting clinical trials on CRCI.  




Improved cancer treatments have led to increased survival rates and a growing number of 
cancer survivors presenting with persistent treatment-related side effects. Cognitive 
malfunctioning is one of the most frequently reported adverse events and poses a big 
challenge for patients who want to return to their former lives. Patients may suffer from 
concentration problems, distractibility, forgetfulness, difficulties in remembering names or 
numbers and a lack of mental sharpness 123, 124, 134, 330, 331.  
Researchers ascribed these problems at first to chemotherapeutic treatments, resulting in a 
term called ‘chemobrain’. Initial trials focused on breast cancer patients, as they reported 
symptoms even long after their treatment had ended 123, 124. Recent research, however, 
indicates that chemotherapeutic agents may not be the sole cause of cancer-related cognitive 
impairments (CRCI). Studies have shown that radiotherapy, external to the brain region, and 
hormonal treatments can also induce CRCI 332-334. Further, prospective studies, including 
neuropsychological assessments before treatment administration but after cancer diagnosis – 
and most often after cancer surgery, have reported high rates of CRCI prior to adjuvant 
chemotherapy. They report increasing problems following chemotherapy and a resolution of 
the findings to baseline levels when performing longer follow-up assessments 134.  
Although the majority of studies now include a baseline assessment that shows that some 
patients present with a CRCI before adjuvant treatment initiation, little is known about why 
these impairments occur. A trial by Schilder et al. (2010) investigated baseline cognition in a 
group of postmenopausal breast cancer patients and found that an individual cognitive domain 
can be influenced by age, IQ and other medical factors 334. Others have suggested that 
psychosocial factors such as worry and fatigue may enhance the risk of presenting with a CRCI 
at baseline in patients diagnosed with breast or colorectal cancer 139, 143, 144.  
Although more research has been conducted into the pathophysiology of baseline CRCI, 
sufficient evidence is lacking. Further, studies have mainly been focussing on how breast 
cancer patients experience these problems. It is only until more recently that researchers have 
broadened their landscape and started to examine CRCI in other cancer types. Another 
shortcoming in current literature is that only few researchers implement some form of IQ 
assessment when investigating CRCI, although it is known that IQ can predict 
neuropsychological assessment results 335.  
In this paper, we tried to closing the gap in some of these shortcomings by performing a cross-
sectional analysis in which we aimed at identifying predictors of baseline CRCI in a group of 
general cancer patients who were scheduled for a treatment with curative intent.  
METHODS  
Participants 
Patients were invited to participate in the CONCEPT-trial (ClinicalTrials.gov Identifier: 
NCT01846260) between May 2013 and September 2015. Baseline data were collected as part 
of an ongoing longitudinal trial in which we aimed to examine whether the distress thermometer 
can predict long-term CRCI (Chapter 4, Part II). All patients were recruited in the Kortrijk 
Cancer Centre (Kortrijk, Belgium). Eligible patients were 18 years or older and natively Dutch 
speaking or bilingual. All patients had a histologically confirmed diagnosis of a solid tumour or 
haematological malignancy, in an early or advanced stage. Patients were scheduled to receive 
a treatment with curative intent. Patients receiving surgery as a sole treatment were excluded. 





Other exclusion criteria entailed: being diagnosed with primary brain tumours or brain 
metastases, having a prior history of cancer -with or without chemotherapy or radiotherapy- 
during the last five years, suffering from an organic brain syndrome, showing signs of mental 
deterioration or being diagnosed with dementia (DSM-IV criteria), having an untreated or 
unstable major medical condition, being alcohol or drug dependent, presenting with a condition 
other than cancer in which fatigue is a prominent symptom (such as chronic fatigue syndrome) 
and having a major psychiatric or neurologic disorder that could potentially invalidate 
assessment; a prior or current diagnosis of a depressive or anxiety disorder was allowed. All 
patients gave written informed consent. The trial was approved by the ethics committee of the 
General Hospital Groeninge, Kortrijk, Belgium.  
Measures 
Patients were evaluated by a baseline neuropsychological assessment (Table 1) including 
patient-reported outcomes (PROMs). All assessments were performed by either a 
neuropsychologist or study trial coordinators trained to perform these measurements.  
Table 1. Neuropsychological assessment 
Cognitive 
domain 






IQ estimation IQ estimation ≥ 0 
Episodic memory  
Visual Rey’s Complex 
Figure Test (CFT) 
Delayed recall Total score 0 – 36 
Verbal  Rey’s Auditory 
Verbal Learning 
Test (RAVLT)  
Delayed recall Total score 0 – 15  
Executive functions  





Time needed to 







Animals Number of correctly 





COWA letter N Number of correctly 





TMT Condition 2 
(number 
sequencing) 
Time needed to 




 Number of correct 
items 
≥ 0 
Working memory  




Total score 0 – 30  
WAIS: Wechsler Adult Intelligence Scale 
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The neuropsychological assessment included standardized neuropsychological tests 
assessing several cognitive domains as advised by the International Cognition and Cancer 
Taskforce (ICCTF) 148.  
The Dutch Adult Reading Test (DART) is the Dutch version of the National Adult Reading Test 
(NART). It consists of a list of 50 words with an irregular pronunciation, which have to be read 
aloud. The DART estimates premorbid intelligence and is relatively insensitive to brain 
dysfunctions and mild dementia 336, 337.  
The Rey-Osterrieth Complex Figure Test (CFT) assesses both visuoconstruction and visual 
memory 338, 339. It consists of three conditions: a copy task, an immediate and a delayed recall 
task. The CFT has been a useful tool for measuring visual episodic memory that is mediated 
by the prefrontal lobe 340.   
The Rey Auditory Verbal Learning Test (RAVLT) measures verbal learning ability and verbal 
memory. Patients are asked to repeat and remember a list of 15 words. It entails both an 
immediate and delayed recall task 341.  
The Trail Making Test (TMT) provides information on a patient’s visual scanning and searching 
abilities, processing speed, mental flexibility and executive function 342. D-KEFS TMT consists 
of five conditions instead of two on the original test. Patients are asked to draw lines 
sequentially connecting encircled numbers or letters distributed on a sheet of paper. The most 
important conditions concerning executive functioning comprises a number and a number-
letter sequencing task 343.  
The Controlled Oral Word Association test (COWA) is one of the most commonly used 
measures of verbal fluency. This rapid and organized word retrieval task is a sensitive indicator 
of brain dysfunctions. Verbal fluency tests typically employ a word-list generation procedure 
and are divided in two forms. Semantic fluency tasks require the patient to generate a list of 
words according to a certain category. Phonemic fluency tasks require that words be generated 
according to a letter of the alphabet 344-346.  
The Digit Span subtest of Wechsler Adult Intelligence Scale-III (WAIS-III) measures attention, 
concentration and working memory, and entails a forward and backward repeating task. The 
score is the total number of correctly repeated sequences before two failed attempts in each 
condition 347, 348. The WAIS-III Digit Symbol measures cognitive and perceptual-motor 
processing speed. The subject is given a code that pairs symbols with digits. The patient is 
asked to match as many series of digits as possible to their corresponding symbols as possible 
in a fixed time span of 120 seconds 348, 349. 
PROMs entailed an assessment of distress (Distress Thermometer including 38-item Problem 
list350), anxiety and depression (Hospital Anxiety and Depression Scale (HADS) 351), fatigue 
(FACIT-fatigue 352), cognitive complaints (Cognitive Failure Questionnaire (CFQ) 353) and 
quality of life (EORTC QLQ-C30 354).  
Statistical considerations 
Statistical analyses were conducted by use of SPSS software (version 23; IBM SPSS 
Statistics, Chicago, IL). Descriptive statistics were performed to present patient and tumour 
characteristics and neuropsychological assessment results. Overall, cognitive impairment was 
calculated by the definition of the ICCTF. Patients were marked as having a CRCI if they either 
presented with two or more test scores at or below -1.5 standard deviations (SDs) from the 
normative mean or if they presented with one test score at or below -2.0 SDs 148. Published 





normative data, adjusted for gender, age and/or education, were used to convert raw test 
scores into standardized z-scores (mean=0; SD=1). Curves based on the binomial probability 
distribution were used to determine that in our test battery, including eight independent test, 
approximately 17% of patients would perform 2SDs below the normative mean on a single test 
355. A binomial test was performed to examine whether our data differed from the binomial 
probability distribution. Data from questionnaires were converted according to standard scoring 
rules, if applicable.  
Independent Student’s t and Chi-square tests were performed to examine patient and clinical 
characteristics between impaired and non-impaired subjects. Binary logistic regression 
analysis was used to examine potential predictors of overall CRCI. Multiple regression analysis 
were used to examine predictors of individual cognitive domains. Models were selected 
through forward and backward analyses. Models were not controlled for age, gender or 
premorbid IQ, as we wanted to evaluate the effect of these variables in our target population. 
Both binary and linear regression analyses included 14 covariates: age, gender, premorbid IQ, 
distress, fatigue, cognitive complaints, days since diagnosis, days since surgery, active 
treatment for diabetes mellitus, active treatment for hypertension, active treatment with 
anxiolytics/antidepressants/antihypnotics, having a prior or current diagnosis of depression or 
anxiety, stage (early vs. late stage) and diagnosis (breast cancer or not). Variables were 
included in the model if they were significant at the p<0.05 level.   
RESULTS 
Patient characteristics 
In total, 125 patients were included in the trial. Patients had a mean age of 60.9 years (range: 
30.0-85.0). The study population comprised primarily female individuals (65.6%). The majority 
of patients finished high school or higher (71.2%). Patients presented with cancer of following 
sites: breast (44.0%), digestive (28.8%), urological (11.2%), gynaecologic (8.0%), 
haematologic malignancy (4.8%) or lung (3.2%). Most patients were diagnosed in an early 
stage (62.4%). Eighty-six patients underwent surgery prior to the baseline assessment. On 
average, there were 38.1 days (range: 13-106) between the day of surgery and the day of the 
assessment. Five patients were included with a prior history of diagnosed depression or 
anxiety disorder. No patient was included with a current diagnosis of any of these conditions. 
Of all patients, 22.4% were prescribed antidepressants, antihypnotics and/or anxiolytics. Only 
few patients received an active treatment for diabetes mellitus (6.4%) whereas almost half of 
patients were on antihypertensive drugs (42.4%) (Table 2).  
Neuropsychological outcomes 
One patient was excluded from the analyses as not all neuropsychological test were 
completed. Table 3 shows mean raw scores, Z-scores and SDs for each cognitive test. 
Patients had a mean premorbid IQ of 105.5 (range: 79.0 – 124.0). Based on the definition of 
the ICCTF, 29.6% of patients presented with an overall CRCI. Thirty patients scored below 
2SDs from the normative mean on a single test (24.2%, Binomial test p<0.001). Independent 
Student’s t-tests did not detect differences between impaired and non-impaired patients for 
age, education age, distress, anxiety, depression, fatigue, subjective cognitive complaints and 
days between surgery and baseline assessment, nor did the Chi-square test show any 
differences between both groups for gender, active treatment with 
anxiolytics/antidepressants/antihypnotics, having a prior or current diagnosis of depression or 
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anxiety , stage (early vs. late stage) or cancer type (breast cancer vs. other cancer type) (data 
not shown). A significant difference was found for premorbid IQ (p<0.01). Non-impaired 
patients presented with a mean premorbid IQ of 107.0 (range: 79.0 – 124.0) whereas the mean 
premorbid IQ of impaired patients was calculated as 101.5 (range: 82.0 – 116.0). 
Table 2. Demographic and clinical data (n=125) 
Demographics n (%) mean (range) 
Age  60.9 (30.0-85.0) 
Gender   
   Female 82 (65.6)  
   Male 43 (34.4)  
Highest education   
   Primary education 0 (0)  
   Lower secondary education 36 (28.8)  
   Higher secondary education 49 (39.2)  
   Higher education 35 (28.0)  
   Other 5 (4.0)  
Clinical data   
Diagnosis   
Breast cancer 55 (44.0)  
Digestive cancer 36 (28.8)  
Urological cancer 14 (11.2)  
Gynaecologic cancer 10 (8.0)  
Haematologic malignancy 6 (4.8)  
Lung cancer 4 (3.2)  
Stage   
   Early (I-II) 78 (62.4)  
   Advanced (III-IV) 47 (37.6)  
Surgery   
Number of patients who received surgery 
before baseline assessment 
86 (68.8)  
Days between surgery and baseline 
assessment 
 38.1 (13-106) 
Medication   
Active treatment diabetes mellitus 8 (6.4)  
Active treatment hypertension 53 (42.4)  
Active treatment with 
anxiolytics/antidepressants/antihypnotics 
28 (22.4)  
  





Table 3. Mean raw and z-scores and SDs per cognitive test score (n = 124) 




DART 105.3 (9.1) NA 
CFT Delayed Recall 19.6 (5.1) 0.07 (0.76) 
RAVLT Delayed Recall 10.3 (3.8) -0.26 (1.48) 
TMT condition 4: number-letter sequencing 104.7 (53.9) 0.06 (1.10) 
COWA Semantic Word Fluency 21.7 (7.0) 0.01 (1.09) 
COWA Phonetic Word Fluency 10.0 (5.0) 0.00 (1.22) 
TMT condition 2: number sequencing 43.8 (22.1) 0.20 (1.09) 
WAIS-III Digit Symbol 63.6 (20.4) 0.28 (1.21) 
WAIS-III Digit Span 14.3 (3.5) 0.10 (1.04) 
DART: Dutch Adult Reading Test, CFT: Complex Figure Test, RAVLT: Rey’s Auditory Verbal 
Learning Test, TMT: Trail Making Test, COWA: Controlled Word Association, WAIS: Wechsler 
Adult Intelligence Scale, SD: standard deviation, NA: not applicable 
All regression analyses started with a list of 14 covariates as mentioned previously. Results of 
the binary logistic regression analyses indicated that overall CRCI, according to the definition 
of the ICCTF, was predicted by a lower premorbid IQ (β = -0.084, p<0.01) and lower score on 
the FACIT-Fatigue scale representing a higher level of fatigue (β = -0.054, p<0.05). Individual 
cognitive domains were evaluated through multiple regression analysis (Table 4.). Results 
revealed that all cognitive domains can be predicted by premorbid IQ, stating that a higher IQ 
results in a better test score. Premorbid IQ alone predicted up to 27.1% of the explained 
variance (R² adjusted) in a single test domain. Visual and verbal episodic memory, information 
processing speed, semantic word fluency and flexibility were also influenced by age, favouring 
younger patients. Including age in the model resulted in an up to 31.7% increase of the 
explained variance. Verbal episodic memory was further predicted by gender resulting in a 
total explained variance of 33.2%. Test scores on the WAIS-III Digit Span were, next to 
premorbid IQ, predicted by an active treatment for hypertension, adding 8.0% to the explained 
variance of the model. Interestingly, processing speed, as measured by the WAIS-III Digit 
Symbol was in part predicted by having a breast cancer diagnosis or not.  
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Table 4. Multiple regression analysis 




CFT Delayed Recall 
IQ 0.140 IQ 0.328 <0.001 
IQ + age 0.204 Age -0.270 <0.01 
RAVLT Delayed Recall 
IQ   0.223 IQ 0.421 <0.001 
IQ + age 0.296 Age -0.255 <0.01 
IQ + gender + age 0.332 Gender 0.204 <0.01 
TMT number-letter sequencing 
IQ 0.186 IQ -0.325 <0.001 
IQ + age 0.467 Age 0.544 <0.001 
COWA Semantic Word Fluency 
IQ 0.245 IQ 0.456 <0.001 
IQ + age 0.283 Age -0.214 <0.01 
COWA Phonetic Word Fluency 
IQ 0.271 IQ 0.526 <0.001 
TMT: Number Sequencing 
IQ 0.105 IQ -0.224 <0.01 
IQ + age 0.372 Age 0.531 <0.001 
WAIS-III Digit Symbol 
IQ 0.170 IQ 0.272 <0.001 
IQ + age 0.487 Age -0.566 <0.001 
IQ + age + having breast 
cancer or not 
0.508 Having breast cancer or not  0.161 <0.05 
WAIS-III Digit Span 
IQ 0.179 IQ 0.399 <0.001 
IQ + active treatment for 
hypertension 
0.259 active treatment for 
hypertension 
-0.294 <0.001 
Covariates: age, gender, premorbid IQ, distress, fatigue, cognitive complaints, days since 
diagnosis, days since surgery, active treatment for diabetes mellitus, active treatment for 
hypertension, active treatment with anxiolytics/antidepressants/antihypnotics, having a prior or 
current diagnosis of depression or anxiety, stage (early vs. late stage) and diagnosis (breast 
cancer or not). CFT: Complex Figure Test, RAVLT: Rey’s Auditory Verbal Learning Test, TMT: 
Trail Making Test, COWA: Controlled Word Association, WAIS: Wechsler Adult Intelligence 
Scale.






This paper aimed at identifying risk factors for baseline CRCI in a group of general cancer 
patients scheduled for a curative treatment. Our data highlights the importance of conducting 
an IQ test when conducting neuropsychological assessments in cancer patients. Results 
indicated that CRCI, which is defined as presenting with two or more test scores at or below -
1.5 SDs from the normative mean or presenting with one test score at or below -2.0 SDs, was 
predicted by premorbid IQ and fatigue. Further, individual neuropsychological test scores were 
all influenced by premorbid IQ. Some cognitive domains were also predicted by gender, age, 
having a breast cancer diagnosis or not and/or by an active treatment for hypertension. 
Our results indicate that IQ predicts baseline CRCI. To our knowledge, we are the first to report 
this finding in case of overall CRCI. Our data also indicate that IQ influences individual 
cognitive domains. These results are in line with previous literature as the IQ of a patient has 
been reported as a strong predictor of neuropsychological test scores in both cancer and non-
cancer subjects. Diaz-Asper et al. (2004) evaluated the influence of IQ on several individual 
cognitive tests in 221 normal adults and stated that IQ predicts concurrent neuropsychological 
performance across the entire spectrum of intelligence 356. In a group of breast cancer patients 
exposed to chemotherapy, Ahles et al. (2010) reported that pre-treatment cognitive reserve, 
assessed by the Wide Range Achievement Test-3 (WRAT-3) was related with post-treatment 
cognitive decline 146. Further, the data of Schilder et al. (2010) is in accordance with our 
findings. They reported IQ to be a predictor of individual cognitive domains in a group of 
postmenopausal breast cancer patients before the administration of adjuvant systemic 
treatment 334. Lange et al. (2014), however, examined baseline cognition in older cancer 
patients and could not detect any correlations between CRCI and clinical characteristics 145. 
When comparing our data to the binomial probability distribution we detected a statistical 
significant result (p<0.001) stating that the number of impaired CRCI can only in part be 
explained by normal variance.  
In our study, overall CRCI was also predicted by fatigue. Although it has been noted that fatigue 
influences subjective cognitive complaints in cancer patients, most studies have failed to find 
an association between objective CRCI and fatigue 357-359. Booth-Jones et al. (2005) examined 
the cognitive function of patients who underwent a bone marrow transplantation and reported 
that both objective and subjective cognitive impairments are influenced by the level of fatigue 
360. Further, recent research by Menning et al. (2015) found that symptoms of fatigue were 
related to observed impairments in breast cancer patients when compared to healthy controls, 
prior to adjuvant treatment 143.  
Our data suggest that age could predict processing speed, executive function, verbal episodic 
memory and semantic word fluency. This finding is in accordance with the results of Lange et 
al. (2014) who examined baseline cognition in older breast cancer patients. They reported that 
more than 40% presented with a CRCI at baseline and that respectively 15%, 16% and 21% 
of patients presented with an impairment in the domain of processing speed, executive function 
or verbal episodic memory 145. Further, age-related decline on cognitive functioning has also 
been noted in non-cancer subjects 361. For example, Kramer et al. (2003) stated that older 
healthy subjects could present with poorer verbal memory results when compared to their 
younger counterparts 362.  
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Verbal episodic memory, as measured by the RAVLT delayed recall was also predicted by 
gender. These findings are in line with Kramer et al. (2003) who found comparable results in a 
group of healthy individuals. In their study, they have noted that men perform worse on a 
delayed recall test 362.  
Our data further indicates that an active treatment for hypertension predicts in part the outcome 
on the WAIS-III Digit Span, which measures attention. It is known that hypertension influences 
cognitive performance. Knecht et al. (2009) reported that hypertension might account for one-
tenth of the cognitive impairments found in non-demented community-dwelling subjects 363. 
Schilder et al. (2010) confirms this finding in a group postmenopausal breast cancer patients 
334. This finding is a reminder that cancer occurs within the context of multiple comorbidities 
that could each have its own influence on the patient’s cognitive abilities and that it is important 
to consider these when conducting clinical trials on CRCI. 
A breast cancer diagnosis seems to affect performance on the WAIS-III Digit Symbol. Although 
we could not find evidence to support this finding at baseline, Schagen et al. (1999) reported 
that breast cancer patients who were treated with chemotherapy (cyclophosphamide, 
methotrexate and 5-fluorouracil, a somewhat outdated treatment scheme nowadays) 
performed worse on the WAIS Digit Symbol compared to breast cancer patients who did not 
receive chemotherapy 364. As previously mentioned, research on CRCI mainly focusses on 
breast cancer patients. A possible explanation for this may be that breast cancer patients are 
more emotionally open and express side effects quicker than others. In our trial, comprising 
44% breast cancer patients, we found that – although not statistical significant, breast cancer 
patients experienced more subjective cognitive complaints compared to other cancer patients. 
On the contrary, a fewer percentage of breast cancer patients than others were found to have 
CRCI (not significant, data not shown).  
The strengths of this study include several aspects. Firstly, although it is also listed as a 
limitation, we did include several cancer types. It is known that most research on CRCI is 
performed in breast cancer patients and that this is a shortcoming in current literature. Although 
more researchers have gained interest in other cancer types, highlighting that not solely breast 
cancer patients experience CRCI remains important. Further, as a result of including a high 
number of breast cancer patients, we were able to use this as a covariate in our analysis 
making it possible to see if breast or rather other cancer patients are more prone to certain 
cognitive impairments. Secondly, we used the DART to examine IQ, which is a quick and easy 
assessment tool. Other trials, investigating mainly post-adjuvant treatment CRCI, used tests 
such as the Wide Range Achievement Test (WRAT) 146, 365. Although clinically useful to screen 
for premorbid intelligence, the WRAT can take up to 45 minutes to administer depending on 
the age the patient, therefore making it less useful to add to an already exhaustive list of 
neuropsychological tests. Thirdly, this trial includes a wide range of cognitive domains and 
implements a number of tests that are advised by the ICCTF 148. Further, we also chose to use 
their definition of CRCI in order to facilitate comparing trial results with others. Lastly, our study 
tried to confirm findings of the few researchers who have reported predictors of baseline CRCI 
in cancer patients.  
The results of our analysis need to be interpreted with caution. First, we did not include a 
healthy control group. Nevertheless, we compared our findings with the binomial probability 
distribution. We estimated that approximately 17% of patients would score at least two SDs 
below the normative mean on a single test score when using a neuropsychological assessment 
including eight independent tests. Results found a statistical significant difference indicating 





that our selected population differs from healthy subjects, thus only in part explaining the 
influence of IQ, which is a known confounder of neuropsychological tests 335. Second, we have 
included patients of all cancer types and did not find a normal distribution across the cancer 
types. Although we believe that it is necessary to perform these studies in patients diagnosed 
with all cancer types, it may mask certain differences. Nonetheless, statistical analysis 
revealed that the cancer type did not influence overall impairment. Having a breast cancer 
diagnosis did influence the outcome on the WAIS Digit Symbol. Further research is warranted 
to compare breast and other cancer patients. Third, some neuropsychological tests, such as 
the RAVLT and CFT, did not provide optimal z-scores for older patients. Z-scores can only be 
calculated in three age categories (>30 years, 30-50 years, <50 years) which may result in 
more impairments in older patients due to this shortcoming in the normative data. On the other 
hand, when conducting the regression analyses, age was included as a covariate. Further, the 
linear regression analyses used raw test score instead of z-scores. Raw scores were selected 
in order to be able to compare our results with findings of other researchers. Therefore, the 
age and IQ effect may be more present in these results. Nonetheless, when using the 
standardized z-scores, IQ effects remain present in all domains. The influence of age remains 
present in the RAVLT and both conditions of the TMT (data not shown).  
To the best of our knowledge, this paper is the first to report baseline cognition of a 
heterogeneous group of cancer patients scheduled to receive a curative treatment. Although 
future research is needed to confirm our findings regarding medical and psychosocial factors 
such as fatigue in particular, we advise other researchers to include a short IQ evaluation such 
as the DART, which is quick and easy to administer, when conducting neuropsychological 
assessments in clinical trials investigating CRCI.  
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Research has indicated that cancer-related cognitive impairments (CRCI) may be influenced 
by psychosocial factors such as distress, worry and fatigue. Therefore, in this trial, we aimed 
to validate the distress thermometer (DT) as a screening tool to predict CRCI six months post 
treatment initiation in a group of general cancer patients.  
METHODS 
Patients (≥18 years, n=106) with a histologically confirmed diagnosis of a solid cancer or 
haematological malignancy, scheduled for a curative treatment, were evaluated at baseline 
(T0) and six months post-treatment initiation (T1) by a neuropsychological assessment 
including patient-reported outcome measures (PROMs). Assessed cognitive domains included 
premorbid intelligence, attention, processing speed, flexibility, verbal and visual episodic 
memory and verbal fluency. PROMs entailed distress (Distress Thermometer (DT), cut-off ≥4, 
range 0-10), anxiety and depression (Hospital Anxiety and Depression Scale), fatigue (FACIT-
fatigue scale) and subjective cognitive complaints (Cognitive Failure Questionnaire). 
RESULTS 
At T0, 60.4% of patients showed a DT score of ≥4, whereas 50% met this criterion at T1. 
According to the definition of the International Cognition and Cancer Taskforce, 25.5% and 
28.3% of patients presented with a CRCI at T0 and T1, respectively. When evaluating the DT 
as a screening tool for CRCI at T1, data showed an inverse relationship between the DT and 
CRCI with an AUC<0.5. ROC-curve analyses evaluating the DT and FACIT-fatigue scale as 
screening tools for subjective cognitive complaints showed an AUC±SE of respectively 
0.642±0.067 and 0.794±0.057. 
CONCLUSION 
The DT failed to predict objective CRCI at T1 but both the DT and FACIT-fatigue scale showed 
potential to be used as screening tools for subjective cognitive complaints. 
  




Chemobrain - a term coined to describe cancer-related cognitive impairment (CRCI) - is a 
common concern among cancer patients receiving chemotherapy 113, 116. It may influence 
cognitive functioning such as executive functioning, processing speed, working memory and 
organizational skills. CRCI can have a detrimental effect on a patient’s quality of life (QoL), 
influencing one’s ability to use complex thinking in making treatment decisions 120-122, 330, 366. 
CRCI can persist throughout the whole illness trajectory and in some domains, complaints 
remain present long after therapy has ended 124. A clear understanding of CRCI is crucial as 
there is a growing group of cancer survivors who have difficulties resuming their former 
activities 113.  
It has been noted that CRCI can be already observed before the administration of systemic 
chemotherapy 367. As a result, some authors suggest an association with psychological risk 
factors such as distress, worry and fatigue 134, 137, 368, 369. Distress is defined as a multifactorial 
unpleasant emotional experience of psychological, social and/or spiritual nature that may 
interfere with the ability to cope with cancer effectively, its physical symptoms and its treatment. 
Distress extends along a continuum, ranging from common normal feelings of vulnerability, 
sadness and fear to problems that can become disabling such as depression, anxiety, panic, 
social isolation, and existential and spiritual crisis 370. Studies have noted that up to 47% of 
newly diagnosed and recurrent cancer patients presented with a significant level of mental 
distress, to an extent that they can be diagnosed with a psychiatric disorder 371. The NCCN 
Guidelines in Distress Management recommend an early evaluation and screening of distress 
as it leads to poorer QoL if left untreated. Therefore, the NCCN Distress Management Panel 
developed the distress thermometer (DT) which uses an 11-point rating scale to identify 
distress caused by any kind of source, even if unrelated to cancer 351, 372. Other factors, 
including hypertension and diabetes mellitus, were also reported as potential confounders of 
CRCI 373.  
In this paper, we present the primary and predefined clinical secondary endpoints of the 
CONCEPT-trial (ClinicalTrials.gov Identifier: NCT01846260) in which we sought to examine 
the feasibility of the DT as a screening tool to predict CRCI in a group of general cancer patients 
receiving a curative treatment. As screening for distress is already implemented in routine care, 
this would allow a faster identification of patients who are prone to develop CRCI. Further, we 
analysed objective versus subjective cognitive complaints, examined cognitive changes over 
time and compared assessment results of patients with (C+) and without (C-) chemotherapy.  
METHODS 
Participants 
Patients were invited to participate in the CONCEPT-trial between May 2013 and September 
2015. All patients were recruited in the Kortrijk Cancer Centre, Kortrijk, Belgium. All patients 
were aged 18 years or above and had a histologically confirmed diagnosis of a solid tumour 
(lung, gastro-intestinal, GIST, urological, breast, sarcoma or gynaecological cancer) or 
haematological malignancy, in an early or advanced stage. Patients were scheduled to receive 
a treatment (radiotherapy, chemotherapy, radiochemotherapy, radiobiotherapy, anti-hormonal, 
targeted therapy or a combination of the above) with curative intent. Patients receiving surgery 
as a sole treatment were not allowed to participate. Other exclusion criteria included: a 
diagnosis with primary or secondary brain tumours, having a prior history of cancer during the 





last 5 years, with or without chemotherapy or radiotherapy, suffering from an organic brain 
syndrome, having an untreated or unstable major medical condition other than cancer, being 
alcohol or drug dependent, showing signs of mental deterioration based on the investigator’s 
judgement or pre-trial routine assessments, being diagnosed with dementia (DSM-IV criteria), 
presenting with a condition other than cancer in which fatigue is a prominent symptom (such 
as chronic fatigue syndrome) and having a major psychiatric or neurologic disorder that could 
potentially invalidate assessment; a prior or current diagnosis of a depressive or anxiety 
disorder was allowed since many cancer patients may suffer from this as a consequence of 
the cancer diagnosis. The trial was approved by the ethics committee of the General Hospital 
Groeninge, Kortrijk, Belgium and all patients gave written informed consent.  
Measures 
Patients were evaluated by a neuropsychological assessment (Table 1) including patient-
reported outcome measures (PROMs, Table 2) at baseline (T0) and six months post-treatment 
initiation (T1) 374. 
The neuropsychological test battery assessed the following cognitive domains: premorbid 
intelligence (Dutch Adult Reading Test (DART) 375), episodic memory (visual: Rey’s Complex 
Figure Test (CFT) delayed recall test 376; verbal: Rey’s Auditory Verbal Learning Test (RAVLT) 
delayed recall test 341), executive functions (flexibility: Trail Making Test (TMT) number-letter 
sequencing 343; phonetic and semantic word fluency: Controlled Oral Word Association Test 
(COWA) 344; processing speed: TMT number sequencing 343 and WAIS-III Digit Symbol 348) 
and working memory (attention: WAIS-III Digit Span 348). An alternative form was used to 
minimise practice effect in case of the Rey’s Auditory Verbal Learning Test (RAVLT) 341. All 
assessments were performed by either a neuropsychologist (MSc) or study trial coordinators 
(MSc, PhD) trained to perform these measurements.  
PROMs included an assessment of distress (Distress thermometer (DT) and 39-item Problem 
List 372), anxiety and depression (Hospital Anxiety and Depression Scale (HADS) 351), fatigue 
(FACIT Fatigue Scale 352) and subjective cognitive complaints (Cognitive Failure Questionnaire 
(CFQ) 377).  
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Table 1. Neuropsychological assessment 
Cognitive 
domain 
Test  Item Outcome measure Range 
Premorbid 
intelligence 
Dutch Adult Reading 
Test (DART)  
IQ estimation IQ estimation ≥ 0 
Episodic memory  
Visual Rey’s Complex Figure 
Test (CFT)  
Delayed recall Total score 0 – 36 
Verbal  Rey’s Auditory Verbal 
Learning Test (RAVLT)  
Delayed recall Total score 0 – 15  
Executive functions  











Controlled Oral Word 
Association Test 
(COWA)  
Animals Number of correctly 





Controlled Oral Word 
Association Test 
(COWA)  
letter N Number of correctly 














WAIS-III Digit Symbol   Number of correct 
items 
≥ 0 
Working memory  
Attention WAIS-III Digit Span  Forward & 
Backward span 
Total score 0 – 30  
WAIS: Wechsler Adult Intelligence Scale 
Table 2. Patient-reported outcome measures 
Measure Indication Range Cut-off 
Distress thermometer (DT) 
and 39-item Problem List  
Distress 0-10 ≥4 
Hospital Anxiety and 
Depression Scale (HADS)  
Anxiety 0-21 ≥8 
Depression 0-21 ≥8 




Questionnaire (CFQ)  
Subjective cognitive 
complaints 
0 – 100 ≥43 
FACIT: Functional Assessment of Chronic Illness Therapy; NA: not applicable 
Statistical considerations 
Statistical analyses were conducted by use of SPSS software (version 23; IBM SPSS 
Statistics, Chicago, IL). Descriptive statistics were performed to present patient and tumour 
characteristics and neuropsychological assessment results. In accordance with the 





International Cognition and Cancer Task Force (ICCTF), patients were marked as having a 
cognitive impairment if they either presented with two or more test scores at or below -1.5 
standard deviations (SDs) from the normative mean or if they presented with one test score at 
or below -2.0 SDs 148. Published normative data, adjusted for gender, age and/or education, 
were used to convert raw test scores into standardized z-scores (mean = 0; SD = 1), if 
applicable. Data from questionnaires were converted according to standard scoring rules.  
It was assumed that the neuropsychological assessment was the gold standard against which 
the DT was compared. Sample size calculations were based on following assumptions. A 
sample of 21 from the positive group and 63 from the negative group would achieve 81% power 
to detect a difference of 0.20 between the area under the roc curve (AUC) under the null 
hypothesis of 0.50 and an AUC under the alternative hypothesis of 0.70 using a two-sided z-
test at a significance level of 5%.  
Paired-sample T-tests were performed to detect differences between neuropsychological test 
scores at T0 and T1 for all patients together and for the C+ and C- group separately. Univariate 
analysis of variance, adjusted for age and IQ, were selected to compare results at T1 between 
the C+ and C-group. Binary logistic regression analysis was performed in order to find 
predictive factors of CRCI. Regression analysis included 13 covariates: age, gender, 
premorbid IQ, distress level, fatigue level, cognitive complaints, days since diagnosis, surgery 
(yes or no), active treatment for diabetes mellitus, active treatment for hypertension,  stage 
(early vs. late stage), treatment (chemotherapy: yes or no) and diagnosis (breast cancer or 
not). Variables were included in the model if they were significant at the p<0.05 level.  
RESULTS 
Patient characteristics 
In total, 125 patients were included in the trial. Baseline patient characteristics are previously 
described 367. Of the 125 patients, 106 (84.8%) completed the second assessment (Table 3). 
Five patients withdrew from the trial without giving a specific reason, five patients felt too ill, 
four patients did not want to make the extra travel to the hospital, three patients had died as a 
consequence of their disease or treatment and two patients declared to have no time. At T0 
and T1, respectively one and five patients did not fully complete the PROMs. The mean age 
of the remaining 106 patients was 59.0 years (range: 30.0-85.0). Patients were more likely to 
be female (69.8%) and presented with following cancer types: breast (48.1%), gastro-
enterological (24.6%), genitourinary (11.3%), gynaecological (9.4%), haematological (5.7%) 
and lung (0.9%). More patients had an early stage disease (65.1%). Exactly half of patients 
(50.0%) received (neo)adjuvant chemotherapy with or without radiotherapy and/or hormonal 
treatment. Other patient characteristics and chemotherapy regimens are presented in Table 3.  
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Table 3. Demographic and clinical data (n=106) 
Demographics n (%) 
Gender  
   Female 74 (69.8) 
   Male 32 (30.2) 
Highest education  
   Primary education 0 (0) 
   Lower secondary education 25 (23.6) 
   Higher secondary education 42 (39.6) 
   Higher education 34 (32.1) 
   Other 5 (4.7) 
Clinical data  
Stage  
   Early (I-II) 69 (65.1) 
   Advanced (III-IV) 37 (34.9) 
Surgery prior to T1 95 (89.6%) 
Treatment  
   Hormonal treatment alone 1 (0.9) 
   Radiotherapy alone 7 (6.6) 
   Chemotherapy alone 29 (27.4) 
   Radiochemotherapy  20 (18.9) 
   Radiotherapy and hormonal treatment 45 (42.5) 
   Chemotherapy and hormonal treatment 1 (0.9) 
   Radiochemotherapy and hormonal 
treatment 
3 (2.8) 
Chemotherapy (n=53)  
Folfox 12 (22.6) 
Cisplatin w/o other compound 10 (18.9) 
Carboplatinum with taxane derivate 9 (17.0) 
5FU 8 (15.1) 
FEC w/o taxotere 3 (5.6) 
Cyclofosfamide with taxane derivate 3 (5.6) 
AC with paclitaxel 2 (3.8) 
ABVD 2 (3.8) 
Gemcitabine 2 (3.8) 
RCHOP21 2 (3.8) 
FU: fluorouracil, FEC: fluorouracil, epirubicine, cyclofosfamide, AC: adriamycine, 
cyclofosfamide, ABVD: doxorubicine, bleomycine, vinblastine, dacarbazine, RCHOP: 
rituximab, vincristine, adriamycine, cyclofosfamide, prednisone 
Primary endpoint results 
At T0, 60.4% of patients showed a DT score of ≥4, whereas 50% met this criterion at T1. 
According to the definition of the ICCTF, 25.5% and 28.3% of patients presented with a CRCI 
at T0 and T1, respectively. When evaluating the DT as a screening tool for CRCI at T1, ROC-
curve analysis revealed an AUC <0.5. Binary logistic regression analysis found that less 
distress at T0 (B=-0.267, p<0.05), having a lower premorbid IQ (B=-0.066, p<0.05), female 





gender (B=1.861, p<0.05) and no surgery (B=-1.745, p<0.05) predicted CRCI at T1. 
Chemotherapy did not influence the risk on CRCI (B=0.186, p=0.666). 
CRCI vs. cognitive complaints 
At both time points, only a small percentage of patients stated to have cognitive complaints 
based on a Cognitive Failure Questionnaire (CFQ) score of 43 or higher (14.3% at T0, 16.8% 
at T1). Fig 1.A and 1.B show the number of patients with a CRCI at T0 and T1 subdivided by 
a CFQ-score of ≥43. At baseline, the distribution of cognitive complaints was more or less 
equal in both groups (Fig. 1.A). At T1, more patients experienced subjective cognitive 
complaints (Fig. 1.B). Surprisingly, the majority of these patients were not diagnosed with a 
CRCI. ROC-curve analyses evaluating the DT and FACIT-fatigue scale as screening tools for 
subjective cognitive complaints showed an AUC±SE of respectively 0.642±0.067 and 
0.794±0.057 (Fig. 2.A and 2.B). 
 




Cognitive changes and subgroup analyses 
Table 4 and 5 show mean PROM scores and mean raw scores per cognitive test at T0 and T1 
for all patients and for the C+ and C-group independently. Paired-samples T-test detected 
significant differences for the WAIS-III Digit Symbol, RAVLT delayed recall and CFT delayed 
recall when comparing T0 and T1 in all patients. An improved performance over time was 
found in all tests except for the RAVLT delayed recall test. 
Mean age and mean education age of the C+ group was calculated as 57.8 and 18.7 years, 
respectively, whereas the C- group had a mean age of 60.2 years and a mean education age 
of 18.5 years. Mann-Whitney U test did not detect statistical significant differences in terms of 
age and education age (p=0.459 and p=0.430, respectively). The C+ and C- group both 
comprised primarily female individuals (58.5% and 81.1%, respectively). However, a significant 
difference was detected (Χ² test: p<0.05). Table 4 and 5 show mean PROM and 
neuropsychological test scores, respectively, at T0 and T1 for the C+ and C- group.  Distress 
decreased over time for the C+ group and slightly increased in the C- group. C+ patients also 
showed significant lower distress at T1 compared to C- patients (p<0.01). Similar results in 
terms of other PROMs and cognitive changes, compared to all patients together, were found 
for both the C+ and C-group. A better performance on neuropsychological tests was found at 
T1 in all domains except for the RAVLT. In both groups, significant within group differences, 
indicating decreased performance at T1, were found for the RAVLT and CFT delayed recall 
between T0 and T1. The C+ group also showed significant within group differences for the 
WAIS-III Digit Span, WAIS-III Digit Symbol and TMT letter-number sequencing. Univariate 
analyses of variance, adjusted for age and IQ, did not reveal any significant differences 
between the C+ and C-group in case of individual cognitive domains at T1 (Table 5). 





Abbreviations: SD: standard deviations, HADS: hospital Anxiety and Depression Scale, 




Table 4. Mean PROM scores of all patients, C+ patients and C- patients at T0 and T1 
 



















































p-value within group <0.01 <0.001 0.838  



























p-value within group 1.000 0.711 0.704  
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Table 5. Mean raw scores of all patients, C+ patients and C- patients at T0 and T1 
 



























































0.306 0.827 0.069  



















































<0.001 <0.05 <0.01  



















































0.094 <0.05 0.777  
*cognitive domains adjusted for age and IQ. Abbreviations: SD: standard deviations, COWA: 
Controlled Oral Word Association, WAIS: Wechsler Adult Intelligence Scale, RAVLT: Rey’s 
Auditory Verbal Learning Test, CFT: Complex Figure Test, TMT: Trail Making Test 






We aimed at 1) validating the widely used DT as a screening tool to predict CRCI in a group 
of general cancer patients scheduled for curative treatment, 2) evaluating objective CRCI 
versus subjective cognitive complaints, 3) analysing cognitive changes over time and 4) 
comparing assessment results of C+ and C- patients. Our data showed that the DT failed to 
predict CRCI at T1. On the contrary, baseline PROMs including the DT and FACIT-fatigue 
scale were able to predict subjective cognitive complaints at T1. We found a lower verbal 
memory performance in all patients over time. Further, we did not detect differences on 
neuropsychological test scores at T1 between C+ and C-patients.  
To our knowledge, this is the first study that looked into in the feasibility of the DT as a 
screening tool to predict CRCI six months post-treatment initiation. In our sample, respectively 
25.5% and 28.3% of patients presented with a CRCI at T0 and T1. We stated that we would 
only accept the DT as a screening tool if we would find an AUC of at least 0.70. Unexpectedly, 
we found a trend for an inverse relationship between the degree of distress and the risk on 
CRCI with an AUC<0.5 indicating that patients with a CRCI indicate a lower distress level. A 
possible explanation for this finding may be that cognitively impaired patients do not 
acknowledge the impact of their diagnosis and upcoming treatment and that they would 
therefore indicate a lower degree of distress.   
Our data indicate that IQ, no surgery and gender may also influence CRCI at T1. We previously 
reported that IQ predicts baseline CRCI in cancer subjects 367. It has also been reported that 
IQ influences neuropsychological test scores 356. Surprisingly, patients not receiving surgery 
are more at risk of developing CRCI at T1. A possible explanation may be that those patients 
had a (non-significant) lower premorbid IQ than patients who did receive surgery (data not 
shown). Further, female gender also increased CRCI risk. In our sample, this may be a result 
of including a high number of female individuals (69.8%) with the majority of those being 
diagnosed with breast cancer (68.9%). Gender differences have been observed previously by 
Lezak et al. (2012) in non-cancer subjects 378. On the contrary, Visovatti et al. (2016) could not 
confirm these findings in a group of colorectal cancer patients 144. A difference should be made 
between having a CRCI at T1 and the development of CRCI from baseline to T1. In our sample, 
12 patients had no CRCI at baseline and developed CRCI by the time assessment six-months 
post treatment initiation. While 12 patients are a rather small group for statistical analysis, data 
showed no difference in terms of treatment, but did indicate a mean increase of in fatigue level 
in these patients (data not shown). Another interesting question is why breast cancer patients 
seem to be more prone to have cognitive troubles after their treatment has ended. One 
explanation may be that the breast cancer patients included in our trials, of which the majority 
only received radiotherapy followed by hormonal treatment, experience more distress as a 
results of less close follow up compared to the C+ group where the period between the end of 
the treatment and the second assessment was much shorter (data not shown). However, more 
research is necessary to look into these hypotheses.  
When comparing objective test scores with subjective cognitive complaints, results did not fully 
match. This is in line with Hutchinson et al. (2012) who stated that objective and perceived 
impairment could be unrelated because subjective complaints may be an indicator of distress, 
rather than of CRCI 379. Interestingly, ROC-curve analysis indicated that the DT and certainly 
the FACIT-fatigue scale at T0 could be used to predict cognitive complaints in cancer patients 
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six months post treatment initiation. Although it has been reported that distress and fatigue 
influences self-reported cognition 380, we are – to our knowledge – the first to report upon the 
possibility predicting cognitive complaints by use of the DT and FACIT-fatigue scale. It is known 
that stress may induce cognitive changes 137. Nonetheless, these findings further highlights the 
importance of the early detection of psychosocial problems so that appropriate care can be 
implemented. A prospective trial, however, should be set up to confirm these findings.  
We compared test scores at T0 and T1 of the individual cognitive domains. Most scores 
improved over time which can be attributed to the practice effect 133. The RAVLT delayed recall 
showed decreased performance at T1. Similar results were found when comparing the C+ and 
C- group. Worse RAVLT performance over time has not always been found in other studies. 
Deprez et al. (2012) for example found worse performance in C+ patients, but increased scores 
in C- patients and healthy controls 381. In our trial, the RAVLT was the last test to be assessed 
in the test battery and was further the only test for which an alternative form was used. 
Therefore, we are left to speculate that lower results could be influenced by these factors.  
Further, we compared C+ and C- patients of all cancer types. Between group analyses did not 
detect any differences between test scores at T1. Although, it has been suggested that 
chemotherapeutic regimens may result in lower cognitive performance, researchers have not 
reached a consensus on the exact pathophysiology 382. Further, others have previously 
suggested that the influence of chemotherapy in the etiology of CRCI may be smaller than 
initially thought 383. A reason why no difference was found could be the result of the different 
types of regimens included in the trial. Patients were allowed to participate in this trial 
regardless their type of chemotherapy. Further, it has been reported that the effects of cytotoxic 
drugs on cognition can recover over time 384. The type of cytotoxic drug probably did not affect 
neuropsychological test score, as all were considered neurotoxic in some level (data not 
shown). As some patients only received a short chemotherapy schedule, cognitive decline may 
have been present shortly after treatment had ended. Another reason could be attributed to 
the dose of the chemotherapy patients received as it has been stated that high-dose 
chemotherapy appears to impair cognitive functioning more than standard-dose chemotherapy 
385. Data is not available regarding this matter and can therefore not be assessed.  
The strengths of this study include multiple aspects. First, we are the first to examine the 
feasibility of the DT to predict CRCI in a group of general cancer patients. Although we obtained 
a negative result, we found that the DT might be able to predict subjective cognitive complaints. 
We also found that fatigue seems to have a high impact on patient-perceived impairment and 
that it may be possible to predict cognitive complaints with the FACIT-fatigue scale. These 
findings emphasize that it is crucial to address psychosocial issues and that it is essential to 
identify those at the beginning of the treatment. By using questionnaires, which are already 
used in routine practice, such as the DT, screening for cognitive complaints could be easily 
implemented. Second, this trial included a variety of cancer types. Other research mainly 
focused on breast cancer patients. Nevertheless, other cancer patients also experience 
cognitive disturbances. Third, we have included an equal amount of patients who did and who 
did not receive chemotherapy. Therefore, we were able to compare assessment results of both 
groups. An interesting finding was that we did not detect any differences in any of the assessed 
cognitive domains at T1 between the C+ and C- group. Although imaging studies have shown 
that white matter integrity may be altered as a result of chemotherapy 131, 381, our data suggest 
that processes other than the chemotherapeutic regimen may induce CRCI. This confirms that 
the term ‘chemobrain’ may have been an unfortunate choice.    





The results of this trial also need to be interpreted with caution. We did not include a healthy 
control group. We were however able to compare assessment results of cancer patients with 
and without a chemotherapeutic treatment. As a result, we were able to compare cognitive 
outcomes of C+ and C- patients. On the other hand, when comparing the number of impaired 
patients to the binomial probability distribution 355, 367, we found significantly more impaired 
patients in our sample at both time points (data not shown). This suggests that other factors 
may also play a role in the existence of CRCI. One of those factors that was not assessed 
within this trial is coping. It has been mentioned that effective coping strategies could act as a 
protective factor for individuals who have a high risk for CRCI. Nonetheless, the way a patient 
deals with cancer influences distress and it could therefore be stated that coping and distress 
are correlated 386, 387. The same could be said for depression 388. Nonetheless, it has to be 
mentioned that distress is a multifactorial variable that includes a variety of emotions such as 
coping, but also anxiety and worry. Therefore, when assessing distress, these factors are 
indirectly taken into account. On the other hand, lower levels of distress and thus lower levels 
of subjective cognitive complaints, could have been the results of closer psychological support 
between the baseline assessment and T1. Though this was not monitored, it should be 
mentioned that psychological support is offered to all patients at the beginning of their cancer 
treatment trajectory. Further, we did not obtain a balanced distribution of cancer types and 
included a high number of breast cancer patients. As initial research focuses on breast cancer 
patients, being able to include ‘having a breast cancer diagnosis’ as a confounding factor in 
the regression analyses was interesting. Especially since this variable did not predict CRCI.  
In conclusion, we can state that the DT cannot be used to predict CRCI, but that it can be used 
as a screening tool to predict subjective cognitive complaints six months after treatment 
initiation. This trial further indicates that psychosocial factors have an important role in self-
reported cognitive complaints and that PROMs may be used to predict those impairments. 
Addressing these issues is crucial to understanding self-reported cognitive dysfunctions. Last, 
our findings suggest that variables other than chemotherapy may influence objective cognitive 
impairments in cancer patients and that more research is warranted to overtake the exact 
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Validation of uHear™ as a screening tool to detect hearing loss in older cancer patients as part 
of a Comprehensive Geriatric Assessment (CGA). 
METHODS 
Patients (≥70 years) with a histologically confirmed diagnosis of cancer, were enrolled at the 
time of CGA screening. Patients were evaluated by uHear™, which was compared to 
conventional audiometry as gold standard. We defined a pure-tone average (PTA) of ≥ 40 dB 
HL as the pass or fail screening cut-off. Validation of uHear™ was defined in terms of 
diagnostic accuracy through Receiver Operating Characteristics (ROC)-analysis. To accept 
uHear™, we estimated that the Area Under the ROC-curve (AUC) had to differ significantly 
from 0.50 with an AUC of at least 0.70. The Whispered Voice Test and Hearing Handicap 
Inventory for the Elderly were also administered.  
RESULTS 
Thirty-three patients consented for participation. In one patient, the results of one ear were 
excluded from the analysis as the patient was documented with a known hearing disorder in 
that ear. Significant hearing loss, defined by a PTA of ≥ 40 dB HL calculated from the air 
conduction thresholds at 0.5, 1.0 and 2.0 kHz, was found in 15.4% of tested ears. uHear™ 
showed excellent diagnostic accuracy with an AUC±SE of 0.98±0.14. It provided maximum 
sensitivity (100.0%) but poor specificity (36.4%) at our predefined cut-off score of ≥ 40 dB HL. 
CONCLUSION 
Based on the AUC, uHear™ could be implemented as a screening tool to detect hearing loss 
in older cancer patients within a CGA. However, as it showed a low specificity, optimization of 
the cut-off score is necessary.  
  




The cancer incidence is 11-fold higher in patients aged 65 or more than in their younger 
counterparts 2. Some older patients may tolerate treatment as well as younger patients, 
although others might suffer from severe toxicity and may require treatment modifications. For 
this reason, it is crucial to identify those patients who have an increased risk of developing 
toxicities 389. Selecting proper treatments solely based on the information the physician 
retrieved during the appointment, is a very difficult task. Therefore, a comprehensive geriatric 
assessment (CGA) has been the key to individualized care in older cancer patients 12, 390. A 
CGA is a multidisciplinary evaluation assessing medical, psychosocial and functional 
capabilities and limitations in older cancer patients. It aims at predicting the functional age of 
patients including the risk on morbidity and mortality through assessing a wide range of 
domains such as functional status, cognition, nutrition, emotional status, polypharmacy, 
comorbidities and sensory dysfunctions including vision and hearing 37, 131, 366, 391.  
Presbyacusis is a common problem among older people, affecting 90% of the people aged 80 
and older 392. It is estimated that at least 40% of people aged 65 years and older present with a 
hearing loss important enough to impair communication 156. Acoustic deterioration can lead to 
social isolation 236, seriously affecting patients’ ability to function properly whilst difficulties with 
communication can lead to a significant reduction in quality of life. In addition, poor hearing reflects 
whether the patient is able to hear instructions regarding potential adverse events, supportive 
care medications and indications of when to seek medical care 7, 393.  A formal audiogram has 
been proposed as the gold standard to define patients’ hearing status 394. However, such 
assessment is time-consuming and requires additional appointments, which may be cumbersome 
for cancer patients who already need to spend a lot of time in the hospital. Further, many 
physicians have little or no time to screen for hearing loss, which urges the necessity of a quick 
and simple screening tool 395.  
The content of a CGA is mainly based on the NCCN Guidelines in Older Adult Oncology 131. As 
mentioned, NCCN recommends assessing not solely functional domains, but they state that it is 
also important to take sensory dysfunctions such as vision and hearing, into account. To screen 
for hearing loss, NCCN advises a whispered voice test in which patients need to occlude an ear 
while the investigator whispers following sentence: “What is your name?”. The patient passes if 
he hears the sentence and is able to answer it. He fails when he does not succeed in this task. 
The test is repeated for the contralateral ear 131. In this paper, we will use the validated Whispered 
Voice Test (WVT) as the screening tool recommended by NCCN. This WVT has been validated 
in several studies in non-cancer subjects, and thus not in our target population, but it has shown 
a good sensitivity, specificity and Area Under the receiver operating characteristics (ROC) - Curve 
(AUC) 235. However, various outcomes have been reported especially due to the inter-rater 
reliability, possibly caused by differences in loudness of the whispering, and thus decreasing the 
usability of the WVT in clinical practice 236.  
The last decade, the use of multimedia applications has increased dramatically. More than six 
billion cell phones have been sold globally. This consumer-driven demand has led to changes in 
the society where almost everyone can afford a hand-held computer and communication device. 
With this growing technology, there are many cultural and infrastructural reasons to adopt cell 
phones as a vehicle to improve health care 396. uHear™ was designed by Don Hayes and runs 
on iOS devices such as iPod, iPad and iPhone. It is easily accessible, free and fast to assess. 
uHear™ is an ear-level pure-tone hearing test designed to determine air conduction thresholds 
in each ear independently. The app has been validated for use in a general population and has 





shown good performance scores in ruling out moderate hearing loss 257, 397. In this trial, we aimed 
at validating uHear™ as a screening tool for hearing loss specifically in older cancer patients as 
part of a CGA.  
METHODS 
Patient selection 
The registered UHEAR-trial was conducted in older cancer patients at the radiotherapy and 
oncology departments of the General Hospital Groeninge (Kortrijk, Belgium) from December 
2014 till June 2015 (UHEAR-trial; clinicaltrials.gov identifier: NCT02381782). An ethics committee 
approval was obtained from the ethics committee of the General Hospital Groeninge. Patients 
were recruited upon presentation at the geriatric oncology clinic, where we try to evaluate all newly 
diagnosed cancer patients, when they received a CGA as part of routine clinical practice 24, 391, 398. 
Eligible patients were at least 70 years old at the time of enrolment and needed to have a 
histologically confirmed diagnosis of a solid cancer or haematologic malignancy. Any type of 
treatment and any type of stage were allowed. Patients had to be cognitively able to perform 
assessments. Ears of patients with a known hearing loss, fitted with hearing aids, clinically 
diagnosed with Meniere’s disease, retrocochlear hearing loss, autoimmune inner ear disease, 
fluctuating hearing loss or a history of sudden sensorineural hearing loss were excluded from 
analyses.  
Measures 
Comprehensive Geriatric Assessment 
Hearing tests were assessed as part of a CGA. In routine practice, patients are screened with the 
Geriatric-8 questionnaire (G8). A cut-off of ≤14 was applied 399. Patients who screen negative are 
deemed fit and are not assessed with a full CGA. However, for uniformity purposes, we aimed at 
assessing all negative screening patients with a complete assessment in this trial.  
The CGA comprises following standardized measures asides to specific questions regarding 
social status: functional status (Activities of Daily Living, Instrumental Activities of Daily Living 
48, 49), physical status (number of falls), nutrition (Mini Nutritional Assessment - Short Form 322), 
emotional status (Geriatric Depression Scale – 15 60), cognition (MMSE or Freund CDT 51, 330, 
366), polypharmacy (number of drugs) and comorbidities (Charlson Comorbidity Index 324). 
Patients were deemed vulnerable if they presented with impairments in two or more domains 
within the CGA 6, 24, 313.  
Audiological evaluation 
A trained and certified audiologist performed all audiological measures. 
Immitance measurement and pure tone audiometry  
A 226 Hz tympanometry was performed with an 85 dB SPL probe tone (Zodiac 901 Middle-ear 
Analyzer, Madsen Electronics). Pure tone audiometry was conducted in a sound booth by use of 
a recently calibrated Interacoustics AC3 audiometer. The Hughson-Westlake technique was 
applied. Air conduction thresholds were established for conventional octave frequencies ranging 
from 0.25 kHz to 8.0 kHz.  
 
 




uHear™ (version 2.0, Unitron, Victoria, BC, Canada) was performed by use of an iPod touch 
(iOS version 8.1.2, Apple Inc., Cupertino, California, USA). Standard iPod touch ear buds were 
used. Testing took place in a quiet hospital room or physician’s office. The application contains 
three modules. In this trial, we used the sensitivity test to determine air conduction thresholds 
at 0.5, 1.0, 2.0, 4.0 and 6.0 kHz, measured in each ear separately. uHear™ uses a 267ms 
pulse duration and employs a simple 10 dB down and 5 dB up approach. The lowest threshold 
with two responses out of three excursions is recorded as the hearing sensitivity 257.  
Whispered Voice Test 
The WVT was performed by the audiologist when standing behind the patient in a quiet hospital 
room or physician’s office. While not documented, background noise in both types of rooms 
are comparable as they are all located in moderately busy hospital corridors. The patient had 
to repeat a set of three different numbers at four decreasing levels of loudness per ear with an 
angle of 180° azimuth: conversational voice at six inches and at two feet from the ear, and 
whispered voice at six inches and at two feet from the ear while the patient occluded the 
external auditory canal of his non-tested ear. The investigator exhaled completely prior to 
testing in order to ensure an equal intensity level in all assessments. A pass was given if the 
patient could repeat all three numbers correctly at each level of loudness or if he achieved 
greater than 50% success over three successive triplet sets. Failure to pass at each level of 
voice testing is considered indicative for hearing impairment 235. 
Hearing Handicap Inventory for the Elderly 
The Hearing Handicap Inventory for the Elderly (HHIE) has been developed as a self-
assessment tool to assess the impact of hearing loss on the emotional and social adjustment 
of older patients. It consists of a 13-item subscale based on emotional side effects and a 12-
item subscale exploring social and situational consequences. The HHIE scores ranges from 0 
to 100 with a cut-off score of ≥43 indicating a significant perceived handicap. Scores ranging 
from 17 to 42 indicate a mild to moderate perceived handicap 244, 400.  
Statistical Analyses 
Statistical analyses were conducted by use of SPPS software (version 22; IBM SPPS 
Statistics, Chicago, IL) and Prism® software (GraphPad Prism 5, Inc., La Jolla, CA). Descriptive 
statistics were performed to present patient and tumour characteristics. Descriptive statistics 
were further conducted to present assessment results of both CGA and hearing tests. The 
Pure-Tone Average (PTA) was calculated as the average air conduction threshold found at 0.5 
kHz, 1.0 kHz and 2.0 kHz. We defined a PTA of ≥40 dB HL as the pass or fail screening cut-off 
as this was proposed by Ventry and Weinstein for individuals aged 65 years or older 246. Since 
data did not meet the criteria of normality, Wilcoxon matched-pairs signed-ranks test was used to 
compare uHear™ and conventional audiometry thresholds. A priori sample size calculations 
were based on literature review and following assumptions 156, 392. We assumed that 
conventional audiometry was the gold standard against which uHear™ was compared. A 
diagnostic test with an AUC of 0.50 has no diagnostic value (comparable to tossing a coin). 
We would therefore only accept uHear™ if the AUC significantly differed from 0.50 at the 5% 
significance level. We aimed to include 63 eligible ears. A sample of 25 from the positive group 
and 38 from the negative group would achieve 80% power to detect a difference of 0.20 
between the AUC under the null hypothesis of 0.50 and an AUC under the alternative 
hypothesis of 0.70 using a two-sided z-test at a significance level of 0.05. The data are discrete 





(rating scale) responses. The AUC is computed between false positive rates of 0.00 and 1.00. 
The ratio of the standard deviation of the responses in the negative group to the standard 
deviation of the responses in the positive group is 1.00. Sensitivity and specificity with 95% 
confidence intervals (95%CI) were calculated at our predefined cut-off score. Positive and 
negative predictive values were also determined (PPV and NPV, respectively). 
RESULTS 
Patient Characteristics 
In total, 34 patients consented for participation. One patient withdrew during the testing phase 
due to deterioration of the overall condition. Of the remaining 33 patients or 66 ears, the results 
of one ear were excluded from the analyses as the patient presented with a known hearing 
disorder in that ear.  
Patients had an average age of 76.4 years (range: 70-85). The majority of patients were males 
(69.7%). Patients presented with a cancer diagnosis of following sites: haematologic 
malignancy (33.3%), genitourinary (27.3%), gastro-intestinal (15.1%), breast (9.1%), head and 
neck (9.1%), gynaecologic (3.0%) and thoracic sites (3.0%). Most patients received systemic 
treatment (51.5%) and were treated with palliative intent (57.6%) (Table 1). 
Patients presented with a mean G8 score of 14.2 (range: 7.0-17.0). The majority of patients 
(57.5%) screened negative on the G8 and were considered ‘fit’. In all but two patients, cognition 
was assessed through either MMSE of Freund CDT. All of those (100%) were considered as 
cognitively adequate. One patient participated in a trial by our group in which a full 
neuropsychological evaluation is performed. He showed good cognitive functioning (data not 
shown). One patient did not undergo any form of cognitive screening as he screened negative 
on the G8 and no full CGA data were obtained.   
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Table 1. Patient characteristics 
Characteristics (n = 33) Mean (range) 
Age (years) 76.4 (70-85) 
 n (%) 
Sex  
Male 23 (69.7) 
Female 10 (30.3) 
Cancer site  
Haematologic malignancy 11 (33.3) 
Genitourinary 9 (27.3) 
Digestive  5 (15.1) 
Breast 3 (9.1) 
Head and neck 3 (9.1) 
Gynaecologic 1 (3.0) 
Thorax 1 (3.0) 
Treatment type  
Systemic 17 (51.5) 
Radiotherapy 6 (18.2) 
Targeted therapy 6 (18.2) 
Combination 3 (9.1) 
Other 1 (3.0) 
Treatment intent  
Curative 14 (42.4) 
Palliative 19 (57.6) 
 
Conventional audiometry vs. uHear™ 
Tympanometry results were not obtained in five ears since occlusion of the ear canal failed. 
Most patients presented with normal tympanograms (Table 2). Mean pure-tone air conduction 
thresholds per frequency as measured by conventional audiometry and uHear™ are presented 
in Figure 1. Figure 1 further shows the average difference between both tests at 0.5, 1.0, 2.0 
and 4.0 kHz. Wilcoxon matched-pairs signed-ranks test indicated a statistical significant 
difference between thresholds found at 0.5, 1.0 and 2.0 kHz (p<0.001). No difference was 
found between uHear™ and conventional audiometry thresholds at 4.0 kHz (p=0.327). 
Table 2. Tympanometry results 
Type (n=60) n (%) 
A 48 (80.0%) 
Ad 7 (11.7%) 
As 2 (3.3%) 
B 2 (3.3%) 
C 1 (1.7%) 
Conventional audiometry indicated 15.4% of tested ears as having a clinically significant 
hearing loss with a PTA ≥40 dB HL (or 10 in the positive group). uHear™ found a PTA of 40 
dB HL or more in 69.2% of cases. As mentioned above, power analysis was based on a ROC-
curve in which uHear™ is compared to conventional audiometry, the gold standard. ROC-
curve analysis showed an excellent AUC±SE of 0.98±0.14 (Figure 2). It provided high S of 





100.0% (95%CI [65.5-100.0]), but poor Sp of 36.4% (95% CI [24.1-50.5]). The PPV and NPV 
were 22.2% (95%CI [11.7–37.5]) and 100.0% (95%CI [80.0–100.0]), respectively (Table 3). 
When excluding all ears without a tympanogram, or those with a type B or type C 
tympanogram, uHear™ showed similar results in terms of S (100.0% (95%CI [65.5-100.0])) 
and Sp (38.3% ((95%CI [24.9-53.6])), indicating its value in detecting sensorineural hearing 
loss. 
  
Figure 1. Mean air conduction thresholds and range measured by conventional audiometry 
and uHear™. Error bars indicate minima (conventional audiometry) and maxima (uHear); HL: 
hearing level 
 
Figure 2. Receiver operating characteristics (ROC) curve of uHear™ compared with 
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Since the cut-off of ≥40 dB HL resulted in a poor Sp of uHear™, exploratory analyses were 
performed in order to look at other cut-off scores. Results indicated that a cut-off of ≥55 dB HL 
would be more optimal to detect a PTA of ≥40 dB HL with conventional audiometry in this 
population (Figure 3.). Although 4.0 kHz had the highest correlation between both hearing 
tests, including this frequency in the PTA calculation did not improve the diagnostic accuracy 
(data not shown). 



















Figure 3. Sensitivity and specificity of uHear™ according to different cut-off scores based on 
the pure tone average 
Whispered Voice Test 
The WVT showed a positive test result in 4.6% of tested ears. S of the WVT was calculated as 
30.0% (95%CI[8.1-64.6]). Its Sp was 100.0% (95%CI[91.9-100.0]) (Table 3).  
Hearing Handicap Inventory for the Elderly  
The HHIE was recorded per patient, and not per ear, as with other results described in this 
paper. Pass or fail results from both ears, obtained through PTA calculation, were put together 
for this analysis. A fail was given to patients who presented with a PTA of ≥40 dB HL in both 
ears.  
The HHIE showed a mean score of 9.2 (0-32). No patient stated that they believed they had a 
significant hearing handicap. Seven patients (21.2%) showed scores between 17 and 42, 
indicating a perceived mild to moderate handicap. HHIE-results showed low S (0.0%, 
95%CI[0.0-53.7]), but maximum Sp (100.0%, 95%CI[85.0-100.0]) when using the cut-off of 
≥43. The HHIE indicated a high AUC±SE when compared to conventional audiometry 
(0.88±0.06) (Table 3).  
  

















(n = 65) 
Hearing Handicap 
Inventory for the 
Elderly 
(n = 33) 
Vulnerability (%) 
PTA ≥ 40 dB 15.4 69.2 * * 
Screening 
failure 
* * 4.6% 0% 
Performance measures 
S[95%CI] * 100.0 [65.5-100.0] 30.0 [8.1-64.6] 0.0 [0.0-53.7] 
Sp[95%CI] * 36.4 [24.1-50.5] 100.0 [91.9-
100.0] 
100.0 [85.0-100.0] 
AUC±SE * 0.98±0.14 ** 0.88±0.06 
Predictive values 
PPV[95%CI] * 22.2 [11.7–37.5] 100.0 [31.0-
100.0] 
** 
NPV[95%CI] * 100.0 [80.0–
100.0] 
88.7 [77.5-95.0] 84.8 [67.3-94.3] 
*: not applicable, **cannot be calculated 
PTA: pure tone average, Se: sensitivity, Sp: specificity, AUC: area under the ROC-curve, PPV: 
positive predictive value, NPV: negative predictive value, CI: confidence interval 
DISCUSSION 
Hearing loss is widespread in older patients and can result in reduced communication and 
cognitive performance, reduced functionality and poor quality of life 401. Therefore, NCCN 
Guidelines in Older Adult Oncology recommend an assessment of sensory functions such 
hearing, as part of a CGA. The NCCN proposes a screening tool that is similar to the WVT 131. 
In previous reports, the WVT showed good diagnostic accuracy, although problems were found 
when accounting the inter-rater reliability 235, 236. In our trial, we aimed to validate uHear™, an 
iOS-based application which is freely available in the iTunes store, to screen for hearing loss 
in older cancer patients within a CGA. 
uHear™ was compared to conventional audiometry, which is considered to be the gold 
standard. We stated that we would accept uHear™ if we found an AUC of at least 0.70. Results 
showed an excellent AUC of 0.98, indicating that we can use uHear™ as a screening tool for 
hearing loss within the CGA. A good screening tool needs a high S and high NPV as it reduces 
the number of false negative cases. uHear™ showed perfect S and NPV scores of 100.0%. 
On the contrary, we found poor Sp (36.4%) and poor PPV (22.2%). Exploratory analyses 
suggested that a cut-off of ≥55 dB HL may be more suited to detect a hearing loss with a PTA 
of ≥40 dB HL with conventional audiometry in this population. The poor Sp and PPV results 
can be attributed to the overestimation of air conduction thresholds as measured by uHear™ 
when compared to conventional audiometry. Wilcoxon matched-pairs signed-ranks test 
detected significant statistical differences between thresholds at 0.5, 1.0 and 2.0 kHz, whereas 
no difference was found at 4.0 kHz. Increased uHear™ thresholds in lower frequencies have 
also been noted in previous studies and may be ascribed to following factors 257, 258. First, 
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uHear™ was administered in a quiet room and not in a sound booth as with conventional 
audiometry. Although ambient noise was reduced to a minimum, it could not be excluded 
completely. Second, the average age of patients included in this trial was 76.4 years. Some 
patients were familiar with touch screens, whereas others had never worked with this type of 
device. Therefore, the tapping on the screen had to be learned upon assessment of uHear™. 
uHear™ demands an immediate tap when a sound is heard. When this does not happen, it 
registers the sound as ‘not heard by the patient’ and would therefore thus unwantedly elevate 
the threshold. However, if this effect would be present in some patients, there would be no 
difference between the results of both ears since frequencies are assessed alternatingly. 
Indeed, when comparing the results of the left and right ear for uHear™ at 0.5, 1.0, 2.0, 4.0 
and 6.0 kHz, no significant differences were detected (p=0.968, p=0.963, p=0.522, p=0.890 
and p=0.947, respectively). Third, both uHear™ and the standard iPod touch earbuds had not 
been calibrated. Therefore, it is impossible to ensure that the level and frequency of the 
auditory stimulus is exactly as it should be 258. Nonetheless, having to calibrate the device and 
its earbuds would lower the easy accessibility of this screening tool. Another possible 
explanation may be found in the type of transducer that is used to asses pure tone audiometry 
and uHear™. Audiometric testing was performed by use of a supra-aural headphone, while 
uHear™ was conducted with standard Apple earbuds. As it has been reported that the use of 
insert earphones results in higher hearing thresholds – especially in the lower frequency range 
due to the loss of vibration on the ear and cranium, this could be in part have attributed to the 
overestimation of the lower frequencies by uHear™ 402.   
When comparing uHear™ to the WVT, the screening tool proposed by the NCCN, it showed 
worse sensitivity results (30.0%). It did show excellent Sp (100.0%). Changing the pass or fail 
criteria, such as failing two out of four conditions, did not improve diagnostic accuracy as S 
improved (100.0%) but Sp decreased (49.1%). This was also the case when using solely the 
most difficult condition (whisper at 2 feet; S: 100.0% and Sp: 40.0%). However, we would still 
advise the use of uHear™ above the WVT. To start, the PTA in older patients can be slightly 
elevated due to poor attention, delayed response, interference from tinnitus and other 
neurophysiologic problems 403. Therefore, patients’ speech reception could better than their 
PTA results indicate. On the other hand, it also possible that a pure tone audiometry is less 
cognitively demanding compared to the processing of speech. When hearing threshold are 
elevated and hearing becomes more difficulties, patients have to put more effort into 
understanding what has been said 270. Consequently, results on the WVT could be 
overestimated, thus limiting the use of this tool. Further, it is know that the WVT has a low test-
retest reliability. One investigator may have a louder whisper of another, and thus leading to 
other results 235.  
The HHIE also did not outstand uHear™ with a lower AUC of 0.88. No patient declared that 
they believed to have a significant hearing handicap, which resulted in a S of 0.0%. This is in 
line with previous reports in which was stated that patients want to postpone the acquisition of 
hearing aids as long as possible 404. The HHIE did reach a high Sp 100.0%, although its clinical 
value is rather redundant for screening purposes. As the HHIE is filled in based on the patient’s 
perspective on his/her hearing for both ears, the results of the audiometry had to be combined. 
For the comparison, it was defined that patients failed pure tone audiometry when they had a 
PTA greater than 40 dB HL in both ears. Nevertheless, the patient’s worse ear may influence 
the result on the HHIE as this ear defines the patient’s handicap. When looking at the 
diagnostic properties of the HHIE compared to a PTA of ≥40 dB HL in the better ear, the S and 
Sp test remained the same (0% and 100.0%, respectively).  





We have already covered in part the limitations in this study. We can summarize them as 
follow. First, uHear™ overestimated air conduction thresholds resulting in a poor Sp. The lower 
the frequency, the higher the difference compared to conventional audiometry. Explanations 
may be found in the ambient noise level that was present in the testing room and the age of 
the population under study resulting in an unfamiliarity with touch screen devices. Exploratory 
analyses further indicated that a cut-off score of ≥55 dB HL could be more suited in this 
population. However, this needs to be confirmed through further research, which we are 
planning in the future. Second, we found a rather low proportion of patients presenting with a 
significant hearing loss since we did not include patients with a known hearing loss. This 
resulted in poorer performance scores of uHear™, WVT and HHIE. Third, since patients were 
recruited on one site of the hospital, we did not find a normal distribution of cancer sites. 
However, we feel that this did not influence results. Fourth, both uHear™ and the WVT 
assessed hearing monaurally. Binaural testing, however, would give more valuable information 
about the patient’s hearing functionality. While binaural testing is not feasible for uHear™, it 
could be easily conducted in case of the WVT. Combining the results of both ears for uHear™ 
could be more beneficial. Further, 6.0 kHz was not included in the pure-tone audiometry and 
could therefore not be compared to the results of uHear™. Nonetheless, evaluating 6.0 kHz does 
not have any benefit regarding the calculation of the PTA. Last, the time needed to assess 
uHear™ and conventional audiometry did not significantly differ. Although recommended by 
the NCCN, screening for hearing loss is not always incorporated in a CGA as it increases total 
assessment time. Nevertheless, looking at the patient’s hearing status is a crucial element of 
the CGA as it provides useful information for health care providers.  
Although uHear™ has some limitations, it also brings many advantages. Firstly, in the 
population under study, despite not being documented, we feel that the assessment time of 
uHear™ and conventional audiometry did not differ significantly since most patients were not 
familiar with touch screens and training was necessary. However, uHear™ does lead to profit 
in time since patients do not have to be transferred to the audiology department. Further, in 
future, training will be redundant since more patients will be familiar with touch screens. 
Secondly, having an idea of the patient’s hearing is crucial to health care providers. Certainly 
for those who have to explain the risk and benefits of the treatment and have to ensure that 
patients know what to do in case of adverse events. A patient with an unknown hearing 
disorder could feel uncomfortable to ask to repeat sentences over and over again. When these 
health care providers would know that the patient has a hearing problem, adequate measures 
can be taken such as improvement in signal to noise ratio, written instructions, etc.  
We want to emphasize that in cancer patients, it is not the main goal to diagnose patients with 
a hearing loss, but we rather want to be able to give physicians a complete view of the patients’ 
capabilities so that tailored care can be implemented. Based on the results of this trial, we can 
conclude that uHear™ is usable as a screening tool for older cancer patients within a CGA and 
that it is more favourable to use when compared to the NCCN proposed WVT or to the HHIE.  
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Validation of uHear™ as a screening tool to detect hearing loss in older cancer patients without 
a known hearing loss, as part of a Comprehensive Geriatric Assessment (CGA). 
METHODS 
Patients, aged ≥70 years, were evaluated by uHear™ and conventional audiometry, which is 
considered the gold standard, as part of a CGA. The pass or fail screening cut-off for uHear™ 
was defined as having ≥2 consecutive hearing grades starting from the moderate-severe 
threshold zone ranging from 0.5 – 2.0 kHz. To accept uHear™ as screening tool, it was 
predefined that the combined sensitivity (S) and specificity (Sp) of the test (S+Sp/2) had to be 
at least 80% and that an actual combined (S+Sp)/2 of 90% would be found.  
RESULTS 
Ninety ears were tested. Of those, 24.4% of tested ears presented with a pure tone average of 
40 dB HL or higher as measured by conventional audiometry, whereas a positive result was 
obtained in 26.7% of tested ears by uHear™. The combined (S+Sp)/2 was calculated as 77.5%.     
CONCLUSION 
uHear™ is a feasible tool for use within the CGA and shows promising results. However, further 
research is warranted in order to obtain the most optimal cut-off method for routinely use within 
geriatric oncology.  
 
  




Presbyacusis is one of the most prevalent conditions affecting older adults 405. Finding a person 
aged 70 years or older without a known hearing disorder or whose hearing sensitivity has not 
declined from youthful levels is rare 156.  The prevalence of hearing loss increases with age, 
and as a result of higher life expectancies the number of individuals presenting with hearing 
impairment is expected to increase in upcoming years 406. It is known that impaired 
communication, e.g. by hearing loss, is associated with decreased cognitive, emotional, 
physical and social functioning and that it can contribute to the development of delirium and 
dementia 407. Consequently, hearing loss can lead to a reduced quality of life 405. Further, 
sensory deficits also affect the ability to give adequate informed consent in oncology 408.  
Therefore, the NCCN Guidelines in Older Adult Oncology recommend an assessment of the 
sensory functions such as vision and hearing, as part of a Comprehensive Geriatric 
Assessment (CGA) 102.    
A CGA has been the cornerstone in the management of older cancer patients for many years 
12. It has found its way into oncology as there is an emerging need to develop a means to 
characterize the functional age of older patients with cancer, rather than their chronological 
age 22. A CGA can be described as a multidisciplinary assessment of the older patient in which 
problems in multiple health domains are uncovered, described and explained, if possible. This 
assessment further aims at predicting morbidity and mortality 409, 410. Its benefits have been 
widely described and include the prevention of geriatric syndromes, recognition of cognitive 
disorders, improved health status and detection of unsuspected conditions that may interfere 
with cancer treatment 410. In cancer patients, it may also predict chemotherapy toxicity and 
quality of life 7, 24. 
Although the NCCN Guidelines in Older Adults Oncology recommend a screening for hearing 
loss, it is not always incorporated into a routine geriatric assessment. Hearing loss can be 
easily detected through pure-tone audiometry. However, such assessment requires a transfer 
to the audiology department of the hospital, is time-consuming and not feasible to schedule in 
a busy geriatric oncology clinic with hundreds of geriatric oncology patients annually. Further, 
it can be considered as cumbersome for the patient who is already scheduled for a large 
number of diagnostic and therapeutic interventions. The NCCN therefore recommends an 
initial screening by use of a whispered voice test in which the patient is asked to repeat a 
sentence or sequence of numbers that is presented by the examiner by use of a whispered 
voice when standing behind the patient 102. However, problems arise when accounting the 
inter-rater reliability, caused by differences in loudness of the whisper 411. Recent work 
conducted by our group looked into the possibility of using uHear™, an iOS-based application 
that runs on iOS devices such as iPod, iPhone and iPad as a screening tool to detect hearing 
loss in older cancer patients as part of a CGA. Data showed promising results as uHear™ 
reached a high area under the ROC curve (AUC) and maximum sensitivity. However, it showed 
poor specificity, hampering the use of uHear™ in clinical practice 412.  
Another limitation of uHear™ is its scoring system. Figure 1 gives an example of results given 
by the screening tool. In our previous trial, the pass or fail screening cut-off was defined as 
having a pure-tone average of at least 40 dB HL, calculated from the air conduction thresholds 
obtained at 0.5, 1.0 and 2.0 kHz 412. Calculation of this numerical cut-off showed some 
difficulties as the thresholds of uHear™ are reported as a hearing grade per frequency rather 
than in sound intensity. Thus, for scoring purposes, a scoring sheet had to be drafted and 
every result obtained with uHear™ had to be compared to the scoring sheet in order to obtain 





numerical thresholds. Another recent trial, conducted by Handzel et al. (2013), in patients with 
a sudden sensorineural hearing loss, also investigated the use of uHear™ and used the 
presence of two or more consecutive hearing grades as a cut-off score to define impaired 
hearing 413. Therefore, in this trial, we will aim at validating uHear™ with a pass or fail screening 
cut-off defined as having two or more consecutive hearing grades starting from the moderate-
severe threshold zone ranging from 0.5 – 2.0 kHz (Modified Handzel-uHear™ screening).  
 
 
Figure 1. Examples of results given by uHear™. Red line indicates pass or fail screening cut-
off. In the left figure, both ears have hearing tresholds above the red line (cut-off line) at 0.5, 
1.0 and 2.0 kHz and pass the test. In the right figure, the left ear fails the test as all three 
frequencies are below the red line. The right ear also fails the test as 0.5 and 1.0 kHz are 
(consecutively) below the moderately severe (red) line.  
METHODS 
Patient selection 
All patients of the UHEAR-BIS-trial (clinicaltrials.gov identifier: NCT02662998) were recruited at 
the radiotherapy and oncology departments of the General Hospital Groeninge (Kortrijk, 
Belgium) between January 2016 and August 2016. Eligible patients needed to be 70 years or 
older at time of enrolment and had to have a histologically confirmed diagnosis of a solid cancer 
or haematologic malignancy. Any type of treatment and any type of stage were allowed. 
Patients had to be cognitively able to perform the assessments. Ears with a known hearing 
loss, hearing aids, clinically diagnosed Ménière’s disease, retrocochlear hearing loss, 
autoimmune inner ear disease, fluctuating hearing loss or a history of sudden sensory neural 
hearing loss were excluded from participation. The ethical committee of the General Hospital 
Groeninge, Kortrijk Belgium, approved the trial. All patients gave written informed consent upon 
participation in the trial.  
Measures 
Comprehensive Geriatric Assessment 
The audiological evaluation was conducted as part of a CGA, which is proposed as the key 
treatment approach for older cancer patients 86. The CGA comprises following standardized 
measures: functional status (Activities of Daily Living, Instrumental Activities of Daily Living 48, 
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49), physical status (number of falls), nutrition (Mini Nutritional Assessment - Short Form 322), 
emotional status (Geriatric Depression scale – 15 60), cognition (Mini Mental State Examination 
(MMSE) and/or Freund Clock Drawing Test (CDT) 51, 330, 366), polypharmacy (number of drugs) 
and comorbidities (Charlson Comorbidity Index 324). Patients were deemed vulnerable if they 
presented with impairments in two or more domains within the CGA 6, 24, 313.  
Audiological evaluation 
All hearing assessments were performed by a certified and accredited – by the Belgian 
government - audiologist. 
Immitance measurement and pure tone audiometry  
A 226 Hz tympanometry was performed with an 85 dB SPL probe tone (Zodiac 901 Middle-ear 
Analyzer, Madsen Electronics, United States). Pure tone audiometry was conducted in a sound 
booth by use of a recently calibrated Interacoustics AC3 audiometer, applying the Hughson-
Westlake technique. Air conduction thresholds were established for conventional octave 
frequencies ranging from 0.25 kHz to 8.0 kHz, including 6.0 kHz in order to compare all 
frequencies to those assessed by uHear™.  The Pure-Tone Average (PTA) was calculated as 
the average of the air conduction thresholds found at 0.5 kHz, 1.0 kHz and 2.0 kHz. We defined 
a PTA of ≥ 40 dB HL as the pass or fail screening cut-off as this was proposed by Ventry and 
Weinstein for individuals aged 65 years or older 246. 
uHear™ 
Hearing loss was screened by an iOS-based application, named uHear™ (version 2.0, Unitron, 
Victoria, BC, Canada) using an iPod touch (iOS version 9.2.1, Apple Inc., Cupertino, CA, USA). 
Standard iPod touch earbuds were used. The test was performed in either a quiet hospital 
room or physician’s office. For this trial, we used the sensitivity test, which determines the 
quietest air conducted sound the subject can hear at 0.5, 1.0, 2.0, 4.0 and 6.0 kHz, measured 
in both ears separately. uHear™ uses a 267 ms pulse duration and employs a simple 10 dB 
down and 5 dB up approach. The lowest threshold with two responses of three excursions is 
recorded as the hearing sensitivity 257. A modified Handzel-uHear™ screening method was 
defined with a pass or fail screening cut-off as having two or more consecutive hearing grades 
starting from the moderate-severe threshold zone ranging from 0.5 – 2.0 kHz (Figure 1). 
Hearing grades were converted from hearing thresholds as advised by Unitron (personal 
communications) according to standard ASHA regulations 225 (Table 1). 
Table 1. Conversion of hearing thresholds to hearing grades 
Threshold (dB HL) Hearing grade 
-10 to 25 Normal hearing 
26 to 40 Mild loss 
41 to 55 Moderate loss 
56 to 70 Moderately severe 
71 to 90 Severe loss 
>90 Profound loss 
Abbreviations: dB HL: decibel Hearing Level 
  






Statistical analyses were conducted by use of SPPS software (version 23; IBM SPPS 
Statistics, Chicago, IL) and Prism® software (GraphPad Prism 5, Inc., La Jolla, CA). Descriptive 
statistics were performed to present patient and tumour characteristics. Descriptive statistics 
were further conducted to present assessment results of both CGA and hearing tests. Wilcoxon 
matched-pairs signed-ranks test was used to compare uHear™ and conventional audiometry 
thresholds. Sample size calculations are based on previous research 412 and are defined as 
following assumptions. We accept conventional audiometry as the gold standard against which 
uHear™ is compared. Sample size calculations are based on the assumption that the 
combined sensitivity (S) and specificity (Sp) of the test (S+Sp)/2 has to be at least 80% and 
that we will find an actual combined (S+Sp)/2 of 90%. S and Sp with 95% confidence intervals 
(95%CI) were calculated with the predefined pass or fail screening cut-off. Positive and 
negative predictive values were also determined (PPV and NPV, respectively). 
RESULTS 
Patient Characteristics 
Forty-five patients, with an average age of 76.4 years (range 70.0-91.0), consented for 
participation. Of those, a slight majority (53.3%) included female individuals. Patients presented 
with cancer of following sites: haematologic malignancy (44.4%), genitourinary sites (15.7%), 
gynaecologic sites (13.3%), digestive sites (6.7%), head and neck (8.9%), unknown primary 
tumour (4.4%), musculoskeletal sites (2.2%), skin (2.2%), and lung (2.2%). All patients but one 
received a systemic treatment. The majority of patients were treated with palliative intent (62.2%) 
(Table 2).  
According to the definition of vulnerability based on the CGA, 40.0 % of patients were deemed 
vulnerable as they presented with two or more deteriorated domains. Although all patients were 
deemed cognitively capable of performing the audiological assessment, two patients (4.4%) 
scored below the cut-off score on the MMSE. The cognitive test was not assessed in another two 
patients due to an incomplete CGA assessment.  
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Table 2. Patient Characteristics 
Characteristics (n = 45) Mean (range) n (%) 
Age (years) 76.4 (70.0-91.0)  
Sex   
Female   24 (53.3) 
Male  21 (46.4) 
Cancer site   
Haematologic malignancy  20 (44.4) 
Genitourinary  7 (15.7) 
Gynaecological  6 (13.3) 
Head and neck  4 (8.9) 
Digestive   3 (6.7) 
Unknown primary  2 (4.4) 
Skin  1 (2.2) 
Musculoskeletal  1 (2.2) 
Lung  1 (2.2) 




 44 (97.8) 
Supportive care  1 (2.2) 
Treatment intent   
Palliative  28 (62.2) 
Curative  17 (37.8) 
Audiological assessment results 
In two ears, tympanometry results could not be obtained, as optimal probe tips were not provided. 
The majority of patients presented with a type A tympanogram (87.8%) (Table 3). Based on 
conventional audiometry, 24.4% of tested ears presented with a PTA of 40 dB HL or higher. Figure 
2 shows mean air conduction thresholds for both conventional audiometry and uHear™ at 0.5, 
1.0, 2.0, 4.0 and 6.0 kHz. Wilcoxon matched-pairs signed-ranks test detected significant 
statistical differences (p<0.001) for all frequencies except for 4.0 kHz. uHear™ tends to 
overestimate air conduction thresholds in the lower frequencies, whereas it underestimates 
them at 6.0 kHz (Table 4).  
Table 3. Tympanometry results 
Type (n=88) n (%) 
A 79 (89.7) 
As 7 (8.0%) 
Ad 1 (1.1%) 
B 1 (1.1%) 
  






Figure 2. Mean air conduction thresholds measured by conventional audiometry and uHear™. 
Abbreviation: dB HL: decibel Hearing Level 


















0.5 25.9 (11.8) 49.9 (15.1) 23.9 (14.2) <0.001* 
1.0 31.1 (12.7) 48.2 (13.5) 17.1 (11.9) <0.001* 
2.0 38.6 (15.1) 44.7 (15.5) 6.1 (9.1) <0.001* 
4.0 55.9 (16.7) 55.1 (18.2) -0.8 (9.5) 0.346 
6.0 64.6 (18.7) 57.1 (19.6) -7.5 (12.1) <0.001* 
Abbreviations: dB: decibel, HL: hearing level, SD: standard deviation 
According to uHear™, 26.7% of the tested ears failed the screening criteria. When looking at 
the diagnostic properties of the test, when using the modified Handzel method, uHear™ 
showed a sensitivity of 68.2% (95% CI [45.1-86.1]) and specificity of 86.8% (95% CI [76.4-
93.8]). It was calculated that uHear™ would only be accepted as a screening tool for hearing 
loss within the CGA if the combined S and Sp of the test (S+Sp/2) was at least 80% and that 
an actual combined (S+Sp)/2 of 90% would be found. In this case, a combined result of 77.5% 
was obtained. The PPV and NPV of the test was calculated as 62.5% (95%CI[40.6-81.2]) and 
89.4% ((95%CI[79.4-95.6]), respectively. 
DISCUSSION 
Older cancer patients are extremely sensitive to functional decline as a result of their cancer 
diagnosis and its treatment. Therefore, the NCCN Guidelines in Older Adult Oncology advise 
to assess patients with a CGA in order to select or adapt an individualised treatment. The CGA 
assesses vulnerability in several domains and states that an evaluation of the patient’s hearing 
is crucial to identify those patients who may not adequately hear the given information 
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concerning their cancer diagnosis and the cancer treatment 86. Since the proposed screening 
tool by the NCCN Guidelines is based on a whispered voice and many problems can arise with 
that type of test, with this trial we aimed at validating uHear™, an easily available iOS-based 
application, to screen for hearing loss in older cancer patients as part of the CGA 412. 
To the best of our knowledge, we are the first to look into the feasibility of uHear™ as a 
screening tool for use within the CGA. Previous research by our group established that a pass 
or fail screening cut-off for uHear™, based on the PTA, is difficult to calculate and reduces the 
usability of the tool. Therefore, we retrospectively determined a new pass or fail screening cut-
off that is defined as having two or more consecutive hearing grades starting from the 
moderate-severe threshold zone ranging from 0.5 – 2.0 kHz. In our sample and based on this 
cut-off, uHear™ identified 26.7% of tested ears of having a significant hearing loss with a PTA 
of ≥40 dB or more as measured with conventional pure-tone audiometry. The latter identified 
24.4% of tested ears as having an actual PTA of 40 dB HL or higher. It was predefined that we 
would only accept uHear™ as a screening tool for use within the CGA if we would find an 
average combined S and Sp of at least 80.0% and that we would find an actual combined 
result of 90.0%. In this sample, a combined (S+Sp)/2 of 77.5% was found, therefore rejecting 
uHear™ as a screening tool within the CGA.  
A good screening tool needs a high sensitivity and high NPV in order to reduce the number of 
false negative cases. Table 5 shows diagnostic accuracy of data obtained in this cohort when 
using different scoring methods. When using a cut-off score based on the PTA ≥40, as was 
used in our previous trial, an S of 100.0%, but Sp of 38.2% was detected which would result 
in a large number of patients with a referral to the otolaryngologist while no significant hearing 
loss is present. When using the modified Handzel method, S and NPV dropped to 68.2% (95% 
CI [45.1-86.1]) and 62.5% (95% CI [40.6-81.2]), respectively. On the contrary, the Sp of the 
test increased to 86.8% (95% CI [76.4-93.8]) and the PPV was calculated as 89.4% ((95% CI 
[79.4-95.6]). Although this modified Handzel method would miss a few of the ears with an 
actual significant hearing loss as measured by conventional audiometry, it does have a much 
better combined diagnostic property compared to using a cut-off score based on a PTA of 40 
dB HL or more. Further, as the new cut-off was based on retrospective findings, which 
accounted for uHear™’s limitations, the higher diagnostic accuracy in this paper can be 
attributed to the newly defined cut-off and is not just the result of using a new set of subjects. 
The limitations of uHear™ have been listed previously. In summary, it is known that uHear™ 
overestimates the lower frequencies. Some reasons can explain this difference. First, uHear™ 
demands an immediate tap when a sound is played. When this does not happen, it registers 
the sound as ‘not heard by the patient’ resulting in an elevated threshold. In this population, 
most patients are not familiar with a touch screen device. Therefore, to reduce this effect, the 
patient was given detailed instructions on how to tap the screen followed by a brief moment of 
exercise. When the audiologist detected difficulties, the patient was asked to raise the hand 
when he/she heard the sound and the audiologist would then immediately tap the screen. 
Second, although ambient noise was reduced to a minimum, it could not be reduced 
completely. Third, non-calibrated standard earbuds were used. As a result, it is not possible to 
guarantee that the intensity level and frequency of the auditory stimulus is exactly as it should 
be 258. Further, it has been reported that higher hearing thresholds in lower frequencies can be 
attributed to the use of insert earbuds. When compared to supra-aural headphones, insert 
headphones show similar or sometimes even slightly better hearing thresholds in higher 
frequencies 402. In order to reduce the latter these limitations, a new screening cut-off was 
calculated in which the overestimation of the lower and mid-frequencies was taken into 





account. Fourth, patients with a known hearing loss were excluded from the trial. Therefore, 
only a limited number of patients with a significant hearing loss were found. Although testing 
patients with a known hearing loss would not give any new information and can thus be 
considered redundant, excluding those patients may alter the diagnostic properties of the 
screening tool. Free field-testing could be of use in patients who are fitted with hearing aids as 
amplification may be insufficient for proper speech understanding. Fifth, as in routine audiology 
screening, outcome results were calculated per ear and not per patient. Nevertheless, in 
normal practice routine, a screening failure in one ear would result in a referral to the 
audiologist of otolaryngologist regardless of the results of the other ear. However, when 
combining results of the two ears, the screening tool shows a comparable S of 68.8% and Sp 
of 82.2% (data not shown). Last, we did not find a normal distribution of cancer types. This is 
the result of recruiting patients in only one oncology day care centre. However, this should not 
have influence hearing results.  
There is a need to further optimize this screening tool as it shows potential for use within the 
CGA. First, for all health care providers who need to give information to older cancer patients, 
it is crucial to know if the patient hears their messages. Older patients are very proud of their 
independence and in many cases, hearing and vision loss are one of the first functional 
declines they have to face. Although wearing glasses is well accepted by both young and older 
people, hearing aids are by many persons not that well accepted. As a result, older patients 
may try to hide their hearing loss which, in this specific population, may lead to missing crucial 
information about the cancer diagnosis, its treatment and its treatment-related side effects 414. 
Second, uHear™ was well accepted by the patients according to the audiologist’s judgement. 
Third, uHear™ is a fast and straightforward screening tool, it decreases the number of 
unnecessary appointments with the audiologist or otolaryngologist and with this new pass or 
fail screening cut-off, it is very easy to score.  
A possible way to increase the diagnostic properties of the screening tool may be to use a 
pass or fail screening cut-off stating that the patient fails the screening if two or more non-
consecutive hearing grades in the 0.5-4.0 kHz region are detected in at least one ear, starting 
from the moderate-severe hearing grade. An exploratory post-hoc analysis, using this criteria, 
was applied to the current cohort and was compared to a PTA of 40 dB HL or greater in at 
least one ear measured by conventional audiometry (Table 5). This showed a better S and a 
comparable Sp compared to the use of the modified Handzel-uHear™. Next, we applied this 
future-uHear™ screening to the data of previous cohort, which can be considered as blinded 
and independent from the current cohort. We obtained a higher S, but a slightly lower Sp, 
compared to the use of the modified Handzel-uHear™ in the current cohort. 
In conclusion, we can state that uHear™ is not ready to be used within the CGA. However, as 
the tool shows promising results, further research is warranted in order to obtain the most 




Table 5. Overview of the results obtained in the current and previous cohort using the different scoring systems 
 Current population (N=45) Previous population (N=33) 412 














































































(S+Sp)/2 (%) 77.5 69.1 80.2 94.6 68.2 78.8 
AUC (±SE) NA 0.881 ± 0.036 NA NA 0.980 ± 0.14 NA 
Abbreviations: S: sensitivity, Sp: specitivity, PPV: positive predictive value, NPV: negative predictive value, AUC: area under the curve, SE: 
standard error; NA: not applicable. 
* validation cohorts 
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The aim of this doctoral thesis was to explore screening measures to detect cognitive 
dysfunctions and hearing loss as part of a CGA in older cancer patients as well as cognitive 
dysfunctions in cancer patients of all ages receiving curative cancer treatment. Figure 1 give 
an overview of the included population within this thesis. Figure 2 shows a schematic overview 
of the main research questions that were addressed.  
Chapter 3 gives an overview of the added value of the use of the Freund Clock Drawing Test 
(CDT) to screen for cognitive losses as part of the CGA. The Freund CDT was compared to 
the well-known and frequently used Folstein Mini Mental State Examination (MMSE). After 
establishing a retrospectively determined cut-off score of ≤4, the Freund CDT was 
prospectively validated as a screening tool to detect cognitive dysfunctions in older cancer 
patients.  
Chapter 4 focusses on cancer-related cognitive impairments (CRCI) in both young and older 
cancer patients. Whereas it was first thought that CRCI were a result of a chemotherapeutic 
treatment, these last few years it has been suggested that psychological variables may also 
influence CRCI. In Part I, an overview is given on predictors of baseline CRCI. Results 
indicated that the IQ of a patient predicts the cognitive performance at baseline. Further, fatigue 
also influenced neuropsychological assessment results. In Part II, the distress thermometer 
(DT) was evaluated as a screening tool to predict CRCI six months after treatment initiation. 
Although the tool failed to predict objective CRCI, it did seem to predict subjective cognitive 
complaints.  
Chapter 5 explores the use of uHear™, an iOS-based application to screen for hearing loss, 
as part of the CGA. In a first trial, uHear™ was evaluated in its current form using a cut-off 
based on the Pure Tone Average, which is calculated as the average air-conduction threshold 
measured at 0.5, 1.0 and 2.0 kHz. As the tool showed a good sensitivity, but poor specificity, 
a new pass or fail screening cut-off was defined as having two or more consecutive hearing 
grades within the 0.5-2.0 kHz zone. Using this cut-off score increased the diagnostic properties 
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Figure 1. Overview of the included population per Chapter
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  Figure 2. Flowchart representing research questions 
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For any oncology health care provider, it is crucial to know if the patient is able to understand 
the presented information. Therefore, the NCCN Guidelines in Older Adult Oncology 
recommend evaluating the patient’s cognitive capabilities when performing a CGA. In most 
cases, the cognitive functioning is assessed through the well-known and widely validated 
MMSE as it is very often used to screen for dementia in various patient populations. However, 
the MMSE can be time-consuming when added to an already extensive list of questionnaires 
and it may be interpreted as cumbersome for the cancer patient, who has – in most cases – a 
normal cognition 29, 415.  
When looking at other available screening tools for cognition to use within the CGA, the CDT 
was chosen above other screening methods such as the MOCA, as it is an easy and fast to 
administer bedside screening tool while still providing sufficient valuable information 416, 417. 
Scoring the CDT, on the other hand, is rather difficult as many scoring methods are described 
418. Further, not a single scoring method provided a cut-off score for use within an oncogeriatric 
population. Another method of screening the older cancer patient’s cognitive function is to use 
the Mini-Cog, which consists out of a clock drawing test combined with the 3-word delayed 
recall (3-WDR) test that is used within the MMSE. The latter test would increase the diagnostic 
properties of the tool and is further advised by the NCCN Guidelines in Older Adult Oncology 
415.  
In Chapter 3, Part I, a cut-off score for the Freund Clock Drawing Test to screen for cognitive 
dysfunctions in older cancer patients as part of a CGA was established. The Freund scoring 
system was selected as it is easy to assess and uses a straightforward scoring method. Part I 
comprised a general geriatric population as well as an oncogeriatric population. As for this 
thesis, only the latter patient population is of our interest, following conclusion will apply only 
to this patient group.  
In total, 105 older patients with cancer were included. Patients were assessed by a full CGA, 
including the MMSE and CDT. Afterwards, the Mini-Cog was calculated. A potential cognitive 
deficit was found in 29.5% of patients when using a cut-off score of 23 or less on the MMSE. 
Median CDT and MMSE scores were 5 and 25, respectively, with a median score of 2 on the 
3-WDR test. The diagnostic properties of both the Freund CDT and Mini-Cog were presented 
with the AUC of the test, the S and Sp. Results indicated an optimal cut-off score of ≤4 on a 
scale ranging from 0 to 7 for the Freund CDT. When using this cut-off score, 37.1% of patients 
had a potential cognitive deficit. When comparing the results of the CDT to the MMSE, the 
AUC (SE) of the Freund CDT was 0.88±0.03. The S was calculated as 80.7% (95% CI [61.9–
91.9]) and Sp as 81.1% (95% CI [70.0–88.9]). When comparing the Mini-Cog to the MMSE, 
the test showed an S and Sp of 80.7% (95% CI [61.9–91.9]) and 83.8% (95% CI [73.0–91.0]), 
respectively. From these latter results, it can be concluded that the added value of the 3-WDR 
is rather limited when accounting the extra assessment time. Further, in Part I, the interrater-
reliability of the Freund scoring method was evaluated. The Kappa score, evaluating CDT 
interrater-reliability, was 0.84 indicating a high agreement between the two raters, in classifying 
patients as cognitively normal or potentially cognitively impaired. Therefore, when accounting 
the good diagnostic properties of the test and the high interrater-reliability, the Freund CDT 
with a cut-off score of ≤4 seemed to be the most optimal test to use within an oncogeriatric 
population.  
Part II focused on the prospective validation of this retrospectively determined cut-off score. In 
the PROACTIVE-trial, the Freund CDT was compared to the Folstein MMSE when using the 
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retrospectively determined cut-off score of ≤4. As the Mini-Cog did not significantly outstand 
the Freund CDT, it was no longer included in the evaluation.  
One-hundred ninety-six patients were included in the analyses. Patients were evaluated by a 
full CGA, including the CDT and MMSE. Potential cognitive deficits were identified in 27.0% of 
patients according to the MMSE. According to the CDT, 34.7% had a potential cognitive 
impairment. Median MMSE and CDT scores were 27 and 5, respectively. Spearman’s 
correlation coefficient showed a significant negative correlation between MMSE and age 
(p<0.01; rs = -0.23) and a significant positive association between MMSE scores and education 
age (p<0.01; rs = 0.24). Results did not detect a significant association between age, education 
age, and CDT test results (p=0.07; rs = -0.13 and p=0.07; rs = 0.13, respectively). 
It was stated that the Freund CDT would only be accepted as a screening tool for cognitive 
dysfunction within an oncogeriatric population when using a cut-off score of ≤4, if the AUC of 
at least 0.85. At the predefined cut-off score, the AUC± SE of the CDT showed excellent 
diagnostic accuracy (0.95 ± 0.17). Further, it provided an S of 94.3% (95% CI [83.4-98.5]) and 
Sp of 87.4% (95% CI [80.6–92.2]). This demonstrates that the Freund CDT can be used to 
screen cognitive functioning in older patients with cancer as part of a CGA. The AUC of the 
CDT in Part II was higher than in the first study (0.95 vs. 0.88), indicating that the 
retrospectively defined cut-off score of ≤4 is optimal within this population.  
Limitations of Chapter 3 
Limitations of Chapter 3 should be mentioned with respect to the study population and study 
measurements. In case of the study population, it should be noted that in Chapter 3, patients 
were included upon representation at the geriatric oncology clinic. As not all oncogeriatric 
patients were referred for a CGA, the distribution of cancer types was not as could be expected 
from known incidence figures. For example, in Chapter 3, Part I, the largest patient group 
comprised head and neck cancer patients while head and neck cancer is not that common 419. 
However, although the distribution of cancer diagnoses in Part I differed from those in Part II, 
results of the first part were confirmed in the second study. As the proposed cut-off was 
selected in the original manuscript of Dr. Freund, it is possible to extrapolate the results to the 
whole geriatric oncology population. Another limitation is the lack of a healthy control group. 
Though considered more vulnerable than the oncogeriatric group, a cut-off score of ≤4 was 
also preferred in the group consisting of general geriatric subjects without cancer. Further, as 
the CDT was prospectively validated in a new cohort with almost 200 patients, it can be stated 
that a comparison with a healthy control group would be more cumbersome than the actual 
added value. Next, only a minority of patients were deemed fit on the CGA as the majority of 
the included patients were evaluated by a full CGA because they had screened positive on the 
G8-questionnaire. In routine practice, patients are initially evaluated with the G8-questionnaire. 
Solely when the patient screens positive, a full CGA is performed. In Chapter 3, the group of 
fit patients had been assessed with a complete CGA because their treating physician 
demanded it. The achieved cut-off score may thus not be representative for patients who 
screened negative on the G8-questionnaire or patients who are evaluated with other 
screeners. However, the G8-questionnaire contains seven items from the Mini Nutritional 
Assessment and age. One of the items included in the G8-questionnaire concerns cognition 
and depression. This item has previously shown to correlate with MMSE test scores 420, 421.  
The following limitations apply to the used measurements. First, in Chapter 3, the MMSE is 
considered the gold standard within the CGA in most hospitals in Belgium. Therefore, the CDT 
was compared to the MMSE and not to other measures such as the MoCA. Despite the MMSE 





to be widely used to screen for dementia, the MMSE has to be considered as a screening tool 
and not as a diagnostic test. When a patient would screen positive on the CDT, it is important 
to understand that the detected cognitive dysfunction may slightly differ from the alterations 
that would be found by the MMSE. In order to properly assess a patient, the CDT had to be 
compared to a full neuropsychological assessment. However, within the CGA, it is not the 
intention of diagnosing patients, but merely to detect those domains in which the older patient 
with cancer shows vulnerabilities. If a patient would screen positive on the CDT, it is advised 
to first assess the patient with the MMSE before a referral to the neurologist or 
neuropsychologist is made. Especially since recent findings regarding geriatric interventions 
based on CGA results, indicated that only a limited number of patients with a referral to the 
memory clinic were actually seen by a neurologist or neuropsychologist (personal 
communications with Dr. C. Kenis). Therefore, no data is available on in-depth 
neuropsychological assessments of patients who were deemed cognitive vulnerable by the 
CDT or MMSE.  Second, in Chapter 3, Part I, the Mini-Cog was also compared to the MMSE. 
As both the CDT and the 3-WDR of the MMSE were assessed, the Mini-Cog was calculated 
retrospectively and not assessed in real time. Further, unlike in other versions of the Mini-Cog, 
a pre-drawn circle for conduction of the CDT was used. A pre-drawn circle prevents 
participants from possibly drawing a circle not large enough to contain the numbers and hands, 
or from not being symmetrical, which may affect the spatial arrangement of the numbers 422. 
However, the CDT was assessed as it was described by Dr. Freund 272. Immediate sequential 
assessment of both the CDT and the Mini-Cog separately would lead to strong recall bias. 
Next, in Part I, the education level of the patient was not asked and could therefore not be 
included in the analysis, which led to the hypotheses that the CDT might be too easy for 
patients with a higher education. However, it had been reported that education did not affect 
the result when using the Freund scoring method 292. Nonetheless, in Part II, the educational 
level of the patient had been assessed and was included in the analysis. Results indicated that 
education age did not influence CDT results and can therefore be used to assess all older 
patients with cancer regardless their education level. Another shortcoming of chapter 3 is that 
the CGA did not include an objective hearing assessment, because it is not yet included in 
routine practice. Therefore, lower outcomes on the CDT or MMSE can be due to a loss of 
hearing. Nonetheless, no correlation was found between the degree of hearing loss and the 
result on the CDT or MMSE in chapter 5 (data not shown). 
Strengths of Chapter 3 
In Chapter 3, the CDT was validated as a screening tool to detect cognitive dysfunctions in 
older cancer patients as part of the CGA. The strengths of this tool are various. For example, 
the CDT was reported as a quick screener for cognition, especially when compared to the 
MMSE or MoCA 417. However, it did not provide an optimal cut-off score for use within a 
geriatric oncology population. Further, as many scoring methods have been published, 
selecting an easy and straightforward system was necessary 423. The scoring method, that was 
selected in Chapter 3, had been published by Dr. Barbara Freund 272 and uses a 7-item scoring 
scale. Scoring the Freund CDT is easy as the scoring rules are clear and direct, as indicated 
by its high interrater-reliability. Further, the retrospective determined cut-off score of ≤4 has 
been validated in Part II in a large and heterogeneous sample of older cancer patients and can 
be implemented directly within the CGA.  
When comparing the MMSE to the CDT, the CDT brings many advantages. First, the CGA is 
performed in the early trajectory of the cancer diagnosis or cancer treatment at a time where 
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many patients still have to cope with the idea of having cancer and the thought of having to 
receive a cancer treatment. Since many cancer patients present with a good cognition, it has 
been reported that the assessment of MMSE can be experienced as annoying by (cancer) 
patients 29, 326. The CDT on the other hand is far less confronting and is therefore more suitable 
to use within this specific population. Further, the CDT can be administered in less time than 
the MMSE, which reduces the total assessment time of the CGA. Further, the CDT is more 
sensitive than the MMSE. While this could lead to a certain number of false positives, it does 
not outweigh the reduced assessment time when choosing the CDT instead of the MMSE. 
Fourth, it has been previously reported that the MMSE can be influenced by the education age 
of the patient, whereas the CDT is not when the patient is given a pre-drawn circle 292, 308.    
Implications for routine practice 
The data in Chapter 3 indicated that the Freund CDT can be used as an initial screener for 
cognitive function as part of the CGA. Proper screening is necessary and the results should 
be reported and made available in the patient’s file. In this way, all health care professionals 
can access this information and are made aware of the patient’s cognitive functioning. As the 
diagnostic properties of the test were even higher in the second set of patients (Part II), it can 
be stated that the CDT is ready to be implemented in routine practice. Since the MMSE is also 
a screening tool, it should be noted that a positive test result on the CDT should be followed 
by an assessment with the MMSE before a referral to another health care professional is made. 
Ideally, a referral should be made to the neurologist or (neuro) psychologist for a 
comprehensive cognitive workup. A referral to the geriatric day clinic where the patient can be 
evaluated by the geriatric nurse, geriatric psychologist, occupational therapist and geriatrician 
is another possibility. Though in case this is not possible, for example, when the patient is too 
ill, health care professionals can take the cognitive dysfunction into account and for example 
give written instructions. The data in Chapter 3 indicated that in case of a general geriatric 
population, the Mini-Cog – including the Freund CDT - should be assessed. However, a 
prospective validation trial should be performed as the results for the Mini-Cog were calculated 
retrospectively. It should also be noted that there is a thin line between general geriatric 
patients and oncogeriatric patients as geriatric patients have a high risk of developing cancer. 
Therefore, the geriatric and the geriatric oncology team should meet regularly to discuss when 
the geriatric oncology team steps in to assess a CGA. Obviously, both teams need to work 
closely together to avoid unnecessary evaluations. 
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These last few years researchers have started to pay more attention to the psychosocial 
problems that cancer patients have to deal with when facing a cancer diagnosis and cancer 
treatment. Cancer-related cognitive impairments, or CRCI, are one of those psychosocial 
aspects that have been studied frequently during the last decade as many cancer patients may 
experience concentration problems, distractibility, forgetfulness, difficulties in remembering 
names or numbers and a lack of mental sharpness 124, 424. 
Initial research tended to focus on breast cancer patients since this patient population was 
amongst the first to report cognitive changes following a chemotherapeutic treatment. As a 
result, cognitive malfunctioning after a cancer treatment was called ‘chemobrain’ 425, 426. 
Researchers have tried to find an explanation why these problems may arise. Some have 
looked into structural and functional changes in the brain using imaging studies, others have 
tried to identify other factors that may cause chemobrain 121, 131, 369. However, it was interesting 
to find that a number of patients experienced cognitive difficulties prior to any adjuvant 
treatment 365. Only few researchers have looked into baseline CRCI and those few focused on 
breast cancer patients alone. Therefore, no consensus has been reached on those factors that 
can explain the number of patients with CRCI at that time 145, 365.  
In Chapter 4, Part I, research focuses on identifying risk factors for CRCI prior to the cancer 
treatment. Identifying possible risk factors for baseline CRCI may lead to new screening 
methods in the early detection of CRCI. In total, 125 patients consented for participation. 
Patients were assessed with a neuropsychological assessment and patient-reported outcome 
measures (PROMs) prior to the cancer treatment. An overall CRCI, based on the definition of 
the International Cognition and Cancer Task Force (ICCTF), was detected in 29.6% of patients 
before treatment 148. Binary logistic regression analysis indicated that overall CRCI, according 
to the definition of the ICCTF, was predicted by a lower premorbid IQ (β = −0.084, p<0.01) and 
a higher level of fatigue (β = −0.054, p<0.05). No differences were found between impaired 
and non-impaired patients for age, gender, education age, distress, anxiety, depression, 
fatigue, subjective cognitive complaints, days between surgery and baseline assessment, 
active treatment with anxiolytics/antidepressants/antihypnotics, having a prior or current 
diagnosis of depression or anxiety, stage (early vs late stage), or cancer type (breast cancer 
vs other cancer type). A significant difference was found for premorbid IQ (p<0.01) as 
measured by the Dutch Adult Reading Test. Non-impaired patients presented with a mean 
premorbid IQ of 107.0 (range: 79.0‐124.0), whereas the mean premorbid IQ of impaired 
patients was calculated as 101.5 (range: 82.0‐116.0).  
When looking at individual cognitive domains, multiple regression analyses revealed that all 
cognitive domains can be predicted by premorbid IQ, which indicates that a higher IQ results 
in a better test score. Visual and verbal episodic memory, information processing speed, 
semantic word fluency, and flexibility were also influenced by age, favouring younger patients. 
Verbal episodic memory was further predicted by gender. Processing speed was also in part 
predicted by an active treatment for hypertension. Similar findings regarding these risk factors 
have been found in other trials 145, 362, 363. However, when screening for CRCI, identifying risk 
factors for overall CRCI is more interesting and more valuable for routine practice.      
One of the most interesting findings in Chapter 4, Part I, is that premorbid IQ seems to play an 
important role when trying to identify those patients who are more prone to present with CRCI 
at baseline. Although it has not previously been reported in a group of general cancer patients 
and in terms of overall CRCI, it is known that neuropsychological test scores are influenced by 
the IQ of the cancer patient. Ahles et al. (2008), for example, reported that pre-treatment 
cognitive reserve was related to post‐treatment cognitive decline in a group of breast cancer 
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patients exposed to chemotherapy 365. Schilder et al. (2010) also reported that IQ influenced 
cognitive outcome results in postmenopausal breast cancer patients 115.  
In addition to premorbid IQ, the level of fatigue of the patient also influenced overall CRCI. It is 
no surprise that cancer patients can experience a high level of fatigue at baseline when 
accounting the number of doctor appointments and exploratory or diagnostic interventions that 
they are faced with 427. Only limited data is available to support this finding. Booth‐Jones et al. 
(2005) examined the cognitive function of patients undergoing a bone marrow transplantation 
and reported that the level of fatigue influences cognitive impairment 360. Another trial stated 
that symptoms of fatigue were related to observed impairments in breast cancer patients when 
compared with healthy controls, prior to adjuvant treatment 143. 
Chapter 4, Part II, continues the search for variables predicting CRCI, but when compared to 
Part I, this chapter aims at evaluating whether the DT can be used to predict objective cognitive 
impairments six months after treatment initiation (T1). As previously mentioned, researchers 
have tried to identify several causes of CRCI. Distress has been suggested as a potential risk 
factor, but it had not been investigated objectively. It was also investigated whether the DT 
could be used to predict subjective cognitive complaints at T1. In Part II, we also looked into 
the degree of cognitive decline between the baseline assessment (T0) and T1. Last, as the 
initial term for CRCI was ascribed as chemobrain, the role of chemotherapy was examined.      
Chapter 4, Part II, includes the same patient population of Part I. Six months after patients had 
started their treatment, they were invited to participate in the second assessment of the 
CONCEPT-trial. A dropout of 15.2% was noted. Of the initial 125 patients, five patients 
withdrew from the trial without giving a specific reason, five patients felt too ill, four patients did 
not want to make the extra travel to the hospital, three patients had died as a consequence of 
their disease or treatment and two patients declared to have no time. The remaining 106 
patients were assessed with the same neuropsychological test battery as in Part I including 
PROMs.  
At T0, 60.4% of patients showed a DT score of ≥4, whereas 50% met these criteria at T1. 
According to the definition of the ICCTF, 25.5% and 28.3% of patients presented with a CRCI 
at T0 and T1, respectively. In order to accept the DT as a screening tool to predict CRCI, it 
was calculated that the AUC under the null hypothesis was 0.50 and that an AUC under the 
alternative hypothesis of 0.70 would be found. ROC-curve analysis showed an AUC <0.5, 
therefore rejecting the alternative hypothesis. With an AUC below 0.5, it can be stated the 
screening tool has less value than tossing a coin and has no value for use within routine 
practice. Binary logistic regression analysis found that fewer distress at T0 (B=-0.267, p<0.05), 
having a lower premorbid IQ (B=-0.066, p<0.05), female gender (B=1.861, p<0.05) and no 
surgery (B=-1.745, p<0.05) predicted CRCI at T1. Chemotherapy did not influence the risk on 
CRCI (B=0.186, p=0.666). 
As premorbid IQ seems to influence assessment results at both T0 and T1, there should be 
no doubt about the role of this variable. Results of Chapter 4, Part II, also indicated that in this 
selected patient group, chemotherapy did not seem to influence assessment results since no 
differences in neuropsychological test scores could be detected when comparing patients with 
and without chemotherapy at T1. This supports why researchers have started to use the term 
‘CRCI’ instead of chemobrain or chemofog 383.  
Interestingly, female individuals tend to have more CRCI at T1 than males. In the selected 
sample, a high number of females were included (69.8%) with the majority of those being 
diagnosed with breast cancer (68.9%). Gender differences have been observed previously in 
non-cancer subjects 378, but have not been confirmed in cancer subjects 144. An interesting 





question is why breast cancer patients seem to be more prone to have cognitive difficulties six 
months after treatment initiation. An explanation may be that the breast cancer patients 
included in our trials, of which the majority only received radiotherapy followed by hormonal 
treatment, experience more distress as a results of less close follow up compared to the cancer 
patients who received chemotherapy where the time period between the end of the treatment 
and the second assessment was much shorter (data not shown). Another interesting finding 
was that only few patients actually developed CRCI from T0 to T1 whereas in other subjects 
the CRCI, detected at baseline, was no longer present at T1. Patient groups seemed similar 
in terms of gender, diagnosis and treatment. The first group, however, showed more signs of 
fatigue at T1 while fatigue in the second group decreased. This also supports the theory that 
psychosocial problems may attribute to CRCI.  
In case of subjective cognitive complaints, as measured by the Cognitive Failure Questionnaire 
(CFQ), ROC-curve analyses showed an AUC±SE of respectively 0.642±0.067 for the DT. 
Although this still not meets the hypothesis criteria of 0.70, it does indicate the role between 
the level of distress and the patients’ perception of their own cognitive functioning. When 
looking into the FACIT-Fatigue Scale to screen for cognitive complaints at T1, the AUC±SE 
was calculated as 0.794±0.057. The latter two AUC’s, when using PROMs, clearly indicate 
that psychosocial factors influence how patients perceive their memory and concentration. 
When looking into changes over time, in most cognitive domains, patients tended to perform 
better at T1 when compared to the baseline assessment. Only in case of verbal memory, 
measured by the Rey’s Auditory Verbal Learning Test (RAVLT), a decline in performance was 
observed. Although this has been previously found in another trial 132, in this test battery, the 
RAVLT was the last test to be assessed. This finding could thus merely be the result of the 
patient’s level of mental fatigue at that point.  
Limitations of Chapter 4 
In Chapter 4, limitations to the study population, study design and used normative data to 
convert raw neuropsychological test scores can be noted. Part I and II are based on findings 
of the CONCEPT-trial. The CONCEPT-trial included a group of general cancer patients. Whilst 
the inclusion of a heterogeneous group of patients has the advantage of obtaining information 
on CRCI in all cancer types, a distribution of the different cancer diagnoses as would be 
expected from prevalence figures was not found. In the trial, a high number of breast cancer 
patients were included. As a result, some results may have been influenced by the high number 
of female individuals with breast cancer that participated in the trial. For example, in Part II, it 
was found that the female gender predicted the CRCI outcome. As the majority of the included 
female subjects were diagnosed with breast cancer, this highly suggests that not females in 
general, but solely breast cancer patients are more prone to present with CRCI. When looking 
at previous research, this finding is not that surprising, as initial trials investigating CRCI have 
been focussing on this patient group. It remains interesting, however, as previously mentioned, 
why breast cancer patient are more vulnerable to cognitive deficits. Regarding the study 
population, it should be mentioned that patients with a current depression or anxiety disorder 
were allowed to participate in the trial, though it is known that these emotional disorders could 
affect cognitive performance. As it has been reported that depressive patients show less 
motivation to complete a task, we hypothesized that patients, were willing to participate, were 
intrinsically motivated to perform well on the neuropsychological assessment. Ultimately 
however, no patient with a depressive or anxiety disorder was included. Results could also 
have been biased if patient’s received psychological support between the baseline assessment 
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and the assessment at T1. Though the number of patients receiving support was not 
documented, all patients were offered psychological guidance by either an oncologist nurse or 
oncopsychologist. Consequently, if this would have altered their test results, this effect 
between patients should be limited.   
Another limitation of the data presented in Chapter 4 concerns the study design. The 
CONCEPT-trial was set up as a prospective, observational study including a group of general 
cancer patients scheduled to receive a curative cancer treatment. In order to fully attribute the 
obtained results to the cancer process, a healthy control group should have been included. 
Nonetheless, it would have been difficult to find a proper control group as these subjects would 
have had to be healthy, but at the same time would have had to suffer from a sufficient degree 
of distress, fatigue, etc. To reduce this limitation, a few methods were selected. First, the 
number of patients that presented with a CRCI was compared to the binomial probability 
distribution by use of a binomial test. When using such test, the number of patients that would 
be expected to present with a CRCI based on the number of neuropsychological test that are 
included in the test battery, has to be calculated. When including eight independent tests, 
approximately 17% of patients would perform 2 SDs below the normative mean on a single 
test. This number was then compared to the actual number of cancer patients that scored at 
least -2 SDs below the normative mean on one test. In both Part I and II, a significant difference 
between the expected and the actual number of patients meeting those criteria was found, 
indicating that normal variance alone could not explain why that many patients score -2 SDs 
below the normative mean on a single test. When looking into the effect of chemotherapy at 
T1, patients without chemotherapy were used as a control group, as an equal number of 
patients were included with and without chemotherapy.  
Regarding the used normative data for converting raw scores into standardized z-scores, it 
has to be mentioned that some neuropsychological tests, such as the RAVLT and Complex 
Figure Test (CFT), did not provide optimal z‐scores for older patients. Z‐scores can only be 
calculated in three age categories (>30, 30‐50, and <50 years), which may result in higher 
number of impaired older patients. On the other hand, when performing the linear regression 
analyses in Chapter 4, Part I, raw test scores were used instead of z‐scores. Raw scores were 
selected to be able to compare our results with findings of other researchers. Therefore, the 
age and IQ effect may be more present in these results. Nonetheless, when using the 
standardized z‐scores, IQ effects remain present in all domains. The influence of age remains 
present in the RAVLT and both conditions of the Trail Making Test (TMT). For the RAVLT, this 
may be due to the suboptimal normative data. In case of the TMT, the age effect should have 
been ruled out when converting into z-scores. Nonetheless, it has been reported that age may 
influence processing speed and executive functioning in cancer patients 145.  
Changes were not evaluated by use of the RCI. The main reason is that, as mentioned in the 
introduction, patients with a lower baseline score would need a greater percentage of decline 
in order to be meaningful by the RCI. As it has been reported that baseline cognition can be 
affected in cancer patients, an RCI would not detect some changes as clinically relevant while 
they do influence the patients’ subjective feeling about their cognition. 
The trials in Chapter 4 also did not include any questionnaires regarding rumination. 
Rumination can be described as the repetitive and recursive rehearsal of cognitive content. 
Rumination could be of interest when looking into predictors of CRCI as research has reported 
an association between rumination and impaired problem solving and concentration 428. In 
cancer patients, rumination has been found to correlate with the level of depression and anxiety 





429. Further, higher levels of rumination were also related with increased psychological distress 
430. Therefore, it could be stated that rumination was indirectly assessed in this chapter. 
Nonetheless, while rumination itself was not directly assessed, the EORTC quality of life 
questionnaire was assessed at baseline and six-months post treatment initiation. One of the 
questions included in this questionnaire asks the patients if they worried during the last week. 
While not examining rumination itself, it was found that the score on the DT and the score on 
the question of the EORTC QoL scale were correlated (rs=0.555; p<0.001). Therefore, it could 
be stated that it was indirectly assessed. Nonetheless, binary logistic regression analysis 
revealed that this question could not predict baseline CRCI nor could it predict objective CRCI 
at T1 (data not shown). However, future research should implement rumination questionnaires 
in order to evaluate its influence on CRCI.     
Strengths of Chapter 4 
CRCI in general is considered as a hot topic within the field of psycho-oncology. Many patients 
experience cognitive troubles and very little is known about its etiology. Screening for CRCI is 
important as to day, there is a growing group of cancer survivors who want to return to work 
and pick up their social activities after treatment. Having to deal with memory and concentration 
problems delays this process, seriously affecting their quality of life. A lot of research has been 
performed these last years in order to learn more about CRCI. Whereas some cancer 
treatments may induce neurotoxicity, most systemic treatments cannot cross the blood-brain 
barrier. In both Part I and II, a large number of hypotheses were tested. New insights were 
found and new hypotheses have become apparent.   
One of the difficulties researchers are faced with when studying CRCI, is to find a good 
definition. In order to compare results of CRCI with others, the ICCTF published following 
definition: patients will be marked as having a cognitive impairment if they either present with 
two or more test scores at or below -1.5 SDs from the normative mean or if they present with 
one test score at or below -2.0 SDs 148. In Chapter 4, this definition was used. The ICCTF also 
published guidelines concerning the minimal neuropsychological data set that a researcher 
should implement when conducting trials into CRCI. As advised, the used neuropsychological 
test battery was based on their suggestions. Implementing the definition and the proposed 
assessment is essential if researchers want to compare their trial results.   
In Chapter 4, a general group of cancer patients was included. Whereas other researchers 
tend to focus on one cancer type, mainly breast cancer, it is important to include patients with 
cancer diagnoses other than breast cancer as they may also experience cognitive 
dysfunctions. Further, as a large group of breast cancer patients was included, it was possible 
to compare the results of those patients with the results of other cancer patients. In Part I, for 
example, it was found that breast cancer patients - although not statistically significant - 
experienced more subjective cognitive complaints when compared to other cancer patients. 
On the contrary, a fewer percentage of breast cancer patients was found to have CRCI 
compared to other cancers. One explanation may be that the breast cancer patients included 
in our trials, of which the majority only received radiotherapy followed by hormonal treatment, 
experience more distress as a results of less close follow up compared to the C+ group where 
the period between the end of the treatment and the second assessment was much shorter 
(data not shown). Further, in Part II, by including an equal number of patients with and without 
chemotherapy, the effect of chemotherapy on CRCI at T1 could be compared between both 
groups. An important finding was that in this selected patient group, chemotherapy did not 
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seem to influence CRCI. This may suggest that the impact of chemotherapy is smaller than 
suggested by others. 
Implication for routine practice 
As it was found that CRCI are influenced by the patient’s IQ, researchers should implement 
some form of IQ test when conducting research into CRCI so neuropsychological assessment 
results can be adjusted for this variable. Further, psychosocial variables such as distress and 
fatigue seem to play an important role in the etiology of cognitive complaints. While for a 
researcher, it is interesting to know the exact number of patients with an objective CRCI, 
subjective cognitive complaints tend to influence the patients’ life far more when they want to 
return to their former lives. An interesting trial could also examine the reciprocal effect of 
coping, rumination and distress on cognitive complaints in cancer patients.  
To date, there are no rehabilitation programs available to cope with cognitive complaints. Next, 
as distress and fatigue influence these problems, reversing distress and fatigue, next to coping 
mechanisms for cognitive difficulties, may be more interesting. Further, it should be noted that 
the results, found in Chapter 4, Part II, might provide a first step towards a proper screening 
method. When screening for subjective cognitive complaints, both the DT as well as the FACIT-
Fatigue Scale could potentially be used. However, as this was not the focus of the CONCEPT-
trial, a prospective study validating these measurements should be set up.  



















When conducting a CGA, the NCCN Guidelines in Older Adult Oncology recommend to 
evaluate sensory (dys)functions including the patient’s vision and hearing 102. Whereas 
difficulties with vision can be easily detected as most patients with vision loss wear eye 
glasses, hearing loss often stays undetected 213. As a logical consequence, the NCCN 
recommends to screen for hearing loss by a screening tool that is comparable to the Whispered 
Voice Test (WVT) 102. Nonetheless, in a busy clinical practice, an evaluation of the patient’s 
hearing status is often not included in the CGA.  
Chapter 5 of this thesis focused on a screening tool to assess hearing loss in older cancer 
patients as part of the CGA. Since the WVT did not seem to be the most optimal test for use, 
especially when one accounts the problems regarding the poor interrater-reliability, it was 
decided to use an existing mobile health application that can be used on a cell phone or tablet. 
uHear™ was selected as the screening tool against which conventional pure tone audiometry 
would be compared. There are several reasons why this particular tool was selected. First, 
uHear™ was freely available to all persons who have a device running on iOS software. 
Second, the interface was user-friendly and straightforward in use. Third, there was no data 
available for any of the other existing hearing applications in which older cancer patients were 
selected. Further, older patients were often not included in trials looking at the diagnostic 
properties of these apps, whereas one trial evaluated uHear™ in older subjects. Further, 
uHear™ showed a good S and Sp in several settings, including an evaluation in a clinical 
setting outside a sound booth. Since the latter was comparable to the setting in which we 
wanted to use the application, uHear™ was favourable when compared to the other existing 
screening tools 431.  
The first research question that was investigated evaluated whether uHear™ could be used 
as a screening tool to detect hearing loss in older cancer patients as part of the CGA, when 
using the application in its current form (Chapter 5, Part I). In Part II, a new scoring method 
was evaluated. Following table (Table 1) gives an overview of the diagnostic properties of 
uHear™ in each cohort. When using the original method, uHear™ was compared to 
conventional pure-tone audiometry both using a pass or fail screening cut-off based on a PTA 
of ≥40 dB HL. In the validation cohort, uHear™ found a PTA of 40 dB HL or more in 69.2% of 
tested ears. It showed an excellent S of 100.0%, but poor Sp of 36.4%. This method showed 
similar results in terms of diagnostic accuracy when calculated in the second cohort. While in 
Chapter 5, Part I, uHear™ - scored with the original method - had an excellent AUC of 0.98, it 
is not suitable as a scoring method as too many patients would be referred to the audiologist, 
even though they would not show a significant hearing loss when assessed by conventional 
audiometry. This highly reduces the usability of the tool in clinical practice. Several 
explanations may be found for this poor Sp results. uHear™ overestimated the actual hearing 
level in the lower frequency region. Although ambient noise was reduced to a minimum, it could 
not be excluded completely. Further, this specific patient population was not familiar with the 
touch screen device. As uHear™ demands an immediate tap when a stimulus is presented to 
the patient’s ear, a delayed tap caused by the unfamiliarity of using a touch screen, may have 
led to higher hearing thresholds. 
Retrospectively, new scoring cut-offs and scoring methods were tested. This led to two new 
possible ways for scoring uHear™. The first improved scoring method was also based on the 
PTA. Instead of using a PTA of 40 dB HL or more as the cut-off score, the cut-off for uHear™ 
was increased to ≥55 dB HL. When comparing this to conventional audiometry hearing results 
with a PTA of ≥40 dB HL, S remained 100.0%, but Sp of the test improved significantly to 
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78.0%. Although this highly improves the diagnostic properties of the test, scoring uHear™ by 
calculating the PTA is not practical as a scoring sheet has to be used since uHear™ results 
are not presented in numerical data, but in hearing grades. Therefore, a new method based 
on these hearing grades may be easier for use in routine practice. Scoring uHear™ by using 
this type of scoring system had previously been tested by Handzel et al. (2013) 413.  
By using the data of Chapter 5, part I, a new pass or fail screening cut-off was defined as 
having two or more consecutive hearing grades starting from the moderate-severe threshold 
zone ranging from 0.5 – 2.0 kHz. When evaluated in the first cohort, uHear™ showed a 
sensitivity of 100% and specificity of 89.1% (Table 1). As this new method showed promising 
results, it was validated in a second set of subjects as discussed in Chapter 5, Part II. Data 
showed a sensitivity of 68.2% and specificity of 86.8%. It was stated that – in order to validate 
the tool - the combined S and Sp of uHear™ (S+Sp/2) in this second cohort, had to be at least 
80% and that an actual combined (S+Sp)/2 of 90% would be found. As the combined (S+Sp)/2 
of the test was calculated as 77.5%, it has to be concluded that the tool cannot be implemented 
within the CGA.  
When comparing the diagnostic properties of uHear™ from Part I and Part II, solely looking at 
the validation cohorts, following conclusion can be noted. First, the S dropped from 100.0% to 
68.2%. On the contrary, the Sp improved from 36.4% to 86.8%. When comparing the combined 
diagnostic property ((S+Sp)/2), results improved from 68.2% up to 77.5%. Although this new 
cut-off score would miss a few of the ears with an actual significant hearing loss as measured 
by conventional audiometry, it does have a much better combined diagnostic property 
compared to using a cut-off score based on a PTA of 40 dB or more. Second, when looking at 
the S and Sp of uHear™ when using a cut-off based on a PTA of 55 dB or more in Part II, 
results did not excel the S and Sp of the test with the pass or fail screening cut-off based on 
hearing grades (data not shown). Third, using a scoring method based on hearing grades 
highly improves the usability of the tool as the result can be read directly from the screen, 
whereas a scoring sheet has to be used when using a cut-off based on the PTA.  
An option to increase the S and Sp of the screening tool may be to use a pass or fail screening 
cut-off stating that the patient fails the screening if two or more non-consecutive hearing grades 
are detected in at least one ear within the 0.5-4.0 kHz frequency region starting from the 
moderate-severe threshold. When comparing this criterion to a PTA of at least 40 dB HL in 
one ear as measured by conventional audiometry, the obtained data in Chapter 5, Part II, show 
an S of 73.9% and a Sp of 86.4% (Table 1). 
In Chapter 5, Part I, the WVT was also compared to conventional audiometry as this was the 
screening tool that was proposed by the NCCN Guidelines. The tool showed a low S (30.0% 
(95%CI[8.1–64.6])), but excellent Sp (100.0% (95%CI[91.9–100.0])). However, a good 
screening tool needs a high S as it reduces the number of false negative cases. While changing 
the pass or fail cut-off for the WVT (for example fail when 2 out of 4 conditions are missed) 
showed a better diagnostic accuracy, using another scoring method for the uHear™ remains 
favourable as results indicate a better combined diagnostic accuracy than any type of pass or 
fail cut-offs of the WVT. In this paper, the diagnostic properties of the Hearing Handicap 
Inventory for the Elderly (HHIE) were also investigated. Since most patients had difficulties 
admitting they had a hearing problem, this tool was unable to screen for objective hearing loss 





Table 1. Overview of the diagnostic properties of uHear™ per cohort and per scoring method 
 First cohort (n=33) 
Population of Chapter 5, Part I 
Second cohort (n=45) 
Population of Chapter 5, Part II 
Original method*  New method Optimised method Original method  New method* Optimised method 
























































(S+Sp)/2 (%) 68.2 94.6 78.8 69.1 77.5 80.2 
AUC (±SE) 0.980 ± 0.14 NA NA 0.881 ± 0.036 NA NA 
Abbreviations: S: sensitivity, Sp: specitivity, PPV: positive predictive value, NPV: negative predictive value, AUC: area under the curve, SE: 
standard error; CI: conficence interval; NA: not applicable. 
Original method: pass or fail cut-off defnided by a PTA of 40 dB or greater 
New method: pass or fail cut-off defined as having two two or more consecutive hearing grades starting from the moderate-severe threshold zone 
ranging from 0.5 – 2.0 kHz 
Optimised method: pass or fail screening cut-off stating that the patient fails the screening if two or more non-consecutive hearing grades are 
detected in at least one ear within the 0.5-4.0 kHz frequency region, starting from the moderate-severe hearing grade 
* validation cohorts 
172 | C H A P T E R  6 ∙ P A R T  I V  
 
 
Limitations of Chapter 5  
Limitations of Chapter 5 relate to the study design, study population and used measurements. 
With respect to the study design, in both the UHEAR and UHEAR-Bis trial, the PTA was 
calculated as the mean of the threshold levels at 0.5, 1.0 and 2.0 kHz. A limitation to the use 
of these three frequencies in older patients is that it eliminates those frequencies that are most 
affected in case of ARHL. Further, stating that the patient has a significant hearing loss if the 
PTA is 40 dB HL or greater when using these frequencies, is very strict and communication 
may be already seriously affected at that point. Turner at el. (1990) reported that a loss 
exceeding 30 to 40 dB on speech frequencies (ranging from 300 to 3000 Hz) is unacceptable 
for proper communication 432. Adding 4.0 kHz into the equation may in part compensate for 
this limitation and provide more information on the hearing capability for speech frequencies. 
In Chapter 5, Part I, the use of these three frequencies was chosen, as these are the 
frequencies that are provided by the ASHA to calculate the PTA. In Part II, three frequencies 
instead of four were used to calculate the PTA as adding 4.0 kHz did not substantially improve 
diagnostic accuracy (data not shown). Nonetheless, a speech-in-noise (SPIN) screening test 
may be more useful in these cases. There are some Dutch SPIN-tests that could be of value 
in this particular population, such as the Digit Triplet Test, developed by Jansen et al. (2013) 
433. Though freely available on the internet, administration is rather time-consuming which 
prolongs the already intensive CGA assessment. Further, those tests requires a computer or 
laptop and is therefore less practical for use in a busy geriatric oncology clinic where many 
patients are seen in patient rooms. There are some SPIN-tests available for use on iOS and 
Android devices such as the SPIN-test included in uHear™, however, those screening 
measures are not available not in Dutch, which limits the use of SPIN-tests in the setting and 
population of interest.  
Another limitation regarding the study design is that both the UHEAR and UHEAR-Bis trial 
excluded patients with a known hearing loss, which was defined as either having a documented 
diagnosis that is available in the patient record or having hearing aids. Consequently, only a 
limited number of patients with a significant hearing loss were included in the trial. This may 
have altered the diagnostic properties of the WVT, HHIE and uHear™ as in a validation study, 
all patients - with or without hearing loss – typically would have been included. If the patient 
has a known hearing disorder, a screening test is redundant as health care providers can 
already approach the patient appropriately. In case of hearing aids however, it could be 
possible that they do not offer optimal amplification as it has been noted that even with 
sufficient elevation of the sound to an audible level, speech intelligibility can remain poor 434. 
Therefore, in these cases, free-field (FF) testing would be more suitable though it would be 
difficult to perform a FF-test based on pure tones in a hospital room of physician’s office where 
background noise cannot be excluded. Further, while mentioning FF testing, another 
shortcoming of uHear™ is that it does not combine the results of both ears, while in normal 
listening situations, the information received by both ears is processed together through central 
processes. As a result, missed information by one ear can be heard by the other and vice 
versa which could improve hearing sensitivity. When conducting uHear™, it is not possible to 
mask the other ear. Thus, in case of a large discrepancy of the hearing thresholds between 
both ears, the non-tested ear may influence the patient’s response and could therefore lead to 
an underestimation of the actual threshold. Another reason to implement FF tests includes the 
type of transducer used in these trials. Audiometric testing was performed by use of a supra-
aural headphone, while uHear™ was conducted with standard Apple earbuds. As it has been 
reported that the use of insert earphones result in higher hearing thresholds – especially in the 





lower frequency range due to the loss of vibration on the ear and cranium, this could be in part 
have attributed to the overestimation of the lower frequencies by uHear™ 402.  
Regarding the study population, the distribution of cancer types was not according to the 
expected incidence. This was a result of including on solely one site of the hospital. However, 
this should not have altered results, as there was no cancer type that was more prominent 
than another.   
In respect of the used measurements, some limitations for uHear™ were reported. First, 
uHear™ tends to overestimate lower frequency. This may be due to the ambient noise that is 
present in the room during testing. Further, higher hearing thresholds per frequency may have 
been detected as a result of the unfamiliarity of the patient with a touch screen device. uHear™ 
demands that the subjects taps the screen immediately when a sound is heard. However, older 
patients are not that familiar with touch screen devices and difficulties with the tapping were 
observed in some cases. When using the screening tool, standard non-calibrated Apple 
earbuds were used accompanied by an iPod Touch of the examiner. Therefore, one cannot 
be 100 percent sure that the sound level of the stimulus presented by the device is exactly the 
sound level it should be. However, the usability of the tool is significantly reduced as in routine 
practice, recalibration of earbuds would interfere with an easy implementation of the screening 
tool. These shortcomings in uHear™ have led to a low Sp of the test, resulting in a large 
number of patients needlessly being referred to the audiologist or otolaryngologist. In order to 
tackle these limitations, a new screening method – accounting for these effects – was 
retrospectively determined and evaluated in part II. This resulted in an improved Sp and 
another step forward in the search of the best cut-off score for uHear™ to screen for hearing 
loss within the CGA.  
In Chapter 5, both hearing and cognition were assessed. While not within the scope of the 
research conducted and not predefined as an endpoint of the trials, looking at the relationship 
between these variables could be interesting as it has been reported that impaired hearing is 
associated with a greater risk of dementia 435. Retrospective analyses looking into the 
correlation of the PTA and the result on the MMSE or CDT, did not reveal any interaction nor 
in the first nor in the second cohort (data not shown). This could be the results of following 
reasons. Firstly, it was predefined that patients with diagnosed dementia or a poor cognition, 
according to the investigator’s judgement, could not participate in the trial. Second, patients 
with a known hearing disorder or known hearing loss were also excluded from participation. 
Therefore, the exact link between hearing and cognition in this population could not be properly 
assessed.  
Strengths of Chapter 5  
In Chapter 5, a new screening method to detect hearing loss in older patients with cancer was 
evaluated. uHear™ was selected since it had shown a good S and Sp in previous research 
257. The tool is very easy to use and the administration time was set at approximately five 
minutes. Further, uHear™ can be used on any device that runs on iOS software, such as an 
iPod, iPad of iPhone and could therefore be easily implemented if results would have been 
excellent. When evaluating uHear™, it was found that the assessment time of the screening 
tool and conventional audiometry did not differ significantly as most patients were not familiar 
with touch screens and training was necessary. However, uHear™ does lead to profit in time 
since patients do not have to be transferred to the audiology department of the hospital. 
Further, in the future, training may become redundant since it can be expected that more 
174 | C H A P T E R  6 ∙ P A R T  I V  
 
 
patients will be familiar with touch screens. uHear™ was also well accepted by patients 
according to the judgement of the audiologist. 
Implications for routine practice 
At present, most geriatric oncology teams do not implement a hearing screening when 
assessing the CGA. The hearing assessment as part of the CGA should not be included to 
define the patient’s total vulnerability. It should be used as an important informative 
assessment as knowing if the patient has a decreased hearing is crucial for cancer patients 
who need to hear and understand a lot of information on their diagnosis, its treatment and 
possible treatment-related side effects. Older patients are very proud of their independence 
and in many cases, sensory dysfunctions including vision and hearing loss are one of the first 
functional declines they have to deal with. Although wearing glasses is well accepted by both 
young and older people, hearing aids are not that well accepted by many persons. As a result, 
older patients tend to hide a hearing loss which, in an oncogeriatric population, may lead to 
missing essential information about the cancer diagnosis, its treatment and/or its treatment-
related adverse events 414. If health care providers know that the patient has trouble hearing, 
they can easily adapt their speech and improve the signal to noise ratio, make sure they have 
a good pronunciation, give written instructions, make sure the patient has heard the 
information, etc. Providing a hearing screening as part of the CGA is the first step toward 
addressing hearing loss in the older cancer patient in an objective manner. Further, it should 
be noted that addressing the patient’s hearing will probably not lead to an increased use of 
hearing aids in this population. Though uHear™ was well accepted by patients, even by those 
with a significant hearing, patients were not eager to go see a hearing aid professional. 
It can be disputed whether uHear™ is the best screening tool to implement within the CGA. It 
has without doubt some benefits such as its accessibility, its user-friendly interface, its 
administration time and its diagnostic accuracy but it cannot be ignored that there is still a need 
for improvement as it shows a large discrepancy between threshold levels measured by the 
tool and standard pure tone audiometry. The use of uHear™ to monitor ototoxicity, however, 
should be evaluated as results in the higher frequency region correspond with those of 
conventional audiometry.   
Further, as shortly mentioned above, a SPIN-test would be more suited to implement within 
the CGA as it provides information the patient’s functional status. As there are no Dutch SPIN-
tests available for use on mobile phones, future research could focus on developing a short 
Dutch and French SPIN-test, equivalent to for example uHear™’ speech-in-noise test, that can 
be used within the CGA. Preferably, this new screening tool offers binaural testing.


















In future, it will remain essential to further explore screening measures to detect cognitive and 
auditory dysfunctions in cancer patients of all ages. For any health care provider and in any 
clinical setting, it is crucial to know whether a patient can hear and understand the given 
information.  
Older patients with cancer are extremely vulnerable to deteriorate as a consequence of their 
cancer diagnosis and cancer therapy. Therefore, a CGA remains the key pre-treatment 
approach in order to establish the patient’s ability to tolerate the proposed therapy as CGA-
based interventions can increase both life expectancy and quality of life. When screening for 
cognitive dysfunctions within the CGA, based on the results of this thesis, it can be concluded 
that the Freund CDT can be implemented within the CGA. A positive result on the CDT should 
always be followed by an assessment with the MMSE before a referral to a neuropsychologist, 
neurologist or geriatric day clinic is made, as our results indicated a number of false positives 
on the CDT. Consecutive assessment by the MoCA instead of the MMSE, since this test is 
more sensitive to detect mild cognitive impairments and assesses more cognitive domains, 
can also be considered. However, it should be noted that this thesis does not provide data on 
the subsequent assessment of the MoCA after a positive CDT result. Cognitive assessment 
results should be reported in the patient’s medical record. In case the CGA assessment reveals 
impaired cognition and an in-depth neuropsychological assessment is not possible, health care 
professional should be made aware of the patient’s cognitive functioning through a notification 
when the patient’s medical record is opened. Further, it is advised to confirm CGA findings 
with a patient proxy in case of declined cognition as answers on e.g. ADL and IADL may be 
different from reality.  
While the CGA aims at identifying pre-existing cognitive impairment, older cancer patients may 
experience cognitive decline due to their cancer, cancer treatment or cancer-related 
psychosocial factors. Further, these problems may be present in both old and younger cancer 
patients. Future research on CRCI is essential as many patients experience cognitive 
complaints and still only little is known about its existence, especially since CRCI negatively 
influences patients’ QoL and return to work process 436. Further, it is necessary to broaden the 
landscape of CRCI and to investigate the influence of a cancer diagnosis and treatment in all 
cancer types and not solely in breast cancer patients. It was surprising that already at baseline, 
many cancer patients presented with cognitive difficulties. Though one could attribute this 
cognitive loss to a pre-existing deficit, this theory does not explain these cancer-related 
cognitive impairments, or CRCI, in younger subjects. As it was found that premorbid IQ is a 
confounding factor for CRCI at baseline, researchers conducting future clinical trials on CRCI 
are strongly advised to implement a short IQ test.  
This thesis also highlights the importance of psychosocial screening in cancer patients as it 
may influence both objective and subjective cognitive dysfunctions at baseline and six months 
after treatment initiation. Future research should focus on the use of psychosocial screening 
measures such as a rumination scale, the DT and FACIT-Fatigue scale to screen for subjective 
cognitive complaints. Since distress is a multifactorial emotion, the individual role of different 
variables such as coping, depression, worry and anxiety should be examined. Further, in 
expectation of the exact pathophysiology, clinical trials should be set up to reduce the cognitive 
side-effects that cancer patients experience before, during and after cancer treatment such as 
the EMOTICON trial which examines the use of emotional freedom techniques, which is a brief 
and easy to learn self-help tool that involves tapping specific acupressure points on the top of 
the head, the face, collarbone and under the arm while pronouncing specific problems of 
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physical or emotional nature, to reduce cognitive complaints (clinicaltrials.gov identifier: 
NCT02771028) 437. The EMOTICON-trial is based on the hypothesis that stress reduction 
leads to a reduction of cognitive complaints.  
It may be difficult to distinguish pre-existing cognitive deficits from CRCI. Therefore, research 
should focus on the detailed investigation of the difference between pathological cognitive 
ageing and induced cognitive decline due to the cancer diagnosis, cancer treatment or related 
psychosocial variables. In most CRCI cases, it is expected that the cognition will return to 
baseline levels after cancer treatment has ended. Nonetheless, awaiting a clear understanding 
of these mechanisms, it is advised to schedule follow-up assessments once the cancer 
treatment has ended in order to re-evaluate the patient’s cognition and prescribe proper 
interventions. Future trials should also focus on the development of a minimal 
neuropsychological dataset that can be used to assess ongoing CRCI in cancer 
patients/survivors.  
The latter domain investigated within this thesis regards screening for hearing loss as part of 
a CGA in older cancer patients. At this point, it is not possible to include uHear™ within the 
CGA as it is not ready to be used in routine practice. Future trials should focus on either 
optimising the screening tool and exploring its value in case of ototoxicity monitoring or on the 
development of an eHealth tool providing a new pure-tone based screening method or short 
SPIN-test. Preferably, this SPIN test should be kept short as listening effort is often increased 
in older subjects and assessment of such test could enhance fatigue, which is already present 
in many cancer patients. Nonetheless, this type of test gives an adequate overview of listening 
in daily situations. It should further be evaluated whether this new screening could be 
conducted binaurally or in free field. Next, as the whispered voice test, the tool proposed in the 
NCCN guidelines, also failed to show excellent diagnostic properties, we advise against the 
use of this tool. We do strongly advise to incorporate a subjective assessment of the patient’s 
hearing. If the person conducting the CGA feels the patient has a hearing loss, this should be 
mentioned in the CGA report. Ideally, a pop-up regarding this matter should appear when any 
health care provider opens the patient’s medical record. It is not advised to ask the patient 
about his or her beliefs of their hearing as our results indicated a large discrepancy between 
patient reported hearing loss and objective audiometry results. Further, as there is an obvious 
interaction between hearing and cognition, future research is needed to examine this 
relationship in cancer patients as decline may be accelerated due to the cancer treatment. 
In conclusion, it can be stated that there is a need to screen for both cognitive dysfunctions 
and hearing loss in cancer patients. While the Clock Drawing Test is ready to be implemented 
within the CGA for use in older patients with cancer, further research is necessary to select 
adequate screening tools for CRCI and hearing loss.
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oncologisch centrum. Ik dank graag alle secretaressen: Heidi, Katrien, Annelies, Stefanie en 
Birgit, om mij op te bellen wanneer mijn patiënten toegekomen waren en om de vele 
bloedstalen me te geven met de koerierdienst en mij hier nadien op de hoogte van te stellen. 
Ook een dikke merci aan Jessie, Steffie en Dominique van het Oncologisch Dagziekenhuis 
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208 | A C K N O W L E D G E M E N T S  
 
 
mee te helpen patiënten te rekruteren. Ook een dikke dankuwel aan Dr. Van Eygen om mee 
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